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ABSTRACT

Chuong, Aurelie. MS, Purdue University, August 2015. Characterization of OrfY in the
PurL Gene Cluster of Acetobacter aceti. Major Professor: T. Joseph Kappock.
FGAM synthetase, or PurL, catalyzes the fourth step of the de novo purine
biosynthetic pathway where N-formylglycinamide ribonucleotide (FGAR), ATP, and
glutamine yield N-formylglycinamidine ribonucleotide (FGAM), ADP, Pi, and
glutamate. Two forms of PurL have been observed: one large, found in Gram-negative
bacteria and eukaryotes; and the other, small, found in Gram-positive bacteria and
archaea. Large PurL is a single gene product that is functional as a monomer whereas
small PurL forms a αβ2γ heterotetramer with two other gene products: PurS and PurQ,
which are analogous to the N-terminal and glutaminase domains of large PurL,
respectively. Regardless of quaternary structure, all FGAM synthetases are thought to
use ATP to O-phosphorylate the FGAR formamide, which is then attacked by ammonia
to give FGAM.
The acetic acid bacterium Acetobacter aceti, and closely related α-proteobacteria,
differ from other Gram-negatives in that they contain purSQL genes. The structural
genes for the PurSQL complex (AaFS) are clustered into an apparent operon, which also
contains an open reading frame (orf) that we designate orf Y and two genes (bolA and
grxD) that have key roles in the assembly of iron-sulfur clusters. OrfY has a narrow
species distribution: it is found in most acetic acid bacteria and several closely related
Gram-negative bacteria. OrfY possesses four conserved cysteines and an N-terminal
export sequence typical of periplasmic or exported proteins. Given this unusual set of
features, and the likelihood of coupled transcription-translation in the purSQYL-bolA-

xii
grxD operon, we speculate that OrfY might be an additional subunit for PurSQL, perhaps
required for function in the acidic cytoplasm of acetic acid bacteria; a participant in ironsulfur cluster assembly, which is essential for the production of the first purine pathway
enzyme PurF and therefore purine biosynthesis; or as a regulatory factor. As a first step
in understanding the role of OrfY, we sought to establish the functional form of the A.
aceti enzyme to determine if orf Y encodes a heretofore unknown fourth subunit of the
small PurL complex. This study focused on construct generation of various purine
biosynthetic genes, purification of the proteins they encode, and preliminary work on
gene complementation, the operon, and growth of A. aceti in minimal media.
Functional complementation studies in an Escherichia coli ∆purL strain have
shown that active AaFS is likely composed of PurS, PurQ, and PurL, although the
stoichiometry of the subunits is still unknown, thus indicating that OrfY is likely not a
subunit of the AaFS complex. The presence of orfY in the gene cluster affected
recombinant PurQ expression and caused a delay in growth in the E.coli ∆purL
strain. Recombinant OrfY was successfully purified from E. coli and mass spectrometry
analysis revealed that OrfY was processed and exported.

1

CHAPTER 1. CONSTRUCT GENERATION AND PURIFICATION OF AAFS
SUBUNITS

1.1

Introduction

FGAM synthase (FS) catalyzes the fourth step of the de novo purine biosynthesis
pathway, which makes purine bases from phosphoribosyl pyrophosphate (PRPP) through
a series of enzyme-catalyzed steps [1]. FS converts formyglycinamide ribonucleotide
(FGAR), ATP, and L-glutamine, to formylglycinamidine ribonucleotide (FGAM), ADP,
Pi, and L-glutamate [1, 2]). Figure 1.1 shows a simplified de novo purine biosynthesis
pathway, with an emphasis on the FS-catalyzed FGAR conversion to FGAM step.

L&Glutamine$

L&Glutamate$
NH3$

PRPP$

Phosphoribosyl$$
Pyrophosphate$

FGAR$

Formylglycinamide$
Ribonucleo>de$

FGAM$

Formylglycinamidine$
Ribonucleo>de$

ATP$ ADP$
Pi$

Purine$
Nucleo>des$

Figure 1.1 The FGAR to FGAM reaction catalyzed by FS.
The glutaminase domain hydrolyzes L-glutamine to L-glutamate and ammonia, the latter
which travels to the FGAM synthetase domain via a channel linking the two active sites.
Nucleophilic attack of ammonia onto the carbonyl carbon of the O-phosphorylated
activated amide and deprotonation yields FGAM.
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FS exists in two forms: the first, a 1300 amino acid-long polypeptide, or “large
PurL”, is found in Gram-negative bacteria (i.e. Escherichia coli, EcFS) and eukaryotes;
and the second, “small PurL”, of about 700 amino acids, is found in Gram-positive
bacteria (i.e. Bacillus subtilis, BsFS) and archaea [1].
Multi-subunit FS studies have demonstrated that PurS and PurQ correspond to
the N-terminal and glutaminase domains of large PurL, respectively [3-6]. The
stoichiometric ratio of the BsFS components was determined to be 2 PurS : 1 PurQ : 1
PurL [7]. Crystal structures have also been solved for Gram-negative Salmonella
typhimurium large PurL (StFS) and Gram-positive Thermotoga maritima small PurL
(TmFS, Figure 1.2 [1]). Putative ammonia channels linking the glutaminase and FGAM
synthetase active sites have been located in the StFS and TmFS crystal structures [5, 6].
This channel is critical to avoid protonation of ammonia to yield ammonium as
demonstrated by the 50-fold activity increase seen with L-glutamine-dependent FGAM
synthesis [7, 8]. Proper channeling of ammonia is likely a result of correct protein
folding or FS complex assembly for maximum FS activity.

S.#typhimurium!PurL!
Gram)nega-ve!

T.#mari.ma#PurSQL!
Gram)posi-ve!

Figure 1.2 Crystal structures of large PurL and small PurL.
Large PurL of Gram-negative S. typhimurium (left) and small PurL of the PurSQL
complex of Gram-positive T. maritima (right) [1]. The two forms of FS have visible
structural similarities. PurQ corresponds to the glutaminase domain of large PurL; PurS
is a dimer (right, in red and yellow) and corresponds to the N-terminal domain of large
PurL. Ligands in the FGAM synthetase and PurL active sites is ADP; in the glutaminase
and PurQ active sites is glutamine.
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EcFS has been reported to require chaperone assistance for proper folding [9];
however, since the internal cavity of the well-studied chaperone GroEL-ES is apt to fit a
~70 kDa protein [10], many proteins require multiple rounds of folding [11]. A multisubunit version of FS complex, composed of smaller and more easily folded proteins,
may be an alternative and a selective advantage to make FS for organisms living in harsh
environments (i.e. heat, salinity, acid). The dependence of small PurL on a chaperone
system has not been reported. The Gram-negative Acetobacter aceti, best known for
acetic acid production, is unusual due to its ability to survive with an acidic cytoplasm
where the pH can range from 3.5 to 6 [12]. We hypothesize that acidophiles, like the
Gram-negative Acetobacter aceti, have developed specialized mechanisms to prevent
cytoplasmic acidification and/or conduct acid metabolism to keep their proteins folded
and functional. Various cytoplasmic A. aceti proteins have been demonstrated to be acidstable (and coincidentally thermo-stable) [13-16], where their stability is likely intrinsic
to the primary structure of the proteins themselves. These proteins are
thermodynamically and kinetically resistant to unfolding, which should lessen the burden
on chaperones and on the cell.
AaFS is hypothesized to contain a multi-subunit FS, as suggested by gene cluster
alignments with BsFS (Figure 1.3).

Figure 1.3 FS gene cluster alignment.
Includes select Gram-negative α-proteobacteria: A. aceti, Gram-negative E. coli, and
Gram-positive B. subtilis. To date, acetic acid bacteria are the only Gram-negative
bacteria that may contain PurS, PurQ, PurL, and even OrfY in some.
Legend: S = purS ; Y = orfY.
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A multi-subunit AaFS is unexpected since A. aceti is Gram-negative; however
closely related α-proteobacteria (Figure 3) also show the same gene cluster structure.
Additionally, A. aceti and closely related acidophilic acetic acid bacteria also contain a
previously uncharacterized open reading frame, orfY, located between purS and purQ
(Figure 1.3).
This chapter focuses on construct design and purification of the tagged AaFS genes.

1.2

Materials and Methods

Materials
All materials were from Sigma Aldrich or Fisher Scientific and of the highest purity
unless otherwise noted. Vent DNA polymerase, OneTaq polymerase, all restriction
endonucleases, T4 DNA ligase, and T4 polynucleotide kinase were from New England
Biolabs. Phusion Hot Start polymerase was from Finnzymes. GoTaq polymerase and
deoxynucleotides (dATP, dGTP, dCTP, and dTTP) were from Promega. Mutagenesis
was performed using QuikChange Mutagenesis kits from Stratagene (Pfu Polymerase).
Oligodeoxynucleotides (ODNs) were from Integrated DNA Technologies (Table 1).
Plasmid Miniprep kits were from either Sigma, Fermentas Life Sciences, or Qiagen.
QIAquick PCR Purification kit was from Qiagen. Chemically competent DH5α cells
were from Invitrogen. Vectors pET23a, pET23d, pET28a, pCDF-Duet, and pET-Duet
were from Novagen. Centrifugation steps were performed on a tabletop Eppendorf
5415D centrifuge. PCR reactions were performed in a Bio-Rad MyCycler Thermal
Cycler or a MJ Research Inc. Programmable Thermal Cycler PTC-100. H6purS and
H6orfY in pUC57 (pJK518) were synthesized by GenScript. A. aceti 1023 was isolated
using the Qiagen Genomic-tip 20/G (Elwood Mullins).
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Table 1.1 Oligodeoxynucleotides used in construction of plasmids and sequencing.
ODN
2074
2076
2091
2092
2103
2104
2105
2113
2115
2116
2117
2118
2119
2120
2121
2122
2123
2131
2132
2133
2193
2194
2195
2196

a

2247
2248
2249
2250
2253
2254
2255
2295
2296
2332
2333
2334

Sequence (5'=>3')a
GTGGTGCTCGAGTGAGTTGCCCATCAGCATCGGGA
AGTGTTCCGACCACATCACA
TAAGAAGGAGATATACATATGAAGGTACGTGTAACC
GTGGTGGTGGTGGTGCTCGAGTTAGTTGCCCATCAGCATCGGGA
TTCCCCGGTACCAACCGGGAGCGCGATATGG
ATTGAAAAGCTTCTGATTGAAGCCTGTCTGGA
CAGGCTTCAATCAGAAGCTTTTCAATAAAGGG
GATATACATATGAAGCGCACCCTTCTTATAGCGCTGG
CCGCGGCCATGGCGAAGGTACGTGTAACCGTCATGCTGAAG
AAGGGTAAGCTTCATTCCACCACCTCTACAGAGTAATCTTCAATCACCAGGTTGGC
TAGCAGATCACGCGCCATAGCATCGGCCTTTTTC
GTGGTGCCATGGCAAAGCGCACCCTTCTTATAGCGCTGG
TAATTGAAGCTTTCATTTTTTCACACTGCACGGATAAGAGG
GGCAGCCATATGCAGCGCATTGCGCCCATGAAGG
GTGGTGCTCGAGTGATTTTTTCACACTGCACGGATAAGAGG
TGTGAACATATGAAAGCAGCAATTATCGTATTC
TTACAGCTCGAGTCACCGGACTACAGCCTCC
TGTAGTCATATGAATAAGCCTGTAACCGTTGATGAATC
ATATACATATGAAAGCTGCGATTATAGTGTTTCCTGGTACTAACCGTGAGCGCGAT
ATGG
TATGAATAAGCCTGTAACCGTTGATGAATCCCTTGCCCGTG
AATTCACGGGCAAGGGATTCATCAACGGTTACAGGCTTATTCA
CTAGCCAACCTGGTGATTGAAGATTACTCTGTAGAGGTGGTGGAATGAAGCGCAC
CCTTCTTATAGCGCTGGCATTGGCATG
CCAATGCCAGCGCTATAAGAAGGGTGCGCTTCATTCCACCACCTCTACAGAGTAAT
CTTCAATCACCAGGTTGG
CTAGCCAACCTGGTGATTGAAGATTACTCTGTAGAGGTGGTGGAATGAAAGCAGC
AATTATCGTATTCCCCGGTAC
CGGGGAATACGATAATTGCTGCTTTCATTCCACCACCTCTACAGAGTAATCTTCAA
TCACCAGGTTGG
CGGGGAATACGATAATTGCTGCTTTCA
TATGAAAGCAGCAATTATCGTATTCCCCGGTAC
GATCCATGAAAGCAGCAATTATCGTATTCCCCGGTAC
CGGGGAATACGATAATTGCTGCTTTCATG
TTGCGGGAAGATTTGTAGGAGCAGTGTTCC
GCCTGTGGGATATGCACACGCACGAAAAAC
GGCAAAAACACTTTCACCAACCGGCTTGTC
CACGCGTTTTCAcCGTTGGCATTGAG
CTCAATGCCAACGgTGAAAACGCGTG
AGTTCCCATATGTCCGCTGAACAC
CTGCTTCTCGAGTTAGACGCTGTAGTA
ATAGTGCTCGAGTCATCCTTCGTTATGC

Letters shown in lower case code for mutagenesis.
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Methods
General cloning procedure. Each recombinant gene was amplified by PCR with genespecific primers (Table 1) Acetobacter aceti 1023 genomic DNA or plasmid DNA as
specified below. E. coli strain DH5α was used for cloning and plasmid maintenance. All
constructs were screened by restriction mapping or colony PCR (Chapter 6). All
numbered plasmids were verified by DNA sequencing at the Genomics Core Facility
DNA Sequencing Low Throughput Laboratory at Purdue University, using primers for
both directions.
Table 1.2 Plasmids used in this chaptera.
pJK
518
520
522
529
530
531
532
533
534
535
537
539
543
544
546
548
549
555
567
571
574
575
576
577
595
596
598
a

Vector
pUC57
pUC57
pET28a
pET23a
pET23d
pET23d
pET28a
pET23d
pET23a
pET23a
pET23a
pET23a
pCDF-Duet
pCDF-Duet
pET-Duet
pET-Duet
pCDF-Duet
pET23a
pCDF-Duet
pUC57
pUC57
pET23a
pUC57
pUC57
pUC57
pUC57
pET23a

Description
purS-H6orfY
purS-H6orfY
H6purS-H6orfY
PCR B Mutant R430L (purL 2nd half)
orfYH6
orfY
H6purQ (silA63)
purS
purQ (Q10C and R13L)-PCR A2
purQ (silA63)-purL(G209D)
purL(G209D)
purL
purS and purL
purS
orfY
orfY and purQ
purL
purQ
orfY
purS-H6orfY-purQ-purL(G209D)
purS-H6orfY-purQ-purL
purLH6
purS-orfY-purQ(part)
purS-purQ(part)
purS-orfY-purQ-purL(part/G209D)
purS-purQ-purL(part/G209D)
purS-orfY-purQ-purL

Source
GenScript
TJK
TJK
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Hyphens indicate overlapping genes (as in the native A. aceti sequence).
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Table 1.2 (continued) Plasmids used in this chaptera.
599
605
606
610
611
612
613
618
619
620
622
623
624
625
a

pET23a
pET23a
pET23a
pET23a
pET23a
pET23a
pET23a
pET28a
pET28a
pET28a
pET28a
pET23a
pET23a
pET28a

purS-orfY-purQ-purLH6
purS-purQ-purL
purS-purQ-purLH6
purQ-purL
purQ-purLH6
purS-orfYΔS70-K123-purQ-purL
purS-orfYΔS70-K123-purQ-purLH6
H6purS-purQ-purLH6
H6purS-orfY-purQ-purL
H6purS
H6purL
orfY-purQ-purL
orfY-purQ-purLH6
H6purS-purQ-purLH6

This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Hyphens indicate overlapping genes (as in the native A. aceti sequence).

Synthetic purS-H6orfY construct plasmid pJK518 (TJK). Synthetic purS (silent D15 and
L66 mutations), H6orfY (silent T40, G67, and H114 mutations) , and the first 45 bases of
purQ were synthesized by GenScript. The plasmid encodes for PurS, H6OrfY, and the
first 11 amino acids of PurQ.
Synthetic purS-H6orfY construct plasmid pJK520 (TJK). pJK518 was digested with
NdeI to remove a 218 bp fragment and ligated to yield from pJK520. The plasmid
encodes for PurS, H6OrfY, and the first 11 amino acids of PurQ.
Synthetic H6purS-H6orfY construct plasmid pJK522 (TJK). pJK520 was digested with
NdeI and HindIII and ligated into the NdeI and HindIII restriction sites of the destination
vector pET28a to yield pJK522 . The plasmid encodes for H6PurS, H6OrfY, and the first
11 amino acids of PurQ.
a. Cloning of orfY
Construction of single orfYH6 construct plasmid pJK530. A 0.4 kb product containing
orfY was amplified from template pJK522, using ODNs 2117 and 2120 with an annealing
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Vent DNA Polymerase. The product was purified using a Qiagen
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PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and
HindIII sites of the destination vector pET23d to yield pJK530. The plasmid encodes for
OrfYH6.
Construction of single orfY construct plasmid pJK531. A 0.4 kb product containing orfY
was amplified from template pJK522, using ODNs 2117 and 2118 with an annealing
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Vent DNA Polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and
HindIII sites of the destination vector pET23d to yield pJK530. The plasmid encodes for
OrfY.
Construction of single orfY construct plasmid pJK567. pJK531 was digested with NcoI
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination
vector pCDF-Duet to yield pJK567. The plasmid encodes for OrfY.
b. Cloning of purS
Construction of single purS construct plasmid pJK533. A 0.2 kb product containing purS
was amplified from template pJK522, using ODNs 2115 and 2116 with an annealing
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Vent DNA Polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NcoI and HindIII, and ligated into the NcoI and
HindIII sites of the destination vector pET23d to yield pJK533. The plasmid encodes for
PurS.
Construction of single H6purS construct plasmid pJK620. A 0.2 kb product containing
purS was amplified from template pJK533, using ODNs 2091 and 2116 with an
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s,
and 30 s for 25 cycles using OneTaq Polymerase. The product was purified using a
Qiagen PCR purification kit, digested with NdeI and HindIII, and ligated into the NdeI
and HindIII sites of the destination vector pET28a to yield pJK620. The plasmid encodes
for H6PurS.
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c. Cloning of purL
Construction of intermediate construct plasmid pJK529. A 1.5 kb product containing the
C-terminus of purL was amplified from A. aceti strain 1023 genomic DNA, using ODNs
2104 and 2092 (Figure 4) with an annealing temperature of 60°C and melting, annealing,
and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent DNA
Polymerase. The product was purified using a Qiagen PCR purification kit, digested with
HindIII and XhoI, and ligated into the HindIII and XhoI restriction sites of the destination
vector pET23a to yield pJK529. The plasmid encodes for the last 488 amino acids of
PurL with a mutation R430L.
2103%(KpnI)%

2104%(HindIII)%

PurQ%

PurL%
2105%(HindIII)%

PCR%A%

2121%(NdeI)% 2123%(NdeI)%

PurQ%
2092%(XhoI)%

PCR%B%

2104%(HindIII)%

PurL%
2105%(HindIII)%

PCR%A2%

2092%(XhoI)%

PCR%B%

PCR%QA2%

Figure 1.4 Schematic for building pJK529, pJK534, and pJK535.
Left, PCRs A and B; and right, PCRs QA2, A2, and B, relative to purQ and purL (genes
not to scale) with ODNs used to obtain the PCR products.
The cloning strategy used to build the purL construct is summarized in Figure 5, on the
next page.
Construction of intermediate construct plasmid pJK534. A 1.4 kb product containing
purQ and the N-terminus of purL (PCR A in Figure 4) was amplified from A. aceti strain
1023 genomic DNA, using ODNs 2121 and 2105 with an annealing temperature of 60°C
and melting, annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles
using Vent DNA Polymerase. PCR A was purified using a Qiagen PCR purification kit,
digested with NdeI and HindIII, and ligated into the NdeI and HindIII restriction sites of
the destination vector pET23a to yield pJK534. The plasmid encodes for PurQ G10C and
R13L (random mutations) and the first 247 amino acids of PurL.
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XhoI
PCR B

XhoI
HindIII
purL 5'
EcoRI
PCR QA2

PCR B
purL

HindIII

pJK534
5041 bp

XhoI

pJK535
6493 bp

purQ

HindIII
G209D

Digest and Ligate

NdeI

EcoRI
PCR QA2
purQ
A63 silent mutation
NdeI
Linker
Digest and Ligate
purQ

EcoRI

NdeI
XhoI

XhoI

pJK539

purL

pJK537

Digest and Ligate

purL

5795 bp

5795 bp
HindIII
PCR A2

HindIII
G209D
HindIII
G209D

HindIII
PCR A2

EcoRI
NdeI

EcoRI

EcoRI

EcoRI
Linker
NdeI

Figure 1.5 Summary of the construction of pJK539.
PCR B (yellow) was ligated into plasmid pJK534, which contains PCR QA2 (green) , to
yield plasmid pJK535. A linker (ODNs 2132 and 2133, tan) was then ligated into
plasmid pJK535 after the excision of purQ (orange), to yield plasmid pJK537. PCR A2
(red) was ligated into plasmid pJK537 to repair the G209D mutation in purL (purple).
Plasmids not to scale.
Construction of intermediate construct plasmid pJK535. A 1.5 kb product containing the
C-terminus of purL (PCR B in Figure 4) was amplified from A. aceti strain 1023 genomic
DNA, using ODNs 2104 and 2092 with an annealing temperature of 60°C and melting,
annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent
DNA Polymerase. PCR B was purified using a Qiagen PCR purification kit, digested
with HindIII and XhoI, and ligated into the HindIII and XhoI restriction sites of the
destination vector pJK534. The plasmid encodes for PurQ silent A63 mutation (random
mutation) and PurL G209D (random mutation).
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Construction of intermediate construct plasmid pJK537. ODNs 2132 and 2133 were
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI
and EcoRI sites of destination vector pJK537. The plasmid encodes for PurL G209D.
Construction of single purL construct plasmid pJK539. A 0.7 kb product (PCR A2)
containing the N-terminus of purL was amplified from A. aceti strain 1023 genomic DNA,
using ODNs 2123 and 2105 with an annealing temperature of 60°C and melting,
annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25 cycles using Vent
DNA Polymerase. PCR A2 was purified using a Qiagen PCR purification kit, digested
with EcoRI and HindIII, and ligated into the EcoRI and HindIII restriction sites of the
destination vector pJK537. The plasmid encodes for PurL.
Construction of single purL construct plasmid pJK549. pJK539 was digested with NdeI
and XhoI and ligated into the NdeI and XhoI restriction sites of the destination vector
pCDF-Duet to yield pJK549. The plasmid encodes for PurL.
Construction of single purL construct plasmid pJK575. A 2.2 kb product was amplified
from template pJK539, using ODNs 2104 and 2074 with an annealing temperature of
60°C and melting, annealing, and extension times of 20 s, 30 s, and 2 min 30 s for 25
cycles using Vent DNA Polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and XhoI, and ligated into the NdeI and XhoI
restriction sites of the destination vector pET23a. The plasmid encodes for PurLH6.
Construction of single H6purL construct plasmid pJK622. pJK539 was digested with
NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination
vector pET28a to yield pJK622. The plasmid encodes for H6PurL.
d. Cloning of purQ
Construction of single H6purQ construct plasmid pJK532. pJK535 was digested with
NdeI and EcoRI and ligated into the NdeI and EcoRI restriction sites of the destination
vector pET28a to yield pJK532. The plasmid encodes for H6PurQ.
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Construction of single purQ construct plasmid pJK555. pJK532 was digested with NdeI
and XhoI and ligated into the NdeI and XhoI restriction sites of the destination vector
pET23a to yield pJK555. The plasmid encodes for PurQ.
e. Construction of double gene constructs
Construction of single purS construct plasmid pJK544. pJK533 was digested with NcoI
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination
vector pCDF-Duet to yield pJK544. The plasmid encodes for PurS (with an additional
Ala2 residue to accomodate the NcoI site).
Construction of double purS and purL construct plasmid pJK543. pJK539 was digested
with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination
vector pJK544 to yield pJK543. The plasmid encodes for PurS (with an additional Ala2
residue to accomodate the NcoI site) and PurL.
Construction of single orfY construct plasmid pJK546. pJK531 was digested with NcoI
and HindIII and ligated into the NcoI and HindIII restriction sites of the destination
vector pET-Duet to yield pJK546. The plasmid encodes for OrfY (with an additional
Ala2 residue to accomodate the NcoI site.
Construction of double orfY and purQ construct plasmid pJK548. pJK532 was digested
with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination
vector pJK546 to yield pJK548. The plasmid encodes for OrfY((with an additional Ala2
residue to accomodate the NcoI site) and PurQ.
f. Cloning the overlapping 2-gene, 3-gene, and 4-gene constructs
The cloning strategies to build the AaFS 4-gene and 3-gene constructs are summarized in
Figure 6 and 7, respectively.
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Figure 1.6 Summary of the construction of the AaFS 4-gene cluster.
PCR A (blue) was ligated into plasmid pJK576, which contains purS (yellow), orfY
(pink), and part of purQ (orange), to yield plasmid pJK595. A PCR product spanning
from the restriction sites NdeI through HindIII was obtained using ODNs 2091 and 2105
from template pJK595. This PCR product was ligated into plasmid pJK539 to complete
the purL gene (purple) to yield plasmid pJK598. The same PCR product was also ligated
into pJK575 to complete the purLH6 sequence to yield plasmid 599.
Plasmids are not to scale.
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Figure 1.7 Summary of the construction of the AaFS 3-gene cluster.
PCR A (blue) was ligated into plasmid pJK577, which contains purS (yellow), and part of
purQ (orange), to yield plasmid pJK596. A PCR product spanning from the restriction
sites NdeI through HindIII was obtained using ODNs 2091 and 2105 from template
pJK596. This PCR product was ligated into plasmid pJK539 to complete the purL gene
(purple) to yield plasmid pJK605. The same PCR product was also ligated into pJK575
to complete the purLH6 sequence to yield plasmid 606. Plasmids are not to scale.
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Construction of intermediate purS-H6orfY-purQ-purL construct plasmid pJK571. A 2.9
kb product was amplified from template pJK535, using ODNs 2103 and 2092 with an
annealing temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s,
and 2 min 30 s for 25 cycles using Vent DNA Polymerase. The product was purified
using a Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the
KpnI and XhoI restriction sites of the destination vector pJK520 to yield pJK571. The
plasmid encodes for PurS, H6OrfY, PurQ, and PurL G209D.
Construction of intermediate purS-H6orfY-purQ-purL construct plasmid pJK574.
pJK539 was digested with EcoRI and XhoI and ligated into the EcoRI and XhoI
restriction sites of the destination vector pJK571 to yield pJK574. The plasmid encodes
for PurS, H6OrfY, PurQ, and PurL.
Construction of intermediate purS-orfY-purQ construct plasmid pJK576. ODNs 2193
and 2194 were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector :
linker into the NheI and SphI sites of destination vector pJK520 to yield pJK576. The
plasmid encodes for PurS, OrfY, and the first 11 amino acids of PurQ.
Construction of intermediate purS-purQ construct plasmid pJK577. ODNs 2195 and
2196 were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker
into the NheI and SphI sites of destination vector pJK520 to yield pJK577. The plasmid
encodes for PurS and the first 11 amino acids of PurQ.
Construction of purS-orfY-purQ-purL construct plasmid pJK595. A 1.5 kb product was
amplified from template pJK535, using ODNs 2103 and 2105 with an annealing
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using Vent DNA Polymerase. The product was purified using a
Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the KpnI and
XhoI restriction sites of the destination vector pJK576 to yield pJK595. The plasmid
encodes for PurS, OrfY, PurQ, and the first 247 amino acids of PurL G209D.
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Construction of purS-purQ-purL construct plasmid pJK596. A 1.5 kb product was
amplified from template pJK535, using ODNs 2103 and 2105 with an annealing
temperature of 60°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using Vent DNA Polymerase. The product was purified using a
Qiagen PCR purification kit, digested with KpnI and XhoI, and ligated into the KpnI and
XhoI restriction sites of the destination vector pJK577 to yield pJK596. The plasmid
encodes for PurS, PurQ, and the first 247 amino acids of PurL G209D.
Construction of purS-orfY-purQ-purL construct plasmid pJK598. A 2.0 kb product was
amplified from template pJK595, using ODNs 2091 and 2105 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using OneTaq polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK539 to yield pJK598. The plasmid encodes
for PurS, OrfY, PurQ, and PurL.
Construction of purS-orfY-purQ-purLH6 construct plasmid pJK599. A 2.0 kb product
was amplified from template pJK595, using ODNs 2091 and 2105 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using OneTaq polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK575 to yield pJK599. The plasmid encodes
for PurS, OrfY, PurQ, and PurLH6.
Construction of purS-purQ-purL construct plasmid pJK605. A 1.7 kb product was
amplified from template pJK596, using ODNs 2091 and 2105 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using OneTaq polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK539 to yield pJK605. The plasmid encodes
for PurS, PurQ, and PurL.
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Construction of purS-purQ-purLH6 construct plasmid pJK606. A 1.7 kb product was
amplified from template pJK596, using ODNs 2091 and 2105 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min
30 s for 25 cycles using OneTaq polymerase. The product was purified using a Qiagen
PCR purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK575 to yield pJK606. The plasmid encodes
for PurS, PurQ, and PurLH6.
Construction of purQ-purL construct plasmid pJK610. ODNs 2247 and 2248 were
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI
and KpnI sites of destination vector pJK605. The plasmid encodes for PurQ and PurL.
Construction of purQ-purLH6 construct plasmid pJK611. ODNs 2247 and 2248 were
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the NdeI
and KpnI sites of destination vector pJK606. The plasmid encodes for PurQ and PurLH6.
Construction of orfY-purQ-purL construct plasmid pJK612. ODNs 2249 and 2250 were
phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the
BamHI and KpnI sites of destination vector pJK598. The plasmid encodes for
OrfY(ΔS70-K123), PurQ, and PurL.
Construction of orfY-purQ-purLH6 construct plasmid pJK613. ODNs 2249 and 2250
were phosphorylated, annealed, and ligated at a 1:10 molar ratio of vector : linker into the
BamHI and KpnI sites of destination vector pJK599. The plasmid encodes for
OrfY(ΔS70-K123), PurQ, and PurLH6.
Construction of H6purS-orfY-purQ-purLH6 construct plasmid pJK618. pJK599 was
digested with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the
destination vector pET28a to yield pJK618. The plasmid encodes for H6PurS, OrfY,
PurQ, and PurLH6.
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Construction of H6purS-orfY-purQ-purL construct plasmid pJK619. pJK598 was
digested with NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the
destination vector pET28a to yield pJK619. The plasmid encodes for H6PurS, OrfY,
PurQ, and PurL.
Construction of orfY-purQ-purL construct plasmid pJK623. A 1.3 kb product was
amplified from template pJK598, using ODNs 2113 and 2076 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Phusion polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK539 to yield pJK623. The plasmid encodes
for OrfY, PurQ, and PurL.
Construction of orfY-purQ-purLH6 construct plasmid pJK623. A 1.3 kb product was
amplified from template pJK598, using ODNs 2113 and 2076 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Phusion polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK575 to yield pJK624. The plasmid encodes
for OrfY, PurQ, and PurLH6.
Construction of H6purS-purQ-purL construct plasmid pJK625. A 1.2 kb product was
amplified from template pJK605, using ODNs 2091 and 2076 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Phusion polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and EcoRI, and ligated into the NdeI and EcoRI
restriction sites of the destination vector pJK622 to yield pJK625. The plasmid encodes
for H6PurS, PurQ, and PurL.

19
Protein expression and purification
Underlined headers indicate the final purification method. Antibiotics were used as
follows: Amp (ampicillin, 100 ug/mL); Kan (kanamycin, 70 ug/mL); and Stm
(streptomycin, 50 ug/mL).
a. OrfYH6
OrfYH6 (pJK530) Prep 1. A single colony of BL21(DE3) cells transformed with pJK530
was used to inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C,
200 rpm). 1 L of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown
overnight (37°C, 200 rpm). Cells were harvested (5,000g, 15 min) and stored at -80°C
until use. All the following steps were performed at 4°C. The cell pellet was
resuspended in 50 mM Tris-HCl pH 8.0, 300 mM KCl (5 mL/g pellet) and disrupted by
sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min
off) on ice. Cell debris was removed by centrifugation (30,000g, 30 min). Streptomycin
sulfate (10% w/v stock) was added to a final concentration of 1% w/v, incubated on ice
for 10 min, then spun (30,000g, 10 min). The soluble lysate was applied to a previously
equilibrated and charged Ni-NTA column (1.5 cm x 2 cm, 3.5 mL) in the above buffer.
The column was washed with 10 mM imidazole in the above buffer. A linear imidazole
gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 300 mM KCl) was used to elute the
protein (35 mL x 35 mL). Fractions containing pure protein by SDS-PAGE were pooled
and the protein was concentrated using an Amicon Centricon YM-3 (7,000 rpm, 2 h).
The protein was dialyzed overnight against 100 volumes (1 L) of 50 mM Tris-HCl pH 8.0,
300 mM KCl using 7,000 MWCO Pierce Snakeskin dialysis tubing (no changes).
Aggregates of the dialyzed protein (flaky precipitates) were removed by centrifugation in
an Eppendorf 5415D microfuge (max speed, 10 min, at 4°C). Protein quantitation was
determined by the Bradford assay (Biorad). 33 mg of OrfYH6 was isolated with a final
protein concentration of 7.5 mg/mL. 1 mg of OrfYH6 was buffer exchanged into i. 50
mM Tris pH 8.0, ii. 50 mM Tris pH 9.0, iii. 50 mM CHES pH 9.0, or iv. 50 mM
ammonium formate pH 4.0 to a final concentration of 2 mg/mL using an Amicon
Centricon YM-3. The protein was stored at 4°C and no precipitate was observed. This
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batch of protein was used for antibody generation (Cocalico Biologicals, Inc.), circular
dichroism (Elwood Mullins, Data Report 2013-01-07), and ESI-MS (described below).
OrfYH6 (pJK530) Preps 9-11. BL21(DE3) carrying pJK530 in ZYM-5052-Amp
medium [17] was grown overnight (30°C, 200 rpm). Cells were harvested (5,000g, 15
min) and used immediately or stored at -80°. All the following steps were performed at
4°C. The cell pellet was resuspended in 50 mM Tris pH 8.0, 300 mM KCl (5 mL/g pellet)
and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a
Fisher Sonic Dismembrator. Cell debris was removed by centrifugation (30,000g, 30
min). Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1%
and the lysate was cleared by centrifugation (30,000g for 10 min). The cleared lysate
was loaded onto a previously equilibrated (in 50 mM Tris pH 8.0, 300 mM KCl) and
charged Ni-NTA column (1.5 cm x 2 cm, 3.5 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM Tris pH 8.0, 300 mM KCl buffer. A
linear imidazole gradient (10-500 mM in 50 mM Tris pH 8.0, 300 mM KCl) was used to
elute the protein (15 mL x 15 mL). Fractions containing pure protein by SDS-PAGE
were pooled and the protein was concentrated using an an Amicon ultrafiltration 8050
cell with a Millipore PL-5 membrane. For prep 9, OrfYH6 was concentrated to 14.0
mg/mL (49 mg total). For prep 10, protein was concentrated to 7.5 mg/mL (15 mg total).
For prep 11, OrfYH6 was concentrated to 18.9 mg/mL and then diluted down to ~ 4.5
mg/mL to prevent precipitate formation (39 mg total). No aggregates were observed thus
far at the various concentrations. These batches were used to set up crystal trays using
the Emerald Wizard I and II solution kits (described below) and alkylation.
Periplasmic isolation of OrfYH6 (pJK530)
Prep 1. Protocol adapted from [18]. BL21(DE3) carrying pJK530 in ZYM-5052-Amp
medium [17] was grown overnight (30°C, 200 rpm). Cells were harvested (5,000g, 15
min) and used immediately or stored at -80°. The cell pellet was resuspended in 400 mL
of 30 mM Tris-HCl pH 8.0, 20% sucrose buffer (hypertonic solution), followed by the
addition of EDTA pH 8.3 to 1 mM [final]. The solution was stirred slowly at room
temperature for 10 min. The following steps were performed at 4°C. Cells were
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collected by centrifugation (10,000g, 10 min). The supernatant was removed and the
pellet was resuspended in ice cold 5 mM MgSO4 (hypotonic solution, unbuffered) and
stirred slowly on ice for 10 min. Cells were then spun down and the supernatant
(periplasmic fraction) was transferred to a new tube. The periplasmic fraction was loaded
onto a pre-equilibrated (in 50 mM Tris-HCl pH 8.0, 300 mM KCl) and charged Ni-NTA
column (1.5 cm x 1.5 cm, 2.7 mL). The column was washed with 10 column volumes of
10 mM imidazole in 50 mM Tris-HCl pH 8.0, 300 mM KCl buffer. A linear imidazole
gradient (10-400 mM in 50 mM Tris-HCl pH 8.0, 300 mM KCl) was used to elute the
protein (15 mL x 15 mL).
Prep 2. Protocol adapted from [19]. The BL21(DE3)-pJK530 cell pellet was washed
with 20 mL 30 mM Tris-HCl pH 8.0, 20% sucrose. The cells were harvested (8,000g, 5
min) and resuspended in 5 mL of the same buffer. 5 mL of 8 mM EDTA and 0.16 mg of
lysozyme/mL were added to the cell resuspension and incubated on ice for 15 min. Cells
were pelleted (8,000g, 10 min) and the supernatant (periplasmic fraction) was collected.
The pellet was resuspended in 2 mL 50 mM Tris pH 8.0, using a 10 mL syringe and 18gauge needle. The cells were frozen and thawed 3 times in dry ice + ethanol and a 25°C
water bath, respectively, as described previously [19]. Cell debris was removed (8,000g,
10 min), and the supernatant (cytoplasmic fraction) was collected. Ammonium sulfate
precipitation was performed on the periplasmic fraction as described previously: 0-35%
(208 g/L); 35-55% (128 g/L); and 55-85% (215 g/L). The 35-55% cut was resuspended
in a minimal amount of 50 mM Tris pH 8.0 buffer and loaded onto a pre-equilibrated and
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL). The column was washed with 10
column volumes of 10 mM imidazole buffer in 50 mM Tris pH 8.0. A linear imidazole
gradient (10-400 mM) was used to elute the protein (15 mL x 15 mL). Fractions
containing pure protein by SDS-PAGE were pooled and the protein was concentrated to
0.04 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore PL-5
membrane.
Prep 3. Same protocol as prep 2 except the periplasmic fraction was directly loaded onto
the Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL). To remove the EDTA, dialysis was
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performed for 1 hr against 100 volumes (300 mL) of 50 mM Tris-HCl pH 8.0, 300 mM
KCl using 7,000 MWCO Pierce Snakeskin dialysis tubing (no changes). Post-dialysis
precipitate was removed by centrifugation and the supernatant (unknown protein
concentration) was loaded onto the recharged and pre-equilibrated Ni-NTA column. The
protein was eluted using 50 mM EDTA, 50 mM Tris pH 8.0, 100 mM KCl. Fractions
containing protein by A280 were pooled. Ammonium sulfate fractionation was
performed as a concentration step: 0-40% (242 g/L); 40-55% (63 g/L). The 40-55%
pellet was resuspended in a minimal amount of 50 mM Tris pH 8.0, 100 mM KCl buffer.
Prep 6. Protocol adapted from [20]. All the following steps were performed at 4°C. In
short, the BL21(DE3)-pJK530 cell pellet was resuspended in 100 mM Tris-acetate, 0.5 M
sucrose, 5 mM EDTA (5 mL/g cell pellet). 40 uL of 2 mg/mL lysozyme (80 ug) and 500
uL of ice cold water were added to the cell resuspension and incubated on ice for 5 min.
MgSO4 was added to 5 mM final (7.5 uL of 1 M stock). Spheroplasts were pelleted in a
microcentrifuge (max speed, 2 min) and the supernatant (periplasmic fraction) was
collected. The pellet was washed with 1 mL 50 mM Tris-acetate pH 8.0, 0.25 M sucrose,
10 mM MgSO4. Spheroplasts were pelleted (max speed, 2 min) and the supernatant was
discarded. The pellet was resuspended in 1 mL 50 mM Tris-acetate pH 8.0, 300 mM KCl
and lysed by sonication using a Misonix sonicator with microtip at 15W (Briggs lab,
Program 3, 3 cycles of 5 s on, 5 s off, 5 s on). The periplasmic fraction was dialyzed
against 100 volumes of 50 mM Tris-HCl pH 8.0, 300 mM KCl (4 buffer exchanges, 30
min, 100 mL) to remove the EDTA prior to loading 1.2 mL onto a Ni-NTA spin column.
Spheroplast cellular debris was removed by centrifugation (max speed, 15 min). Qiagen
Ni-NTA spin columns were equilibrated with 400 mL of 50 mM Tris-HCl pH 8.0, 300
mM KCl (800g, 2 min). 1.2 mL of dialyzed periplasmic solution and 700 uL of soluble
spheroplast lysate were loaded onto the Ni-NTA spin columns (200g, 5 min). The spin
columns were washed with 700 uL 50 mM Tris-HCl pH 8.0, 300 mM KCl, 10 mM
imidazole (800g, 2 min). Bound protein was eluted using 200 uL 50 mM Tris-HCl pH
8.0, 300 mM KCl, 500 mM imidazole. Fractions were analyzed by SDS-PAGE and
Western blot.
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b. PurS
H6PurS and H6OrfY (pJK522). T. J. Kappock expressed pJK522 in BL21(DE3) cells in
ZYM-5052-Amp medium [17]. All the following steps were performed at 4°C. The cell
pellet was resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 ml/g pellet) and
disrupted by sonication using a Fisher Sonic Dismembrator at 12% output with a microtip.
Cell debris was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10%
w/v stock) was added to a final concentration of 1% w/v, incubated on ice for 10 min,
then spun (30,000g, 10 min). Ammonium sulfate fractionation was performed as
described above: 0-25% cut (144 g/L); 25-65% cut (265 g/L). The last cut was
equilibrated overnight. The 25-65% pellet was resuspended in about twice the volume of
the pellet and applied to a previously equilibrated and charged Ni-NTA column (1.5 cm x
4 cm, 7 mL) in the above buffer. The column was washed with 10 column volumes of 10
mM imidazole in the above buffer. A linear imidazole gradient (10-500 mM) was used to
elute the protein (70 mL x 70 mL). Fractions containing pure protein by SDS-PAGE
were pooled and the protein was stored as an 85% saturated ammonium sulfate pellet
(608 g/L). 214 mg of H6PurS was isolated. The sample was to the Purdue University
Campus-Wide Mass Spectrometry Center for MALDI-TOF.
Ammonium sulfate fractionation of PurS (pJK533). A single colony of BL21(DE3)
transformed with pJK533 was used to inoculate a 50-mL LB-Amp starter culture and
grown to saturation (37°C, 200 rpm). 1 L of ZYM-5052-Amp medium [17] was
inoculated 1:100 and grown overnight (37°C, 200 rpm). Cells were harvested (5,000g,
15 min) and stored at -80°C until use. All the following steps were performed at 4°C.
The cell pellet was resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet)
and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles:
1 min on, 1 min off) on ice. Cell debris was removed by centrifugation (30,000g, 30
min). Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1%
w/v, incubated on ice for 10 min, then spun (30,000g, 10 min). Ammonium sulfate
fractionation was performed as described above: 0-25% (144 g/L); 25-35% (60 g/L); 3545% (62 g/L); 45-55% (64 g/L); 55-65% (66 g/L); 65-85% (143 g/L).
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H6PurS (pJK620). A single colony of BL21(DE3) transformed with pJK620 was used to
inoculate a 50-mL LB-Kan starter culture and grown to saturation (37°C, 200 rpm). 1 L
of ZYM-5052-Kan medium [17] was inoculated 1:100 and grown overnight (37°C, 200
rpm). Cells were harvested (5,000g, 15 min) and stored at -80°C until use. All the
following steps were performed at 4°C. The cell pellet was resuspended in 50 mM TrisHCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell debris
was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock)
was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun
(30,000g, 10 min). The cleared lysate was loaded onto a previously equilibrated and
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.
A linear imidazole gradient (10-500 mM) was used to elute the protein (5 mL x 5 mL).
Fractions containing pure protein by SDS-PAGE were pooled and the protein was
concentrated to 5.7 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore
PL-5 membrane.
c. PurQ
Co-expression of PurQ with pREP4-GroESL. C41(DE3)-pREP4-GroESL were
transformed with pJK555 and used to inoculate a 50-ml LB-Amp culture which was
grown to saturation. Two 250 mL cultures of ZYM-5052-Amp medium[17] were
inoculated 1:50 and grown overnight at 30°C or 37°C (200 rpm). For the 15°C autoinduction, the culture was first grown at 37°C for two hours and then moved to 15°C for
overnight growth and induction. Cells were harvested (5,000g, 15 min) and stored at 80°C until use. All the following steps were performed at 4°C. The cell pellet was
resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by
sonication using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min
off) on ice. Cell debris was removed by centrifugation (max speed, 15 min) in an
Eppendorf microfuge 5415D at 4°C.
Inclusion body prep of PurQ (pJK555). Protocol adapted from [21]. BL21(DE3) cells
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transformed with pJK555 were used to inoculate 1 L of ZYM-5052-Amp medium [17] at
1:200 and grown for 24 hours (37°C, 200 rpm). All the following steps were performed
at 4°C. Cells were harvested (5,000g, 15 min) and used immediately or stored at -80°C
until use. The cell pellet was resuspended in 50 mM Tris pH 8.0, 100 mM KCl (5 mL/g
pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3
cycles: 1 min on, 1 min off) on ice. Cell debris was removed by centrifugation (30,000g,
30 min). The pellet was resuspended in 100 mM Tris HCl pH 7.0, 5 mM EDTA, 15 mM
βME, 2 M urea, 2% Triton X-100 (5 mL/g) using transfer pipets (Wash 1). The solution
was centrifuged (30,000g, 30 min). 2 additional washes were performed as described
previously. The final washing step was the same as above except for the buffer did not
contain any urea or Triton X-100. 4 different extracting conditions were used at room
temperature: 6 M guanidine-HCl, 8 M guanidine-HCl, 6 M urea, and 8 M urea. The
pellet from the final wash was split up into 4 aliquots and resuspended in 50 mM Tris
HCl, 5 mM EDTA, 15 mM βME, and urea or guanidine-HCl (4 mL/g). The solutions
were centrifuged (30,000g, 30 min). The guanidine-HCl samples were subjected to
ethanol precipitation to avoid precipitation when running SDS-PAGE: 225 uL of cold
100% ethanol was added to 25 uL of sample and vortexed. After 10 min at -20°C, the
solution was pelleted at max speed in a microcentrifuge for 10 min. The ethanol was
removed and 25 uL of H2O and 225 uL of cold 100% ethanol was added to the pellet.
After resuspension, the solution was pelleted at max speed for 5 min. The pellet was
resuspended in 25 uL 2X SDS buffer prior to loading.
d. PurL
H6PurL (pJK622). A single colony of BL21(DE3) transformed with pJK622 was used to
inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L
of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown overnight (37°C, 200
rpm). Cells were harvested (5,000g, 15 min) and stored at -80°C until use. All the
following steps were performed at 4°C. The cell pellet was resuspended in 50 mM TrisHCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell debris
was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock)
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was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun
(30,000g, 10 min). The cleared lysate was loaded onto a previously equilibrated and
charged Ni-NTA column (1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.
A linear imidazole gradient (10-500 mMin 50 mM Tris-HCl pH 8.0, 100 mM KCl) was
used to elute the protein (5 mL x 5 mL). Fractions containing pure protein by SDSPAGE were pooled and the protein was concentrated to 3.4 mg/mL using an an Amicon
ultrafiltration 8050 cell with a Millipore PL-30 membrane.
PurLH6 (pJK575). A single colony of BL21(DE3) transformed with pJK575 was used to
inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L
of ZYM-5052-Amp medium [17] was inoculated 1:100 and grown overnight (37°C, 200
rpm). Cells were harvested (5,000g, 15 min) and stored at -80°C until use. All the
following steps were performed at 4°C. The cell pellet was resuspended in 50 mM TrisHCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a Fisher
Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell debris
was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock)
was added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun
(30,000g, 10 min). The cleared lysate was loaded onto a previously equilibrated and
charged Ni-NTA column (1.5 cm x 1.8 cm, 3.2 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer.
A linear imidazole gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 100 mM KCl) was
used to elute the protein (15 mL x 15 mL). Fractions containing pure protein by SDSPAGE were pooled and the protein was concentrated to 3.2 mg/mL using an an Amicon
ultrafiltration 8050 cell with a Millipore PL-30 membrane.
PurSQLH6 (pJK606). A single colony of BL21(DE3), C41(DE3)-pREP4-GroESL,
C41(DE3) transformed with pJK606 was used to inoculate a 50-mL LB starter culture
and grown to saturation (37°C, 200 rpm). BL21(DE3) cells were propagated in1 L of
ZYM-5052 medium [17] was inoculated 1:100 and grown overnight (37°C, 200 rpm).
C41(DE3) cells with or without pREP4-GroESL were grown in LB-IPTG. In short, 1 L
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LB was inoculated 1:100 and grown to OD600 ~0.4 at 37°C. The temperature was
decreased to 15°C and when the OD600 reached 0.6, isopropyl-β-thiogalactopyranoside
(IPTG) was added to a final concentration of 0.4 mM from a 1M stock and the cells were
induced for 20 hrs. Cells were harvested (5,000g, 15 min) and stored at -80°C until use.
All the following steps were performed at 4°C. The cell pellet was resuspended in 50
mM Tris-HCl pH 8.0, 100 mM KCl (3 mL/g pellet) and disrupted by sonication using a
Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. If
metabolites were included, ATP, ADP, and/or glutamine would be spiked into cell lysates
in this step to a final concentration of 1 mM. Cell debris was removed by centrifugation
(30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was added to a final
concentration of 1% w/v, incubated on ice for 10 min, then spun (30,000g, 10 min). The
cleared lysate was loaded onto a previously equilibrated and charged Ni-NTA column
(1.5 cm x 1.5 cm, 2.7 mL) and the column was washed with 1-5 column volumes of 10
mM imidazole in 50 mM Tris-HCl pH 8.0, 100 mM KCl buffer. A linear imidazole
gradient (10-500 mM in 50 mM Tris-HCl pH 8.0, 100 mM KCl) was used to elute the
protein (5 mL x 5 mL) or an EDTA elution using 50 mM EDTA in 50 mM Tris-HCl pH
8.0, 100 mM KCl buffer. Batch purification using Qiagen Ni-NTA columns were used
according to the manufacturer’s instruction instead of using the 1.5 cm x 1.5 cm column.
Co-expression studies of AaFS proteins. LB starter cultures containing appropriate
antibiotic (Tables 3-6) were inoculated with single colonies and grown to saturation
(37°C, 200 rpm). Empty vector controls included pET23a, pET-Duet, or pCDF-Duet
vectors. 250 mL of ZYM-5052 medium [17] supplemented with appropriate antibiotics
was inoculated 1:100 and grown overnight (30°C, 200 rpm). Cells were harvested
(5,000g, 15 min) and stored at -80°C until use. All the following steps were performed at
4°C. Cell pellets were resuspended in 50 mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g
pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20% output (3
cycles: 1 min on, 1 min off) on ice. Cell debris was removed by centrifugation (30,000g,
30 min or max speed, 15 min in a microfuge).
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Table 1.3 Single-gene constructs (Figure 1.8, top)
pJK
531
555
533
539

Vector Antibiotic Gene(s)
pET23d
Amp
orfY
pET23a
Amp
purQ
pET23d
Amp
purS
pET23a
Amp
purL

S

Y
x

Q

L

x
x
x

Table 1.4 Duet vector constructs (Figure 1.8, bottom)
pJK
532
543
548
549

Vector
pET28a
pCDF-Duet
pET-Duet
pCDF-Duet

Antibiotic
Kan
Stm
Amp
Stm

Gene(s)
H6purQ
purS and purL
orfY and purQ
purL

SL

YQ

SYQL

x

x
x

x

SQL
x
x

QL
x
x

Table 1.5 Overlapping gene constructs as in the native A. aceti sequence (Figure 1.9)
pJK Vector Antibiotic
Gene(s)
SYQL SYQLH6 SQL SQLH6 SYQL* SYQLH6*
pCDF567
Stm
orfY
x
x
Duet
598 pET23a
Amp purS-orfY-purQ-purL x
purS-orfY-purQ599 pET23a
Amp
x
purLH6
605 pET23a
Amp
purS-purQ-purL
x
x
606 pET23a
Amp
purS-purQ-purLH6
x
x

*OrfY was expressed in trans
Table 1.6 purQ-purL constructs (Figure 1.10)
pJK Vector
610 pET23a
611 pET23a

Antibiotic
Amp
Amp

Gene(s)
purQ-purL
purQ-purLH6

QL
x

QLH6
x

Mass Spectrometry
ESI-MS. OrfYH6 from prep 1 was analyzed on a Thermo Scientific LTQ (Parker
laboratory) with Steven Ouellette’s assistance. Samples were diluted by volume in
50:50:01 water: acetonitrile: formic acid. MS peaks were analyzed using ESIprot1.0
[22].
Tandem-MS. OrfYH6 was analyzed by Anton Iliuk (Tao laboratory) as follows. The
protein sample was denatured and reduced in 50 mM trimethyl ammonium bicarbonate.
Three sample preparations were performed: (i) 0.1% RapiGest (Waters) and 5 mM
dithiothreitol (DTT); (ii) 0.1% RapiGest; or (iii) untreated (where both RapiGest and
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DTT were omitted). Rapigest and/or DTT treatments were incubated for 30 minutes at
50°C. Only the sample in condition (i) was further alkylated in 15 mM iodoacetamide
for 1 hour in the dark at room temperature. All samples were digested with proteomics
grade trypsin at 1:100 ratio overnight at 37 °C. The pH was adjusted below 3 and the
sample was incubated for 40 minutes at 37 °C. The sample was centrifuged down at
16,100g to remove RapiGest and to collect supernatant. The sample was desalted with a
100-mg Sep-Pak C18 column (Waters) and dried completely. Peptide samples were redissolved in 8 uL of 0.1% formic acid and injected into an Agilent nanoflow 1100 HPLC
system. The reverse phase C18 was performed using an in-house C18 capillary column
packed with 5 µm C18 Magic beads resin (Michrom; 75 µm i.d. and 12 cm of bed length)
on an 1100 Agilent HPLC. The mobile phase buffer consisted of 0.1% HCOOH in ultrapure water with the eluting buffer of 100% CH3CN run over a shallow linear gradient
over 60 min with a flow rate of 0.3 µl/min. The electrospray ionization emitter tip was
generated on the prepacked column with a laser puller (Model P-2000, Sutter Instrument
Co.). The Agilent 1100 HPLC system was coupled online with a high resolution hybrid
linear ion trap orbitrap mass spectrometer (LTQ-Orbitrap XL; Thermo Fisher). The mass
spectrometer was operated in the data-dependent mode in which a full-scan MS (from
m/z 300-1700 with the resolution of 30,000 at m/z 400) was followed by 4 MS/MS scans
of the most abundant ions. Ions with charge state of +1 were excluded. The mass
exclusion time was 180 s. The LTQ-Orbitrap raw files were searched directly against
Saccharomyces cerevisiae database with no redundant entries using SEQUEST algorithm
on Proteome Discoverer (Version 1.0; Thermo Fisher). Proteome Discoverer created
DTA files from the raw data with minimum ion threshold of 15 and absolute intensity
threshold of 50. Peptide precursor mass tolerance was set at 5 ppm, and MS/MS
tolerance was set at 0.8 Da. Search criteria included a static modification of cysteine
residues of +57.0214 Da and a variable modifications of +15.9949 Da to include potential
oxidation of methionines and carbamidomethylation of cysteines. Searches were
performed with full tryptic digestion and allowed a maximum of two missed cleavages on
the peptides analyzed from the sequence database. False discovery rates (FDR) were set
for 1% for each analysis.

30
Western blotting
Antibody generation. Purified antigens OrfYH6 (pJK530) and PurLH6 (pJK575) were
sent to Cocalico Biologicals Inc. for custom polyclonal antibody generation (Cocalico
ELISA titers for anti-OrfYH6 and anti-PurLH6 showed signal at 1:10000 dilution).
Antisera were tested by dot blot [23] or Western blotting as described below.
Western blot protocol. Protocol adapted from [24]. In short, soluble proteins from
soluble lysates (A. aceti or E. coli) were separated by SDS-PAGE and transferred to a
nitrocellulose membrane (0.2 or 0.45 µm, Osmonics, Inc.). Transfer was performed at
100V for 1 h in Towbin Buffer (25 mM Tris, 192 mM glycine, 20% (v/v) methanol, 0.1 %
(w/v) SDS). The membrane was blocked in TBS (100 mM Tris-HCl pH 7.5, 150 mM
NaCl) with 5% (w/v) nonfat milk for 1 h, shaking at room temperature, followed by three
10 min washes in TBST (TBS with 0.1% (v/v) Tween-20). The membrane was probed
for 1 h with custom polyclonal rabbit primary antibody (1:10,000 for anti-OrfYH6
antibody; 1:20,000 dilution for anti-PurLH6 antibody in TBS with 2% (w/v) nonfat milk)
or anti-His H15 probe (1:50,000, Santa Cruz Biotechnology). Excess antibody was
removed by three TBST washes. The membrane was then probed for 1 h with goat antirabbit IgG (H+L) HRP conjugate secondary antibody (1:10,000 dilution in TBS with 2%
(w/v) nonfat milk, Jackson ImmunoResearch). Excess antibody was removed by three
TBST washes. The membrane was soaked for 5 min in a 1:1 mixture of stable peroxide
and luminol/enhancer solutions (ThermoScientific). Typically, signal was recorded by
film or using a ChemiImager 5500 imaging system (Alpha Innotech) where membranes
were exposed 30 s - 5 min.
The LI-COR Odyssey was also used with Brett Bishop’s help (Ogas laboratory). For the
LI-COR, membranes were blocked using the LI-COR Blocking buffer, incubated with
custom antiserum for the primary and goat anti-rabbit IRDye 800 CW secondary
antibody, and immediately visualized on the instrument after excess antibody was
removed.
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Dot blot. Protocol adapted from [23]. In short, typically 1-5 µg protein or lysate were
spotted onto nitrocellulose membrane and let to dry. Non-specific sites were blocked by
soaking the membrane in 5% (w/v) BSA or nonfat milk in TBST for 1 hr at room
temperature in a Petri dish, followed by three 5 min washes in TBST. The membrane
was incubated with primary antibody (diluted 1:25,000; 1:10,000; or 1: 5,000 in 0.1%
BSA or 0.2% nonfat milk in TBS) for 30 min - 1 h. Excess antibody was removed by
three TBST washes. Secondary antibody (anti-rabbit) was diluted 1:10,000 and
incubated for 30 min at room temperature. Excess antibody was removed by three TBST
washes and the signal was recorded as previously described.
Anti-OrfYH6 and anti-PurLH6 antibody purification. Protocol adapted from [25]. In
short, Ni-IDA resin (~1.5 mL) was stripped using 100 mM EDTA. The resin was washed
twice with water and recharged with 50 mM CoCl2. Excess solution was removed and
washed with PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, pH
7.2 [26]. 14 mg of OrfYH6 (prep 1) was used to bind the resin in PBS (30 min on ice
with constant mixing, 10 mL total volume). No wash step was performed to remove
unbound protein. 200 uL of 30% H2O2 was added to the resin and the latter was
incubated at room temperature for 1 hr (Co2+ oxidation to Co3+ leads to a color change
from pink to purple). The resin was then washed with PBS+100 mM EDTA and stored at
4°C in PBS until use. 2 mL of antiserum was incubated for 25 min with the resin on ice
while mixing. The suspension was poured into a 0.75 cm diameter column (final
dimensions 0.75 cm x 3.3 cm). Flowthrough was collected and the resin was washed
with 10 column volumes of 20 mM Tris-HCl, pH 7.5, 150 mM NaCl (binding buffer) and
10 column volumes of 20 mM Tris-HCl, pH 7.5, 1 M NaCl (washing buffer). The
antibody was eluted from the column with 5 column volumes of 100 mM Tris-acetate,
pH 4, 150 mM NaCl; 5 column volumes of 100 mM acetate, pH 3, 150 mM NaCl; and 5
column volumes of 100 mM glycine-HCl, pH 2.5, 150 mM NaCl. Drops were collected
in ~1 mL aliquots in tubes containing 100 uL 1M Tris-HCl pH 8.3. Fractions containing
protein by A280nm (> 0.2 were collected), concentrated, and buffer exchanged into PBS
using an Amicon UltraCentrifugal filter (2 mL; 30,000 MWCO). Purified antibody was
stored at -20°C in 25% glycerol.
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OrfYH6 Crystallization. Previously isolated OrfYH6 (prep 9 and 10) was used to set up
crystallization trays by the hanging drop diffusion method using the Emerald Biosystems
Wizard Kits I and II. In short, 500 uL of crystallization solution was aliquoted 24-well
crystallization plates (Hampton Research). 4 uL drops were set up by mixing 2 uL of well
solution and 2 uL of protein solution at various concentrations. Protein concentrations
were determined by the Bradford assay after buffer exchanging into 10 mM Tris-HCl, pH
8.0 using Millipore Microcon YM-10 centrifugal concentrators. Trays were stored at the
Hockmeyer building at Purdue University in the 21.5°C temperature-controlled
crystallization room. Cryo solutions were made up by adding 15% w/v ethylene glycol to
the mother liquor (Wizard Kit 1 Solution 13 (1.26 M ammonium sulfate (dibasic), 0.1 M
sodium cacodylate/HCl pH 6.5) aka 1-13 or Wizard Kit 2 Solution 17 (2.5 M sodium
chloride, 0.1 M Tris/HCl pH 7.0, 0.2 M magnesium chloride) aka 2-17. K. Sullivan
dipped the crystals in cryo solution prior to freezing them in liquid nitrogen. Crystals
were shot via remote data collect LS-CAT beam line 21-ID-F.
OrfYH6 alkylation with N-ethylmaleimide (NEM) and methoxypolyethylene glycol
maleimide MAL-PEG. Samples that were used were unpurified periplasmic fraction
containing OrfYH6, purified OrfYH6 (from total lysate, prep 11), and A. aceti
thioredoxin (Jesse Murphy). The periplasmic fraction from cells overexpressing OrfYH6
were freeze-thawed once as described above, and the supernatant was kept for further
processing. NEM was added to samples to a final concentration of 10 mM in 50 mM
TrisHCl, pH 6.5. As for MAL-PEG, 5 molar equivalents over the total number of
cysteines was added in 50 mM TrisHCl, pH 6.5. Samples that were first treated with
DTT had 5 molar equivalents over the total number of cysteines found in OrfYH6.
Excess MAL-PEG was neutralized with 5 molar equivalents of β-mercaptoethanol (BME)
prior to analysis by SDS-PAGE.
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1.3

Results and Discussion

ExPASy [27] predicted the sizes of PurS, OrfY, PurQ, and PurL to be 8.7 kDa,
12.9 kDa, 25.1 kDa, and 77.7 kDa, respectively. The sizes of A. aceti PurS, PurQ, and
PurL are similar to previously characterized Gram-positive FS [5-7].
Co-expression studies of AaFS proteins
After single gene constructs were obtained, double gene constructs were made in
Duet vectors where each gene was under its own T7 promoter. A preliminary
overexpression of the AaFS genes is shown in Figure 1.8.
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Figure 1.8 Expression of AaFS proteins.
Top, individual construct expression. Bottom, Duet vector constructs (NB - PurQ is
actually H6PurQ (pJK532) in the last 2 lanes of the gels). Tables 3 and 4 in Materials
and Methods lists the plasmids used for expression. SDS-PAGE (12% acrylamide), 10
uL of 1:5 dilution/lane (protein concentration unknown).
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OrfY, PurS, and PurL were soluble. PurQ, like its tagged version (data not shown), was
insoluble. When PurQ is co-expressed with the other three A. aceti genes, a portion
becomes soluble, thus PurQ might rely on the other subunits of the AaFS complex or
even GroESL for proper folding and therefore solubility. An OrfY dimer is visible and
looks to co-migrate with PurQ when expressed alone (Western blotting in Figure 24, right,
on purified OrfYH6 with purified anti-OrfYH6 antibody probing supports the dimer
hypothesis). Induction failed with pJK548, which carries OrfY and PurQ on the same
Duet vector.
Constructs where the overlapping nucleotides were conserved between the AaFS
genes were obtained and expressed as shown in Figure 1.9. Additionally, OrfY on a
separate plasmid (pJK567) was re-added to the 3-gene constructs (pJK605/606) to test if
OrfY has a cis or trans effect.
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Figure 1.9 Expression of FS proteins (overlapping genes).
Table 1.5 lists the plasmids used for expression. For trans, pCDF-Duet was used in the OrfY lanes (right-most lanes). * denotes duplicate sample. SDS-PAGE (12%
acrylamide), 10 uL/lane after 1:10 dilution (protein concentration unknown).
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pJK606 induction failed in the cis experiment, but OrfY was observed to have a
repressive effect in cis on PurQ and potentially PurL. Re-addition of OrfY (in trans) has
no effect on the over-expression of PurQ or PurL. More definitive conclusions could be
drawn if the same amount of protein was loaded. A small amount of soluble PurQ was
observed in the presence of PurS and PurL. QL(H6) constructs were obtained and
expressed (Figure 1.10).
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Figure 1.10 Coexpression of PurQL.
Expressed constructs were as follows: PurQL (pJK610) and PurQLH6 (pJK611). SDSPAGE (12% acrylamide), 10 uL/lane after 1:10 dilution (protein concentration unknown).
The solubility of PurQ seems to require the presence of both PurS and PurL, as not much
soluble PurQ was observed when only PurL is present.
H6PurS/H6OrfY (pJK522)
pJK522 encodes for H6PurS and H6OrfY, where the 4-nucleotide overlap was
preserved as in the native sequence, despite the presence of the His-tag at the N-term of
OrfY. The idea behind using pJK522 for purification was that both H6PurS and H6OrfY
would be able to be purified in the same prep. 214 mg of protein was isolated. Since one
band was observed by SDS-PAGE, the sample was analyzed by MALDI-TOF where
only H6PurS was detected (10703.33 Da). The expected sizes for H6PurS-Met1 and
H6OrfY-Met1 were 10.7 kDa and 13.8 kDa, respectively. Analysis of isolated OrfYH6
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by ESI-MS below revealed that OrfY is N-terminally processed, thus explaining why
only H6PurS was isolated here.
OrfYH6 (pJK530)
Prep 1. Expression of OrfYH6 showed that the protein was soluble (data not shown).
The elution profile is shown in Figure 1.11.
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Figure 1.11 OrfYH6 prep 1 elution profile (linear imidazole gradient).
Ladder used was bovine serum albumin (BSA, 66 kDa) and hemoglobin, Hb (Chain A,
16 kDa; Chain B, 17 kDa). SDS-PAGE (12% acrylamide), 10 uL/lane (protein
concentration unknown).
Flaky precipitate was observed after overnight dialysis and was spun down. The final
purification gel is shown in Figure 1.12.
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Figure 1.12 OrfYH6 final purification gel (prep 1).
SDS-PAGE (12% acrylamide); 5 ug/lane except for the pellet post-dialysis (protein
concentration unknown).
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The observed flaky precipitate after dialysis is likely OrfYH6 by SDS-PAGE (Figure
1.14). 33 mg of soluble protein was isolated and appeared to remain in solution when
stored at 4°C in 50 mM Tris pH 8.0, 300 mM KCl at a protein concentration of 7.5
mg/mL,; 50 mM Tris pH 8.0; 50 mM Tris pH 9.0; 50 mM CHES pH 9.0; or 50 mM
ammonium formate pH 4.0 at 2 mg/mL for at least one year.
Steven Ouellette (Parker laboratory) and Anton Iliuk (Tao laboratory) helped with ESIMS analysis of OrfYH6 and after deconvolution using ESIprot 1.0, the molecular weight
was determined to be 11927.45 Da (expected 14094.76 Da). SignalP 3.0 algorithm
analysis [28] of the OrfYH6 sequence predicts a cleavage site between A22 and Q23
(Figure 1.13 shows those residues to be A21 and Q22 as Met1 was omitted when the
protein sequence was entered into the algorithm).

Figure 1.13 SignalP 3.0 output for the analysis of OrfYH6.
A cleavage site is predicted between A22 and Q23 (A21 and Q22 in graph as Met1 was
omitted).
The SignalP 3.0 output for OrfYH6 resembles that of a secretory or periplasmic protein
thus suggesting OrfYH6 secretion or export. The predicted molecular weight of
processed OrfYH6 is 11935.6 Da, a few Da off from the ESI-MS experimental value of
11927.45 Da.
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Elwood Mullins used circular dichroism (CD) to further characterize OrfYH6.
The CD spectrum is shown in Figure 1.14 and the data summary is in Table 1.7.

Figure 1.14 CD spectrum of OrfYH6.
Refer to EAM Data Report 2013-01-07 for experimental details.
Table 1.7 CD structural element summary for OrfYH6.

According to CD, OrfYH6 is 40% α-helical while β-sheets and random coils make up the
remaining 60%.
Anton Iliuk (Tao laboratory) helped with tandem MS analysis of OrfYH6.
Multiple cysteine residues can be found within the OrfY protein sequence (C13, C36,
C45, C76, and C119). The last four residues were found to be conserved in at least 14
other OrfY sequences as summarized in Figure 1.15.
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Figure 1.15 Sequence logo for the conserved residues of 14 OrfY sequences.
The more highly conserved residues are larger.
OrfYH6 was analyzed by tandem-MS analysis in reducing and non-reducing conditions
in attempt to identify any existing disulfide bridges (Figure 1.16).
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Figure 1.16 Tandem-MS peptide coverage of OrfYH6.
Detected peptides were underlined in different sample prep conditions (black - no
RapiGest/no DTT; red - no RapiGest/ + DTT; blue - + RapiGest/no DTT). The vertical
dashed line denotes the predicted N-term processing site and the vertical green lines,
tryptic digest site.
Out of the 111 amino acids in processed OrfYH6, only 12 amino acids were not covered
when the three experiments were combined (89% coverage). As expected, the first 22
amino acids (note that the accommodation of the NcoI site at the N-term leads to an
additional alanine residue at position 2, which was not included in the Figure 1.18
sequence) were not detected. The first cysteine residue, C13, is part of the processed Nterm. In untreated cell lysate (black underline in Figure 1.16), C45 and C72 were
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detected (their reduced state may have been due to reductants found in cell lysate). In
reducing conditions (red underline in Figure 1.16), C45, C72, and C119 were detected.
In non-reducing conditions (blue underline in Figure 1.16), C45 and C72 were detected.
For all experiments, C36 was likely on a peptide that was too small for detection. Since
only the +DTT sample was alkylated with iodoacetamide, it is still unclear if all the
cysteine residues in OrfYH6 are reduced.
Isolation of OrfYH6 in 100 mM KCl (vs. 300 mM KCl in prep 1) showed a poor
yield of OrfYH6 as only 2 mg of protein was isolated in prep 2 (data not shown). A
decrease in the auto-induction temperature from 37°C to 30° seemed to help expression
in prep 3 (data not shown). A spreading out effect was observed in both the imidazole
and EDTA elutions (data not shown).
Prep 9-11. The buffer conditions from prep 1 were used and a linear imidazole gradient
(10-500 mM) was used to elute the protein. The final purification gel and accompanying
Western blot using custom antiserum (not antigen-affinity purified yet) for prep 9 and the
final purification gel for prep 10 is shown in Figure 1.17.
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Figure 1.17 OrfYH6 preps 9 and 10 final purification gels.
Left, final gel for prep 9. Center, Western blot using custom antiserum (LI-COR). Right,
final gel for prep 10. SDS-PAGE (15%), 5 ug protein/lane.
49 mg of OrfYH6 was isolated from 4L of cells for prep 9, and 15 mg from 1L for prep
10. The Western blot results were not as expected. Although OrfYH6 was detected in
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the crude, soluble, and OrfYH6 lanes, two strong signals were observed at higher
molecular weights. At first glance, the bands could be OrfYH6 oligomers. However due
to the lack of marker signals and a very faint signal for the purified protein, possible
explanations include non-specific reactivity of the antiserum to E. coli contaminating
proteins or the latter’s emission at 800 nm. Other Western blots where signal was
recorded on film show non-specific reactivity of antiserum to E. coli empty vector lysate
(Figure 1.18).

Figure 1.18 PU81 Antiserum has non-specific reactivity to E. coli lysate.
Left, Coomassie-stained SDS-PAGE (12%), 5 ug protein/lane. Right, Western (15 s
exposure).
M. Hall and N. Dudareva suggested antigen affinity purification of the antiserum to
enrich for the anti-OrfYH6 antibody. Dot blot results showed interaction with OrfYH6,
as expected, but also, E. coli and A. aceti lysates, likely due to an error in the blocking
step where 5% BSA (w/v) was used instead of 5% nonfat milk (w/v) in TBST (data not
shown). Instead of repeating the dot blot, a Western blot was performed using the
purified OrfYH6 antibody and is shown in Figure 1.19. 5% nonfat milk (w/v) was used
for blocking.
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Figure 1.19 Western blot of OrfYH6 total lysate and purified OrfYH6.
Santa Cruz H-15 His probe or antigen affinity purified anti-OrfYH6 antibody were used.
Left, SDS-PAGE (12% acrylamide), 5 ug protein/lane. Center, blot using anti-His
antibody. Right, blot using purified anti-OrfYH6 antibody. 2 min exposure. Legend:
molecular weight standard, S; total lysate, Tot; purified OrfYH6 (prep 9), YH6.
Both the anti-His and the purified OrfYH6 antibodies were able to detect monomeric
OrfYH6 in total lysates, although the signal was very faint. In the purified OrfYH6 lanes,
both antibodies were observed to probe for the monomeric and potentially dimeric
OrfYH6. The putative OrfYH6 dimer was not observed in the total lysate lane. The
antigen purified antibody seemed to work well as the anti-His antibody was observed to
from non-specific interactions at very high molecular weights in the purified OrfYH6
lane.
Purified OrfYH6 from preps 9 and 10 were used to set up crystal trays. After 4
months, some crystals were observed in two buffers: (1-13) 1.26 M ammonium sulfate,
0.1 M sodium cacodylate/HCl, pH 6.5 and (2-17) 2.5 M sodium chloride, 0.1 M Tris/HCl
pH 7.0, 0.2 M magnesium chloride.
Tray 1 Well C1 (NB3-137, 2012-06-15) with crystallization buffer 1-13 contained a
single crystal with 2 faces and was also not birefringent and Izit negative. This crystal
was dubbed “OrfY1” and had the following unit cell parameters, and OrfYH6 being a
potential hexamer:
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The F 2 3 space group calculated for OrfY2 is not common, therefore crystallization
conditions should be optimized in 1.26M ammonium sulfate, 0.1M sodium
cacodylate/HCl, pH 6.5 for OrfYH6 for further crystallographic studies.
OrfYH6 prep 11, which yielded 39 mg of protein from 3 L of cells (Figure 1.20),
was used for NEM and MAL-PEG alkylation of cysteine residues (Figure 1.21).
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Figure 1.20 OrfYH6 prep 11.
Left, elution gel (10 uL/lane, protein concentration unknown). Right, final purification
gel (5 ug protein/lane). SDS-PAGE (15% acrylamide).
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Figure 1.21 Alkylation of OrfYH6 with NEM and MAL-PEG.
Left, NEM alkylation (SDS-PAGE, 15%; 10 uL/lane). Center and right, alkylation of
isolated OrfYH6 with MAL-PEG (SDS-PAGE, 15% urea and 9% urea, respectively; 7.5
ug protein/lane). * indicates sample was purified with a Ni-NTA spin column.
Successful NEM and MAL-PEG modification of cysteine residues in the absence of DTT
would indicate reduced cysteines. On the other hand, if no shift is observed in the
absence of DTT, the cysteine residues are likely to be oxidized. Regardless of the state of
the cysteines (oxidized or reduced), a shift should be observed in the presence of both
DTT and alkylator. The NEM treatment did not yield a large enough shift to be
convincing by SDS-PAGE (Figure 1.21, left) so MAL-PEG was used on purified
OrfYH6 (Figure 1.21, center and right) since it would add ~ 5 kDa per modified cysteine.
SDS-PAGE urea gels were used to hopefully get better band resolution; however urea
does not seem to help as smears and fuzzy bands were observed. Since 12% gels led to
OrfYH6 migrating to the very bottom of the gel (Figure 1.18) and 15% caused smearing
(Figure 1.20), 13.5% gels should be used. Previous studies have reported that MAL-PEG
alkylation caused a greater mass shift of 10-15 kDa than the expected 5 kDa by SDSPAGE [29]. OrfYH6 treated with MAL-PEG in the absence of DTT showed a smear at ~
25 kDa. In reducing conditions, a smear was observed at higher molecular weights,
however it is unclear how many MAL-PEG residues are attached to OrfYH6 (Figure 1.21,
right). Together with the tandem MS data obtained thus far (Figure 1.16) and the
unresolved SDS-PAGE alkylated bands, it is still unclear if the OrfYH6 residues are
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reduced or not. More samples and new gels (i.e. 13.5% acrylamide) will have to be used
to resolve the different molecular weight species due to alkylation.
An attempt at isolating MAL-PEG-modified OrfYH6 (no DTT) using Ni-NTA spin
columns failed (Figure 1.21, right, last lane) in order to eventually use that method to
concentrate OrfYH6 isolated from the periplasm. One reason is that a small amount of
protein was input (45 ug protein) onto the spin-column for recommended elution volume
(>200 uL).
Periplasmic Isolation of OrfYH6
OrfY was predicted to be an exported protein by SignalP 3.0 (Figure 1.13) and
ESI-MS data supports N-term processing of OrfYH6. Many, but not all, secreted and/or
periplasmic proteins undergo N-term processing. To test this hypothesis, OrfYH6
periplasmic isolations were attempted.
In prep 1, cells were lysed by osmotic shock [18]; however, the OrfYH6 in the
periplasmic fraction was extremely dilute, well below the level of detection by SDSPAGE and Coomassie staining (data not shown). Lysozyme was used in another
periplasmic isolation and was utilized in prep 2, followed by a freeze-thaw protocol [19].
The final purification gel is shown in Figure 1.22.
CD
K
#AB
1
,1
(@
0 7.% /0,
6L
%
/
N
5
#
%
0
"
# ."
:9
? &? &? <K "/K 5."<
$% ,- .6 -.
/5
"# %# /5 <5 >& =& =H J
3/
89
! + 34 ;9 '= >& && I.5 M

(FG

#%

C

AB

@#

D(E

*&($)"
&'($)"
>*($)"
2&($)"

Figure 1.22 Periplasmic isolation of OrfYH6 using lysozyme (prep 2).
SDS-PAGE (12%); 10 ug/lane except for “Wash” (3 ug) and “Isolated OrfYH6” (1 ug).
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Once again, the isolated OrfYH6 was very dilute and below the detection level of
Coomassie staining. Lysozyme and OrfYH6 are very close in size and were observed to
migrate closely on SDS-PAGE (Figure 1.22). A higher percentage gel may be useful for
better resolution of both proteins as it is unclear if OrfYH6 is present at all; a Western
blot was performed using an anti-His antibody to determine the presence of OrfYH6
(Figure 1.23).
"#
$:
&01
(3 ,
)
&
/.
6$ *+
.(
)
9
/
&
(
8
(
9
,
4/ .73 $%&' "=< )*+
#
3( (6
8 '(
2 5/ !"
;<

"#
$:
&01
(3 ,
)
&
/.
6$ *+
.(
9
/
)
&
(
8
( 3 &'
9 +,
%
=<
4/ .7
3( (6 #$
8" '()*
2 5/ !"
;<

Figure 1.23 Western blot visualization of periplasmic OrfYH6.
Santa Cruz H-15 anti-His probe was used. Left, SDS-PAGE (9% acrylamide), 10 ug/lane.
Left, chemiluminescence signal after 1 min exposure.
OrfYH6 migrated with the dye front; however, successful probing of periplasmic
OrfYH6 and previously purified protein was observed. As expected, lysozyme was not
detected by Western blot. The Western protocol seemed to work well and periplasmic
OrfYH6 was isolated although very dilute. Switching some of the steps around may
increase yield. In prep 3, ammonium sulfate was performed after running the affinity
column; however, there was still 4 mM EDTA, which was enough to strip the Ni-NTA
column. The flowthrough was dialyzed and the affinity purification was repeated. As in
the OrfYH6 prep 1, flaky precipitate after overnight dialysis (no buffer changes) was
observed so dialysis should be avoided. No signal by Western blot was observed in preps
3 and 4.
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Prep 5. The protocol for prep 3 was attempted again since no OrfYH6 was detected by
Western blot. OrfYH6 was once again very dilute and was not visualized on SDS-PAGE
by Coomassie staining (data not shown). A Western was performed using anti-His and
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the custom antisera from Cocalico (Figure 1.24).
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Figure 1.24 Western blot for the periplasmic isolation of OrfYH6 prep 5.
Different primary antibodies were used: left, anti-His (Santa Cruz); center, custom
antiserum from PU80 rabbit (Cocalico); right, custom antiserum from PU81 rabbit
(Cocalico). The last 2 lanes denoted “OrfYH6” were from prep 1.
The secondary bleed antiserum from Cocalico (note that this periplasmic prep was
performed before the OrfYH6 antibody was purified) were able to successfully detect
purified OrfYH6 but not the periplasmic form likely due to exported OrfYH6 being too
dilute.
Prep 6. Issues encountered in previous preps included using too much lysozyme and a
very dilute periplasmic fraction, both of which contributed to visualizing OrfYH6
difficult by SDS-PAGE. Cells were resuspended in a smaller amount of buffer (5 mL/g
cell pellet) and treated with less lysozyme (80 ug) [20].
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The gels for the periplasmic purification attempt and Western are shown in Figure 1.25.
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Figure 1.25 Periplasmic isolation of OrfYH6 prep 6.
Left, isolation of OrfYH6 from periplasmic and spheroplasts (periplasmic fraction: 12 ug;
periplasmic OrfYH6: 6 ug; spheroplast solubly lysate: 22 ug; spheroplast OrfYH6: 6 ug;
other lanes: protein concentration not determined). Center, Coomassie gel for Western
blot analysis of periplasmic fractions for OrfYH6 (5 ug protein/lane). Right, Western
blot detection of OrfYH6 (5 ug protein/lane) using the purified anti-OrfYH6 custom
antibody (Cocalico), 5 min exposure. SDS-PAGE (13.5% acrylamide). Legend: M marker; P - periplasmic fraction; D - dialyzed periplasmic fraction; FT - flowthrough; W
- wash; C - crude; S - soluble; SO - spheroplast (cytoplasmic) OrfYH6; PO - periplasmic
OrfYH6; O - purified OrfYH6 from total lysate (prep 11).
The amount of lysozyme loaded onto the SDS-PAGE gels in Figure 1.25, left, was
determined to be 1.5 ug in the periplasmic fraction lane. By SDS-PAGE, it is unclear if
the protein band at ~ 12 kDa is OrfYH6 or lysozyme, but it is present in all the lanes,
including the spheroplasts (cytoplasmic) fractions with the exception of the periplasmic
wash. Previous experience with the periplasmic fraction was the inability to detect much
protein since it was so dilute. A Western blot was performed on the periplasmic,
dialyzed periplasmic, purified periplasmic OrfYH6 and previously purified OrfYH6 from
total cells (prep 11) as a positive control (Figure 1.25, center and right). The antiOrfYH6 antibody was found to have some non-specific interaction with the protein
marker; however, as expected, a strong signal was observed for the isolated monomeric
OrfYH6 (Figure 25, right, last lane, band at ~ 12 kDa). A strong signal at ~25 kDa,
which could correspond to a putative OrfYH6 dimer, was detected by the purified anti-
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OrfYH6 antibody in the pre and post-dialysis periplasmic fraction (Figure 1.25, right),
but the monomeric form of OrfYH6 was not detected. The SDS-PAGE loading buffer
contained 300 mM BME yet the dimer was resistant to denaturing and reducing
conditions. One hypothesis is that OrfYH6 exists as a dimer in the periplasm and binds a
metabolite (maybe iron?). No signal for the monomeric or the dimeric forms of OrfYH6
were observed after the Ni-NTA spin column was used (Figure 1.25, right, PO lane),
which suggests that the His tags of OrfYH6 in the dimer failed to interact with the resin.
It is important to note that isolated OrfYH6 from total lysate has yielded the monomeric
form, although a faint dimer was observed by SDS-PAGE in crude/soluble lysates
(Figure 1.8). It has not yet been determined if the dimer flowed through and/or came out
in the wash (flowthrough and wash have not been tested by Western blot). One possible
explanation for the OrfYH6 dimer failing to interact with the Ni-NTA resin is that the
His-tags become buried upon dimer formation and are no longer solvent-exposed. A
larger tag (i.e. GST) could be used however its size may interfere with dimer formation.
PurSQLH6 (pJK606)
B. subtilis FS, composed of PurS, PurQ, and PurL, was purified and assembled in
vitro [7] in the presence of small metabolites. If AaFS behaves like BsFS, the complex
could be co-purified using the pJK606 construct since it encodes for PurS, PurQ, and
PurLH6. Prep 1 buffers did not contain any metabolites. Although not much PurL or
PurQ was expressed, some PurLH6 and PurQ enrichment was observed (data not shown);
however, since the buffer only contained 100 mM KCl, higher salt may help with
maintaining electrostatic interactions between subunits.
C41(DE3) carrying the pREP4-GroESL and pJK606 constructs successfully
expressed GroEL and GroES but failed to produce PurSQLH6 (data not shown). PurS
could have migrated with GroES in the dye front. A band migrating at ~ 25 kDa was
observed and could correspond to PurQ (data not shown); however, there still is work to
be done in optimizing expression of pJK606.
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Batch purifications using the Ni-NTA spin columns proved unsuccessful as well (data not
shown) mainly due to the small amount of starting recombinant protein. A quick and
dirty attempt where a larger pellet was processed and a Ni-NTA column was used for copurification in the presence of metabolites is shown in Figure 1.26.
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Figure 1.26 PurSQLH6 pulldown in the presence of metabolites.
SDS-PAGE (15% acrylamide), 10 uL/lane undiluted (protein concentration unknown).
Legend: PSS - post streptomycin sulfate, FT - flowthrough.
The elution fractions were dirty, due to the small volume of wash buffer applied (1
column volume), but bands that could correspond to PurS, PurQ and PurL were able to be
visualized. A 15% acrylamide gel was used here for better visualization of PurS. The
presence of small metabolites ATP, ADP, glutamine, or combinations of those did not
seem to improve complex formation for co-isolation. PurS seemed to be enriched
compared to PurQ and PurL, maybe due to the 2 PurS : 1 PurQ : 1 PurL as previously
described in BsFS [3, 7] and TmFS [5]. Since PurQ was found to be insoluble even in
the presence of PurL (Figure 1.9), characterization of AaFS may best be achieved by
kinetic studies of a ΔpurL BL21(DE3) strain overexpressing pJK605 (PurSQL) or
pJK606 (PurSQLH6).
Ammonium sulfate fractionation of PurS (pJK533). The salting out profile of PurS is
shown in Figure 1.27.

51

Figure 1.27 Ammonium sulfate fractionation of PurS (pJK533).
SDS-PAGE (15%), 5 ug protein/lane. The six right-most lanes are the ammonium sulfate
cuts (numbers denote percentages).
PurS seems to precipitate out of solution in all cuts; however, the cleanest and most
highly concentrated (at 26 mg/mL) cut was the 35-45% cut, which will be used in
subsequent purifications. No further work on untagged PurS was performed.
H6PurS (pJK620). Some H6PurS was isolated from the pJK522 construct, however,
pJK522 also coded for H6OrfY, which was not isolated due to an N-terminal truncation
(consistent with ESI-MS data). The N-terminal His tag on PurS should not affect FS
complex formation as crystal structures show it to be solvent exposed even when PurS
was crystallized alone [5, 30]. The pJK620 construct only encodes for H6PurS. The
elution and final purification gels are shown in Figure 1.28.
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Figure 1.28 Purification of H6PurS (pJK620).
Left, elution profile, 10 uL/lane. Right, final purification gel, 5 ug/lane. SDS-PAGE
(15%).
Fractions 2 and 3 were pooled and a total of 20 mg H6PurS was isolated from 1 L of cells.
No further characterization has been done for H6PurS.
PurQ.
Co-expression of PurQ with pREP4-GroESL. In the preliminary co-expression studies
above, PurQ was observed to be produced in large amounts but as an insoluble protein.
Co-expression of PurQ with pREP4-GroESL may help solubilize PurQ. Different
expression temperatures were tested and the gel is shown in Figure 1.29.

Figure 1.29 Co-expression of PurQ (pJK555) with plasmid pREP4-GroESL.
Protein expression was tested at 15°C, 30°C, and 37°C. SDS-PAGE (12%), 10 uL/lane
after a 1:10 dilution.
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The presence of GroESL does not seem to improve PurQ solubility regardless of the
growth temperature. Other alternatives to solubilize PurQ are inclusion body preps or
fusion constructs.
Inclusion body prep of PurQ (pJK555). Co-expression of PurQ with GroESL failed to
improve PurQ solubility so inclusion body prep was attempted (Figure 1.30).

Figure 1.30 Inclusion body prep of PurQ (pJK555).
SDS-PAGE (12%), 10 uL/lane (crude and soluble samples diluted 1:5).
Extraction was successful and it looks like inclusion body prep will work for PurQ,
although the presence of double bands may be due to proteolytic cleavage. Refolding of
denatured PurQ was not attempted.
PurL
H6PurL (pJK622). Protein-protein interaction interfaces between PurS, PurQ, and PurL
are currently unknown for the AaFS complex. The TmFS complex shows that both the C
and N-termini of PurL are solvent exposed [5]. The elution and final purification gels are
shown in Figure 1.31.
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Figure 1.31 Purification of H6PurL (pJK622).
Left, elution gel, 10 uL/lane (protein concentration unknown). Right, final purification
gel, 5 ug/lane. SDS-PAGE (9% acrylamide).
Fractions 3 and 4 were pooled. The column was overloaded as a lot of unbound H6PurL
was observed in the flowthrough. 11 mg of protein was isolated with some lower
molecular weight contaminating proteins, however a bigger column should be used for
future isolations.
PurLH6 (pJK575). The C-terminally tagged PurL was also isolated and the gels are
shown in Figure 1.32
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Figure 1.32 Purification of PurLH6 (pJK575).
Left, elution profile, 10 uL/lane. Right, final purification gel, 5 ug/lane. SDS-PAGE
(9%). Legend: PSS - post streptomycin sulfate; FT - flowthrough.
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Fractions 7-9 were pooled and 12 mg were isolated. This prep was sent to Cocalico
Biologicals in order to get a custom antibody made for PurLH6. As for the OrfYH6

=>6@@@@
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=>?@@@

antibody, PurLH6 antiserum was affinity purified and tested via dot blot (Figure 1.33).
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Figure 1.33 Dot blot for purified PurLH6 antibody.
4 ug each of PurLH6, lysozyme, E. coli, and A. aceti lysates were spotted on
nitrocellulose membrane. 30 min exposure using the ChemImager. Image is reverse of
original and auto-contrast was used.
The Prozone effect was observed, where a stronger signal was observed at the lower
dilution (1:20,000) than at the higher dilution (1:5,000). According to J. Whitesell
(Cocalico), the ELISA results also reflect this effect. The Prozone effect [31] occurs
when there is more antibody than there is antigen, the antibody of interest cannot attach
to the antigen due to the presence of other antibodies so a lower signal is observed at the
lower dilution than at the higher dilution. The purified antibody will be used at a
1:20,000 dilution and it has not yet been tested for Western blots. The purified antibody
will not only be able to be used for Westerns but also pull-down of the AaFS complex,
although more studies on AaFS complex formation need to be performed.

1.4

Conclusion

OrfYH6 was isolated on multiple occasions from total cell lysate and was
observed to be monomeric and stable at 4°C for over a year in 50 mM Tris pH 8.0, 300
mM KCl at a concentration of 4.3 mg/mL to 7.5 mg/mL. Overnight dialysis of OrfYH6
(from total cells or periplasmic) is not recommended as flaky precipitate was observed

56
the next morning. The higher amount of salt (300 mM KCl) in the buffer led to a greater
yield of purified OrfYH6. From nickel affinity chromatography, the majority of the
isolated species was observed to be monomeric by reducing and denaturing SDS-PAGE;
the Western blot in Figure 1.19 suggests that some OrfYH6 dimer was detected in the
purified fraction. ESI-MS data supported the prediction of an N-terminally processed
protein; however further work needs to be performed in isolating OrfYH6 in the
periplasm so the identity of the cysteine residues (oxidized or reduced) and why the
dimer is visible by reducing SDS-PAGE can be elucidated. Current hypotheses are that
OrfYH6 may contain disulfide bonds or that it could be involved in binding iron for ironsulfur cluster biogenesis due to the proximity of bolA and grx (Chapter 4). The dimer
was also detected by Western blot in the periplasmic OrfYH6 isolation prep 6 (Figure
1.25) and potentially rules out the disulfide hypothesis since the dimer subunits would
become monomeric in reducing SDS-PAGE sample buffer. Conclusions cannot be
drawn at this time for the oxidized or reduced states of the cysteines within OrfYH6 from
tandem-MS and MAL-PEG alkylation data. Optimization for the enrichment of the
periplasmic OrfYH6 dimer should consider the possibility of the C-term His-tags being
buried upon dimer formation as no signal at ~ 25 kDa was detected by Western blot in
the Ni-NTA resin elution fraction (Figure 1.25).
Tagged FS proteins (H6PurS, H6PurL, and PurLH6) have been isolated except for
H6PurQ which was found to be insoluble like the untagged protein. None of the
untagged AaFS proteins were isolated, but some preliminary work was done for the
ammonium sulfate fractionation of PurS (pJK533).
Further work will have to be performed on the co-purification of the AaFS
complex. Preliminary results suggest that the PurSQL complex may not require
metabolites (ATP, ADP, and/or glutamine) to assemble; however due to the low amount
of starting recombinant protein, protein expression for the pJK606 construct may have to
be optimized. Enzymatic characterization of the active AaFS complex may be performed
in a ΔpurL BL21(DE3) strain as an alternative to purifying the complex; however
determination of the subunit stoichiometry will require purification. PurQ insolubility
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will make the purification of the individual subunit difficult and unlike BsFS, the
presence of PurL does not drive PurQ into the soluble fraction significantly [7].
Functional complementation studies (Chapter 2) have determined that functional AaFS is
composed of PurS, PurQ, and PurL, although the stoichiometry of the subunits is still
unknown. If enough AaFS can be co-purified, gel filtration or Edman degradation and
crystallization could be performed to define the subunit composition stoichiometry of
AaFS.
Anti-OrfYH6 and anti-PurLH6 antibodies were generated and will be useful to
detect OrfY and PurL in A. aceti crude lysates, where their expression levels may be low,
depending on the culture conditions, which have yet to be developed for A. aceti
(preliminary work in Chapter 5). For Westerns, the final dilutions for probing were
1:10,000 for the anti-OrfYH6 and 1:20,000 for the anti-PurLH6 antibodies. The
antibodies could also be used for immunoprecipitation of any interacting partners (for
example, OrfYH6 as an iron-sulfur chaperone would interact with iron-sulfur cluster
target proteins).

1.5
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CHAPTER 2. FUNCTIONAL COMPLEMENTATION STUDIES OF AAFS

2.1

Introduction

Previous characterizations of FS have revealed the existence of a complex of
single domain proteins versus one large multi-domain protein, both of which are able to
catalyze the same reaction, the conversion of FGAR, ATP, and L-Gln to FGAM, ADP, P ,
i

and L-Glu [1-7]. Gene cluster alignments suggest that AaFS is composed of PurS, PurQ
and PurL (Chapter 1); however the presence of orfY is unexpected. OrfY can be found in
the genomes of other α-proteobacteria but to date, there are no characterized OrfY
orthologs. This chapter focuses on functional complementation studies of the AaFS
genes in a ΔpurL E. coli strain.
2.2

Materials and Methods

Materials
All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the
highest purity unless otherwise noted. E. coli Keio JW2541 (ΔpurL::kanR) and parent
(wild-type) BW25113 strains were obtained from the Keio Collection [8]. pET vectors
were from Novagen and oligodeoxynucleotides (ODNs) were from IDT.
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Table 2.1 Oligodeoxynucleotides used in this chapter.
ODN
2146
2147
2154
2155
a

Sequence (5'=>3')a
GTTCGTAATCCAGGCCAAAA
ATGCTAACCGAGGGGAAGTT
CTGTATTTTCAGGGCGGATCtATGATGGAAATTCTGCGTG
CACGCAGAATTTCCATCATaGATCCGCCCTGAAAATACAG

Letters shown in lower case code for mutagenesis.

Table 2.2 Plasmids used in this chapter .
a

pJK

Vector

Description

Source

530

pET23d

orfYH6

Chapter 1

531

pET23d

orfY

Chapter 1

532

pET28a

purQ (silA63)

Chapter 1

533

pET23d

purS

Chapter 1

539

pET23a

purL

Chapter 1

543

pCDF-Duet purS and purL

Chapter 1

544

pCDF-Duet purS

Chapter 1

546

pET-Duet

orfY

Chapter 1

548

pET-Duet

orfY and purQ

Chapter 1

549
555

pCDF-Duet purL
pET23a

Chapter 1

purQ

Chapter 1

556

pET22bHT EcH6purLb

567

pCDF-Duet orfY

598
599
605
606
610
623
674
NA

pET23a
pET23a
pET23a
pET23a
pET23a
pET23a

This study
Chapter 1

purS-orfY-purQ-purL

a

purS-orfY-purQ-purLH6
purS-purQ-purL

a

purS-purQ-purLH6
purQ-purL

Chapter 1
a

Chapter 1
a

a

orfY-purQ-purL

Chapter 1
Chapter 1

a

pET22bHT EcH6purL2
pCP20

Chapter 1

FLP recombinase

Chapter 1
[9]
[8]

a

Hyphens indicate overlapping genes (as in the native A. aceti sequence). bEc indicates
the E. coli gene. NA - not applicable
Media were supplemented with antibiotics in the final concentrations as follows: Amp
(ampicillin, 100 ug/mL) for overnight cultures or Cb (carbenicillin, 100 ug/mL) for longterm cultures; Kan (kanymycin, 70 ug/mL); streptomycin (50 ug/mL).
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Repaired E. coli H6purL construct plasmid pJK556. QuikChange mutagenesis (Qiagen)
was performed on pJK674 [9] to repair a frame shift mutation using ODNs 2154 and
2155.
Preparation of competent cells. Keio JW2541 cells were made competent for
transformation as previously described [10].
Keio strain JW2541 kanamycin cassette pop-out. The kanamycin cassette was removed
by homologous recombination as previously described [11] by transforming pCP20 [12]
into the strain of interest. In short, pCP20-transformed JW2541 cells were plated and
grown for 42 hrs at room temperature on LB-Amp. The pCP20 plasmid was obtained
from Charles Constantine’s -20°C box and no glycerol stocks were made from the
intermediate strains. A single colony was picked to inoculate a 5 mL LB culture (no
antibiotics) and grown for 4 hrs at 42°C to induce expression of FLP [12]. After making
a 1:1000 dilution, 50 uL of cells were plated on LB, LB-Amp, and LB-Kan, to test for
loss of antibiotic resistance and of the plasmid. The plates were incubated at 42°C
overnight. To further confirm loss of the kanamycin cassette to generate Keio JW2541
KanS, colony PCR was performed on colonies from the LB plate using ODNs 2146 and
2147.
Complementation on M9 minimal medium. Procedure adapted from [13, 14]. Keio
JW2541 KanR and KanS were transformed with pET23a, AaFS plasmids, or pJK674 [9].
For growth on solid M9 medium, a single colony was used to inoculate a 5 mL LB
culture and grown at 37°C to OD600 ~ 0.5 (~3 hr). Cultures were diluted to a final OD600
of 0.0005 and 50 uL was plated on M9 agar plates supplemented with
antibiotic(s)/thiamin or antibiotic(s)/thiamin/hypoxanthine (10 uM thiamin and 1.5
ug/mL hypoxanthine final). Antibiotics are listed in Table 2.3. For growth in liquid M9
medium, single colony was used to inoculate a 5-mL LB culture and grown at 37°C to
OD600 ~ 0.5 (~3 hr). Cells were harvested at 4,000 rpm, 10 min and washed with M9
medium. 250 mL Klett flasks containing 50 mL of M9 minimal medium (supplemented
with thiamin or thiamin and hypoxanthine) were inoculated to a final OD600 of 0.005.
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The cultures were grown at 37°C (200 rpm) and growth was monitored using a KlettSummerson colorimeter (blue filter #42, spectral range 400-465 nm). No other filter was
available at the time.
Table 2.3 Antibiotic list used in the M9 medium.
Antibiotics
Plasmid(s)
JW2541 Kan Cb
Stm
R
No plasmid
Kan
+
R
pET23a (Empty Vector, EV)
Kan
+
+
S
544 (purS) + 531 (orfY)
Kan
+
+
S
544 (purS) + 532 (purQ)
Kan
+
+
S
543 (purS and purL)
Kan
+
S
548 (orfY and purQ)
Kan
+
R
530 (orfY) + 549 (purL)
Kan
+
+
+
R
532 (H6purQ) + 549 (purL)
Kan
+
+
S
544 (purS) + 548 (orfY and purQ)
Kan
+
+
S
543 (purS and purL )+ 531 (orfY)
Kan
+
+
S
548 (orfY and purQ) + 549 (purL)
Kan
+
+
S
532 (H6purQ) + 543 (purS + purL)
Kan
+
+
R
543 (purS and purL) + 548 (orfY and purQ)
Kan
+
+
+
R
539 (purL)
Kan
+
S
533 (purS)
Kan
+
S
531 (orfY)
Kan
+
S
532 (H6purQ)
Kan
+
R
S
+ denotes use, - omission. resistant, sensitive.
Complementation on MOPS minimal medium. Growth medium was prepared as
previously described [15, 16]. The M9 protocol was followed as described above using
JW2541 Kan but 1X MOPS was used to wash the cells twice. For the second liquid
S

complementation (8 hr intervals), the green filter #54 (spectral range 500-570 nm) was
used for a closer approximation to typical O.D.600 nm readings. All media were
supplemented with Amp or Cb since only overlapping gene constructs for AaFS genes
were used (Table 2.2).
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96-well plate format (MOPS). Nina Serratore helped with setting up a 96-well plate
growth assay on the Briggs lab Biotek Synergy 4 heated microplate reader. Each well
contained 150 uL of media (n=3 for each strain ± hypoxanthine) and 2xMOPS-washed
cells were used to inoculate the wells to a final O.D.600 nm of 0.005. The plate that was
used was a sample from MidSci (Brandplates pureGrade S, Ref. 781660, U-bottom).
(R)

The instrument parameters were for a Grainer 96 round bottom plate, set point
temperature of 37°C, shake: fast (continuously), (A) 600 nm, and read every 2 hrs. Blank
and WT wells did not contain any carbenicillin; however all wells contained thiamin.
Unused wells were filled with 150 uL sterile water and the sides of the plate were
parafilmed to minimize evaporation effects.

2.3

Results and Discussion

Complementation in M9. Keio JW2541 Kan and Kan were used for the
S

R

complementation on M9 medium (solid or liquid). Since 2 different strains were used
those results were not comparable. Additionally the cells were not washed so some
growth was observed on all plates, even on the negative control, pET23a. Despite those
mistakes, the major trend was that the addition of thiamin and hypoxanthine helped
growth. Studies of liquid cultures would better resolve the differences between growth
phases better in the different constructs (e.g. lag phase). Klett flasks were used in order
to minimize contamination opportunities as the flasks do not need to be open to take
aliquots for turbidity readings. In the liquid cultures, pJK674 [9], which was used as a
positive control, did not complement as well as expected (data not shown), and
sequencing revealed a base insertion at position 51 (right after the N-term His-tag),
multiple silent mutations (G729, G761, G769, L770, S803, V811, P817, A1043, V1044,
and V1223), and a N869E missense mutation, the latter which seems to be located on the
surface of the protein (based on the Salmonella typhimurium PurL structure (PDB: 1T3T
[6]). The frame-shift was repaired by site-directed mutagenesis to yield pJK556. It is
important to note that the wild type E. coli BW25113 strain was not tested on M9
medium.
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Complementation in MOPS Minimal Medium. The recipe for M9 does not contain metal
supplements (i.e. iron) whose presence may be necessary for growth so MOPS minimal
medium [15] was chosen. Figure 2.1 shows the preliminary MOPS growth curves.
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Figure 2.1 Preliminary MOPS growth curves.
Constructs used were pET23a (empty vector, EV), pJK556 (EcH6L, labeled EcL);
pJK539 (AaL); pJK598 (SYQL); pJK599 (SYQLH6); pJK605 (SQL); and pJK606
(SQLH6).
The E. coli H6PurL (pJK556) successfully complemented the deletion strain in the
thiamin only medium. Cells transformed with the empty vector pET23a showed poor
growth in thiamin only medium (the curve is hidden underneath AaL, A. aceti PurL
alone), but it should be noted that the culture touched the foil lid at 48 hours therefore
time points thereafter were omitted due to possible contamination. Cells carrying the
PurS-PurQ-PurL (SQL) construct grew as well if not better than the E. coli H6PurL. A.
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aceti PurL showed very poor complementation. The presence of the C-term His tag on
PurL did not affect its ability to complement the purL deletion in JW2541 for the
constructs containing PurS-PurQ-PurL (SQL) and PurS-OrfY-PurQ-PurL (SYQL). It is
important to note that the wild type E. coli BW25113 strain was not tested here.
Functional AaFS seems to be composed of PurS, PurQ, and PurL as the SQL and
EcH6PurL lag phases were very similar. The stoichiometry of the subunits required for a
functional AaFS complex cannot be determined from these functional complementation
studies. The presence of OrfY seems to delay reaching stationary phase and is not
necessary for FS complementation as observed by the growth of SQL being similar to
that of E. coli H6PurL. The presence of a His-tag at the C-term of AaPurL does not seem
to affect complex formation and complementation ability. The observed growth of AaL
after 64 hrs may be due to high enough concentrations of free ammonia in the medium.
Previous B. subtilis in vitro characterization determined that small PurL had 50-fold less
activity when enough ammonia was in the assay buffer compared to PurL complexed
with PurS and PurQ [2].
The growth curves were repeated once the QL and YQL constructs were obtained (pJK
610 and pJK 623, respectively), with monitoring at 8 hr intervals in MOPS minimal
medium are summarized in Figure 2.2 (error bars included) and Figure 2.3 (error bars
omitted). Figures 2.4 and 2.5 show the unaveraged curves for each strain. It is important
to note that the wild type E. coli BW25113 strain did not grow when monitored for 80 hrs
in thiamin or thiamin and hypoxanthine-supplemented MOPS medium (one biological
replicate, data not shown).
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Figure 2.2 Functional complementation of AaFS proteins in JW2541 Kan in MOPS
minimal medium including error bars.
S

Biological replicates were n = 3. Constructs used were pET23a (EV), pJK556 (EcH6L);
pJK539 (AaL); pJK598 (SYQL); pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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Figure 2.3 Functional complementation of AaFS proteins in JW2541 Kan in MOPS
minimal medium excluding error bars.
S

Biological replicates were n = 3. Constructs used were pET23a (EV), pJK556 (EcH6L);
pJK539 (AaL); pJK598 (SYQL); pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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Figure 2.4 Unaveraged curves for JW2541 Kan in MOPS minimal medium with thiamin.
S

Constructs used were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL);
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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Figure 2.5 Unaveraged curves for JW2541 Kan in MOPS minimal medium with thiamin
and hypoxanthine.
S

Constructs used were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL);
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
As previously observed, SQL grew similarly if not better than EcH6L. SYQL showed a
slight lag in growth when compared to SQL and EcH6PurL. The QL construct showed a
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significant delay in the lag phase and the EV curve surprisingly mirrored the QL growth
profile, where growth was not expected. Upon disposal, cultures smelled sweet therefore
growth observed after 72 hrs may not have been solely E. coli JW2541. Cells containing
YQL did not grow much at all and an unpredictable growth pattern was observed for AaL
(one culture did not grow at all, the second started at 72 hrs, and the third at 96 hrs).
A higher concentration of hypoxanthine may have to be supplemented as cultures
containing nonfunctional AaFS constructs (i.e. AaL, YQL, and EV) could not grow past a
Klett reading of 100 (O.D.

600 nm

equivalents still have not been determined experimentally -

the Klett meter manual suggests the use of R = 1000 x D / 2 for conversion, where R:
Klett reading; D: optical density, so 100 Klett units would correspond to 0.2 O.D.
according to the formula). The other strains thrived as they carried the right combination
of AaFS genes to make up active AaFS.
Use of the green filter (#54, spectral range 500-570 nm) rather than the blue filter
(#42, spectral range 400-465 nm) on the Klett meter gave lower readings likely due to the
absorbance of compounds (i.e. flavins) in the blue filter range. When the Klett meters
were first obtained from Vic Rodwell, no other filters other than the blue one were
available.
96-well plate MOPS complementation. The 8-hr interval readings used previously were
too far apart to monitor the lag phase. Nina Serratore (Briggs laboratory) had been using
a heated microplate reader for growth curves so experimental parameters were designed
according to her experience. 150 uL of MOPS minimal medium were inoculated at a
starting O.D.

600 nm

and monitored every two hours (n = 3). Figures 2.6 through 2.8 show

the averaged curves with and without error bars and the unaveraged curves, respectively.
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Figure 2.6 Averaged curves for the 96-well plate complementation with error bars for
BW25113 (WT) and JW2541 Kan in MOPS + thiamin.
S

Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL);
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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Figure 2.7 Averaged curves for the 96-well plate complementation without error bars for
BW25113 (WT) and JW2541 Kan in MOPS + thiamin.
S

Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL);
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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Figure 2.8 Unaveraged curves for the 96-well plate complementation for BW25113 (WT)
and JW2541 Kan in MOPS + thiamin or MOPS + thiamin + hypoxanthine.
S

Constructs were pET23a (EV), pJK556 (EcH6L); pJK539 (AaL); pJK598 (SYQL);
pJK605 (SQL); pJK610 (QL); and pJK623 (YQL).
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The WT strain (BW25113) grew the best out of all of the strains tested and reached a
maximum O.D.

600 nm

of ~ 1.2 (Figures 2.6-2.8). No other strain was able to reach that high

of an O.D. thus indicating that the leakiness of the pET constructs was not enough to
complement the purL deletion. JW2541 may have to have the genes of interest inserted
into the genome for full complementation of the purL deletion.
No contamination was observed in the blanks over the course of 70 hrs (Figure 8,
± hypoxanthine). Some of the curves suddenly dipped in the middle of the growth (i.e.
MOPS+Thiamin EcH6L), showed biphasic growth (i.e. MOPS+Thiamin SYQL and
MOPS+Thiamin+Hypoxanthine QL), or suddenly dropped and stabilized (i.e.
MOPS+Thiamin EV, AaL, SQL) (Figure 2.8). Nina Serratore did not observe any
anomalies in her yeast growth curves but Luyen Nguyen and Michael Melesse mentioned
some inconsistencies in theirs (i.e. the instrument appeared to reset itself in the middle of
a run for random wells and at random times). Although, this experiment should be
repeated when the instrument issues are fixed, the same general trends observed in the
100 mL scale were seen in the 96-well plate format (Figures 2.6 and 2.7): SQL entered
the lag phase sooner than EcH6L and the latter grew better than SYQL. A delay in lag
phase was observed for EV, AaL, and QL (Figures 2.6-2.8). Growth of the YQL strain
was not observed in the 100 mL scale however, in the 150 uL scale, a variable delay in
entering the lag phase was observed at 20, 30, 40 hrs for no hypoxanthine and 0, 20, 30
hrs for + hypoxanthine (Figure 2.8, ± hypoxanthine). No growth was observed in two out
of the three hypoxanthine SQL replicates even though those wells were inoculated. It is
still unclear why cells cannot grow to as high of a density as the wild type in the presence
of hypoxanthine.
The 150 uL 96-well plate scale with starting O.D.

600 nm

of 0.005 seemed to work

well for monitoring the functional complementation of AaFS genes in JW2541. All
unused wells should be filled with water or fresh media to minimize evaporation, as
recommended by Nina Serratore. Saturation of the WT strain was observed after 16 hrs
and the slowest growing strain, EV, after 40 hrs (Figure 2.8), so the experiment could be
done in 3 days or less.
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2.4

Conclusion

OrfY is not required for AaFS activity and active AaFS is composed of PurS,
PurQ, and PurL (Figure 2.4), although the stoichiometry of the subunits cannot be
determined at this time. PurS does not seem necessary when PurQ and PurL are present,
but there is a significant delay in growth (unless cultures were contaminated), which may
indicate that similarly to TmFS, PurS may contribute to an ammonia channel that links
the glutaminase and FGAR synthetase active sites [3, 4]. The A. aceti PurS-PurQ-PurL
(SQL) construct was observed to complement as well, if not better, than E. coli H6PurL.
Other combinations of the AaFS genes showed a significant delay in entering the lag
phase. Although the wild type strain, BW25113, did not grow at the 100 mL scale (n =
1), it did grow in the 150 uL (96-well plate) format (n = 3). The same general trends for
SQL, SYQL, and EcH6L were observed despite instrument issues. Surprisingly, YQL
growth was observed at the 150 uL scale, but with a significant delay when compared to
WT and SQL. It is still unclear why the different strains do not grow to the same density.
One suggestion is to insert the genes of interest in JW2541 to test if they can complement
the purL deletion.
The presence of OrfY was observed to cause a slight delay in the lag phase when
the other three AaFS genes (PurS, PurQ, and PurL) were present, but no growth was
observed in the OrfY-PurQ-PurL (YQL)-carrying strain. Taken together with the protein
overexpression studies (Chapter 1), OrfY may have a regulatory role on PurQ (and
potentially PurL) and be involved in iron-sulfur biosynthesis due to the proximity of bolA
and grx genes (Chapter 4).
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CHAPTER 3. CONSTRUCTION GENERATION AND ENZYME PURIFICATION
FOR FGAR SYNTHESIS

3.1

Introduction

Formylglycinamide ribonucleotide (FGAR), the FGAM synthetase (FS) substrate,
cannot be chemically synthesized, therefore constructs for the de novo purine enzymes
were obtained from E. coli, where they have been extensively characterized. The de novo
purine biosynthetic pathway begins with phosphoribosylpyrophosphate (PRPP) (Figure
3.1). Since PRPP is expensive and unstable, the synthesis will start with ribose-5phosphate (R5P).
R5P
ATP

PrsA

PurF

PRPP
AMP

=

L-Gln

X

NTP
ckmT

Y

NDP

PurD

PRA
L-Glu
PPi

ATP
Gly

Creatine
Creatine phosphate
ADP

PurT

GAR
ADP
Pi

=

ATP
formate

X

Gln

Y

Glu

glnA

FGAR
ADP
Pi

NH3
ADP
ATP

plsA

NMP

ATP

Figure 3.1 FGAR biosynthesis schema (modified from [1]).
Legend for substrates/products: R5P, ribose-5-phosphate; PRPP,
phosphoribosylpyrophosphate; PRA, phosphoribosylamine; GAR, glycinamide
ribonucleotide; FGAR, formylglycinamide ribonucleotide. Recycling systems are
denoted by the red (ATP regeneration) and blue circles (glutamine regeneration). NTP,
NDP, and NMP would have adenosine as the base.
E. coli FS will be used to monitor successful FGAR synthesis via the Bratton-Marshall
assay by coupling the reaction with PurM.
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3.2

Materials and Methods

Materials
All materials were from Sigma Aldrich or Fisher Scientific and of the highest purity
unless otherwise noted. Vent DNA polymerase, OneTaq polymerase, all restriction
endonucleases, T4 DNA ligase, and T4 polynucleotide kinase were from New England
Biolabs. Phusion Hot Start polymerase was from Finnzymes. GoTaq polymerase and
deoxynucleotides (dATP, dGTP, dCTP, and dTTP) were from Promega. Mutagenesis
was performed using QuikChange Mutagenesis kits from Stratagene (Pfu Polymerase).
Oligodeoxynucleotides (ODNs) were from Integrated DNA Technologies (Table 1).
Plasmid Miniprep kits were from either Sigma, Fermentas Life Sciences, or Qiagen.
QIAquick PCR Purification kit was from Qiagen. Chemically competent DH5α cells
were from Invitrogen. Vectors pET23a and pET28a were from Novagen. Centrifugation
steps were performed on a tabletop Eppendorf 5415D centrifuge. PCR reactions were
performed in a Bio-Rad MyCycler Thermal Cycler or a MJ Research Inc. Programmable
Thermal Cycler PTC-100.
Table 3.1 Oligodeoxynucleotides used in construction of plasmids and sequencing.

a

ODN
2197
2218
2219
2224
2225
2226
2295
2296
2332
2333
2334

Sequence (5'=>3')a
ACCTGTGGATCCCATATGTGCGGTATT
CTACGCTCGAGACTTCCTTCGTTATGCATTTCGAGATTTTCC
GGATATACCATGGCTAAAATCGTCGCCTGTA
GTGGTGCTCGAGTGAGTTCTGCTCGCGTTCGATAG
GTGGTGCTCGAGTGAGTCAAACAGGGAGGAAA
GTGGTGCTCGAGTCAGTCAAACAGGGAGGAAA
CACGCGTTTTCAcCGTTGGCATTGAG
CTCAATGCCAACGgTGAAAACGCGTG
AGTTCCCATATGTCCGCTGAACAC
CTGCTTCTCGAGTTAGACGCTGTAGTA
ATAGTGCTCGAGTCATCCTTCGTTATGC

Letters shown in lower case code for mutagenesis.

Methods
General cloning procedure. Each recombinant gene was amplified by PCR with genespecific primers (Table 1) from Escherichia coli BL21(DE3) genomic DNA, Acetobacter
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aceti 1023 genomic DNA, or plasmid DNA as specified below. E. coli BL21(DE3)
genomic DNA was isolated using the Promega Wizard Genomic DNA Purification kit
according to the manufacturer’s instructions. A. aceti 1023 genomic DNA was isolated
using the Qiagen Genomic-tip 20/G (E. A. Mullins). E. coli DH5α was used for cloning
and plasmid maintenance. All constructs were screened by restriction mapping or colony
PCR. All numbered plasmids were verified by DNA sequencing at the Genomics Core
Facility DNA Sequencing Low Throughput Laboratory at Purdue University, using
primers for both directions.
Table 3.2 Plasmids used in this chaptera.
pJK
Vector
Description
b
515
pET23a
EcpurTH6
556
pET22bHT EcH6purLb
592
pET23a
EcpurDb
614
pET23a
EcpurDH6b
621
pET28a
EcH6purDb
630
pET23d
AaprsAa
631
pET23d
AaprsAH6a
633
pET22b
EcH6purMb
638
pET23a
EcT7purFH6b
639
pET23a
EcpurFH6b
642
pET28a
EcH6glnAb
649
pET23a
EcpurFb
650
pET23a
EcglnAb
668
pET22bHT EcH6glnAb
669
pET22bHT EcH6plsAb
670
pET22bHT EcH6prsAb
673
pET22bHT EcH6purFb
675
pET22bHT EcH6purM G324Eb
a
Aa indicates the A. aceti gene. bEc indicates the E. coli gene.

Source
TJK
Ch. 2
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
[1]
[1]
[1]
[1]
[1]

Construction of E. coli intermediate T7-tagpurFH6 construct plasmid pJK638. A 1.5 kb
product was amplified from E. coli BL21(DE3) genomic DNA, using Taq Polymerase
from the Chapple laboratory (Purdue University) and ODNs 2197 and 2218 with an
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annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s,
and 1 min 30 s for 25 cycles. The product was purified using a Qiagen PCR purification
kit, digested with BamHI and XhoI, and ligated into the BamHI and XhoI restriction sites
of the destination vector pET23a to yield pJK638. The plasmid encodes for E. coli T7tagPurFH6.
Construction of E. coli PurFH6 construct plasmid pJK639. pJK638 was partially
digested with NdeI due to an additional internal NdeI site within the purF sequence
where the reaction was stopped after 10 min by the addition of EDTA. After using the
Qiagen PCR purification kit, the digested DNA was re-ligated and digested with BamHI
before transforming the reaction into DH5α cells. The plasmid, pJK639, encodes for E.
coli PurFH6.
Construction of E. coli purF construct plasmid pJK649. A 1.5 kb product was amplified
from pJK639, using Vent Polymerase (New England Biolabs) and ODNs 2197 and 2334
with an annealing temperature of 50°C and melting, annealing, and extension times of 30
s, 1 min, and 1 min 30 s for 25 cycles. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and XhoI. Digestion with NdeI was limited to 5 min
where the reaction was stopped by the addition of EDTA. The digested PCR product was
re-purified using a Qiagen PCR purification kit and ligated into the NdeI and XhoI
restriction sites of the destination vector pET23a to yield pJK649. The plasmid encodes
for E. coli PurF.
Construction of E. coli purD construct plasmid pJK592. A 1.3 kb product was amplified
from BL21(DE3) genomic DNA, using ODNs 2222 and 2223 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 1min
30 s for 25 cycles using Vent polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NdeI and XhoI, and ligated into the NdeI and XhoI
restriction sites of the destination vector pET23a to yield pJK592. The plasmid encodes
for E. coli PurD.
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Construction of E. coli purDH6 construct plasmid pJK614. A 1.3 kb product was
amplified from BL21(DE3) genomic DNA, using ODNs 2222 and 2224 with an
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s,
and 1min 30 s for 25 cycles using Vent polymerase. The product was purified using a
Qiagen PCR purification kit, digested with NdeI and XhoI, and ligated into the NdeI and
XhoI restriction sites of the destination vector pET23a to yield pJK614. The plasmid
encodes for E. coli PurDH6.
Construction of E. coli H6purD construct plasmid pJK621. pJK592 was digested with
NdeI and XhoI and ligated into the NdeI and XhoI restriction sites of the destination
vector pET28a to yield pJK621. The plasmid encodes for E. coli H6PurD.
Construction of A. aceti prsA construct plasmid pJK630. A 0.9 kb product was amplified
from A. aceti strain 1023 genomic DNA, using ODNs 2219 and 2226 with an annealing
temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s, and 30 s
for 25 cycles using Phusion polymerase. The product was purified using a Qiagen PCR
purification kit, digested with NcoI and XhoI, and ligated into the NcoI and XhoI
restriction sites of the destination vector pET23d to yield pJK630. The plasmid encodes
for A. aceti PrsA.
Construction of A. aceti prsAH6 construct plasmid pJK631. A 0.9 kb product was
amplified from A. aceti strain 1023 genomic DNA, using ODNs 2219 and 2225 with an
annealing temperature of 55°C and melting, annealing, and extension times of 20 s, 30 s,
and 30 s for 25 cycles using Phusion polymerase. The product was purified using a
Qiagen PCR purification kit, digested with NcoI and XhoI, and ligated into the NcoI and
XhoI restriction sites of the destination vector pET23d to yield pJK631. The plasmid
encodes for A. aceti PrsAH6.
Repair of E. coli purM construct plasmid pJK633. QuikChange mutagenesis was
performed on pJK675 [1] to repair a G324E mutation using ODNs 2295 and 2296.
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Construction of E. coli H6glnA construct plasmid pJK642. A 1.5 kb product was
amplified from pJK668 using Vent Polymerase (New England Biolabs) and ODNs 2332
and 2333 with an annealing temperature of 50°C and melting, annealing, and extension
times of 30 s, 1 min, and 1 min 30 s for 25 cycles. The product was purified using a
Qiagen PCR purification kit, digested with NdeI and XhoI, and ligated into the NdeI and
XhoI restriction sites of the destination vector pET28a to yield pJK642. The plasmid
encodes for E. coli H6GlnA Y397F.
Construction of E. coli glnA construct plasmid pJK650. pJK642 was digested with NdeI
and XhoI and ligated into the NdeI and XhoI sites of the destination vector pET23a to
yield pJK650. The plasmid encodes for E. coli GlnA Y397F.
Protein expression and purification
Underlined headers indicate the final purification protocol. Antibiotics were used as
follows: Amp (ampicillin, 100 ug/mL) and Kan (kanamycin, 70 ug/mL).
PurF
E. coli H6PurF (pJK673 [1]). Protocol adapted from Schultheisz et. al [1]. A single
colony of BL21 (DE3) cells transformed with pJK673 [1] was used to inoculate a 50 mL
LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L of ZYM-5052Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200 rpm). Cells
were harvested (5,000g, 15 min) and used immediately or stored at -80°C until use. All
the following steps were performed at 4°C. The cell pellet was resuspended in 40 mL of
50 mM Tris-HCl pH 7.5, 250 mM NaCl and disrupted by sonication using a Fisher Sonic
Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell debris was
removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was
added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun
(30,000g, 10 min). The cleared lysate was loaded onto a nickel-charged and equilibrated
(in 50 mM Tris-HCl pH 7.5, 250 mM NaCl) Ni-NTA agarose column (1.5 cm x 1.5 cm,
2.7 mL) and washed with 10x column volumes of the above buffer with 20 mM
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imidazole. The protein was eluted using 250 mM imidazole in the above buffer. Since
the protein is catalytically inactive, it was discarded.
E. coli PurFH6 (pJK639). BL21(DE3) cells transformed with pJK639 were used to
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L
of ZYM-5052-Amp [2] was inoculated 1:100 from a starter culture and grown overnight
(37°C, 200 rpm). The following steps were performed at 4°C. Cells were harvested
(5,000g, 15 min) and used immediately or stored at -80°. All the following steps were
performed at 4°C. The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (5
mL/g pellet) and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output
using a Fisher Sonic Dismembrator. Cell debris was removed by centrifugation (30,000g,
30 min). Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1%
and the lysate was cleared by centrifugation (30,000g for 10 min). The cleared lysate
was loaded onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and
charged Ni-NTA column (1.5 cm x 4.4 cm, 7.8 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM phosphate buffer pH 7.5. A linear
imidazole gradient (10-500 mM in 50 mM phosphate buffer pH 7.5) was used to elute the
protein (20 mL x 20 mL). Fractions containing pure protein by SDS-PAGE were pooled
and the protein was concentrated to 19.1 mg/mL using an an Amicon ultrafiltration 8050
cell with a Millipore PL-30 membrane. Isolated PurFH6 was stored at -80°C.
E. coli PurF (pJK649). Protocol adapted from [3, 4]. In short, BL21(DE3) cells
transformed with pJK649 were used to inoculate a 50 mL LB-Amp starter culture and
grown to saturation (37°C, 200 rpm). 2 L of LB-Amp were inoculated 1:100 from a
starter culture and grown overnight (37°C, 200 rpm). The following steps were
performed at 4°C. Cells were harvested (5,000g, 15 min) and used immediately or stored
at -80°. All the following steps were performed at 4°C. The cell pellet was resuspended
in Buffer A (50 mM Tris-HCl pH 7.5, 1 mM EDTA, 5 mM MgCl2, and 1 mM glutamine
(3.5 mL/g pellet)) and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25%
output using a Fisher Sonic Dismembrator. Cell debris was removed by centrifugation
(30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was added to a final
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concentration of 1% and the lysate was cleared by centrifugation (30,000g for 10 min).
The cleared lysate was loaded onto a previously equilibrated (in Buffer A) DEAESepharose CL6B column (2.5 x 14.5 cm, 71.2 mL) and the column was washed with 250
mL Buffer A. A linear ammonium sulfate gradient (0.14-0.3 M in Buffer A) was used to
elute the protein (200 mL x 200 mL). Fractions containing activity were pooled and 28.3
mg protein was concentrated to 10.1 mg/mL using an an Amicon ultrafiltration 8050 cell
with a Millipore PL-30 membrane in 57.5 mM Tris-HCl pH 7.5. Glycerol was added to a
final concentration of 15%. Isolated E. coli PurF was stored at -80°C.
E. coli PurD.
E. coli PurD (pJK592) Prep 1. Protocol adapted from [5]. BL21(DE3) cells transformed
with pJK592 were used to inoculate a 50 mL LB-Amp starter culture and grown to
saturation (37°C, 200 rpm). 1 L of ZYM-5052-Amp medium [2] was inoculated 1:100
and grown overnight (37°C, 200 rpm). Cells were harvested (5,000g, 15 min) and used
immediately or stored at -80°. All the following steps were performed at 4°C. The cell
pellet was resuspended in 50 mM KP pH 7.5, 5 mM β-mercaptoethanol (BME), and 1
i

mM phenylmethanesulfonyl fluoride (PMSF) (5 mL/g pellet) and disrupted by sonication
(3 cycles, 1 min on, 1 min off) at 20-25% output using a Fisher Sonic Dismembrator.
Cell debris was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10%
w/v stock) was added to a final concentration of 1% and the lysate was cleared by
centrifugation (30,000g for 10 min). Ammonium sulfate fractionation was performed as
described previously: 0-33% (196 g/L); 33-65% (214 g/L). The 33-65% ammonium
sulfate pellet was resuspended in a minimal amount of 50 mM KP pH 7.5, 5 mM BME, 1
i

mM PMSF buffer and loaded onto a Sephadex G25 medium column (2.5 cm x 34 cm,
167 mL). The column was developed and fractions containing protein (A

280nm

> 0.2) were

pooled and loaded onto a Whatman DE52 cellulose column (2.5 cm x 29.5 cm, 145 mL).
The DE52 column was washed with 300 mL 50 mM KP pH 7.5, 5 mM BME, 1 mM
i

PMSF buffer before the protein was eluted with a linear gradient (0-300 mM KCl, (300
mL x 300 mL) in 50 mM KP pH 7.5, 5 mM BME, 1 mM PMSF). Fractions were pooled
i

by purity by SDS-PAGE. The protein was concentrated to 6.7 mg/mL and buffer
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exchanged using an Amicon ultrafiltration 8400 cell and a YM-10 membrane. The
isolated protein was discarded due to lack of detectable activity.
E. coli PurD (pJK592) Prep 2. LB-IPTG was used for protein production. 1 L of LBAmp was inoculated 1:25 with a starter culture and grown (37°C, 200 rpm) until an
O.D. ~0.7 was reached. IPTG was then added to a final concentration of 0.4 mM from
600

a 1M stock. The culture was induced for 2.5 hrs at 37°C, and the cells were harvested.
The same protocol as prep 1 was followed except for buffers did not contain PMSF or
BME.
E. coli PurDH6 (pJK614). BL21(DE3) cells transformed with pJK614 were used to
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 2 L
of LB-Amp were inoculated 1:100 from a starter culture and grown overnight (37°C, 200
rpm). The following steps were performed at 4°C. Cells were harvested (5,000g, 15 min)
and used immediately or stored at -80°C. All the following steps were performed at 4°C.
The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (3.5 mL/g pellet) and
disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a Fisher
Sonic Dismembrator. Cell debris was removed by centrifugation (30,000g, 30 min).
Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% and the
lysate was cleared by centrifugation (30,000g for 10 min). The cleared lysate was loaded
onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and charged Ni-NTA
column (1.5 cm x 4.9 cm, 8.7 mL) and the column was washed with 10 column volumes
of 10 mM imidazole in 50 mM phosphate buffer pH 7.5. A linear imidazole gradient (10500 mM) was used to elute the protein (30 mL x 30 mL). Fractions containing pure
protein by SDS-PAGE were pooled and the protein was concentrated to 107 mg/mL
using an an Amicon ultrafiltration 8050 cell with a Millipore YM-10 membrane. Isolated
E. coli PurDH6 was discarded due to low activity.
E. coli H6PurD (pJK621) Prep 1. BL21(DE3) cells transformed with pJK621 were used
to inoculate a 50 mL LB-Kan starter culture and grown to saturation (37°C, 200 rpm). 1
L of LB-Kan were inoculated 1:100 from a starter culture and grown overnight (37°C,
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200 rpm). The following steps were performed at 4°C. Cells were harvested (5,000g, 15
min) and used immediately or stored at -80°. All the following steps were performed at
4°C. The cell pellet was resuspended in 50 mM phosphate buffer pH 7.5 (5 mL/g pellet)
and disrupted by sonication (3 cycles, 1 min on, 1 min off) at 20-25% output using a
Fisher Sonic Dismembrator. Cell debris was removed by centrifugation (30,000g, 30
min). Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1%
and the lysate was cleared by centrifugation (30,000g for 10 min). The cleared lysate
was loaded onto a previously equilibrated (in 50 mM phosphate buffer pH 7.5) and
charged Ni-NTA column (1.5 cm x 4.9 cm, 8.7 mL) and the column was washed with 10
column volumes of 10 mM imidazole in 50 mM phosphate buffer pH 7.5 buffer. A linear
imidazole gradient (10-500 mM in 50 mM phosphate buffer pH 7.5) was used to elute the
protein (25 mL x 25 mL). Fractions containing pure protein by SDS-PAGE were pooled
and the protein (14.4 mg) was concentrated to 2.9 mg/mL using an an Amicon
ultrafiltration 8050 cell with a Millipore PL-30 membrane. Isolated E. coli H6PurD was
not kept.
E. coli H6PurD (pJK621) Prep 2. Same protocol as prep 1 except 1 L ZYM-5052-Kan [2]
was used as the production culture and 1 mM PMSF was added to the buffers. The
isolated protein (117 mg) was concentrated to 14.7 mg/mL and stored at -80°C.
E. coli PurTH6 (pJK515). A C41(DE3) cell pellet grown by T. J. Kappock was
resuspended in 50 mM Tris-HCl pH 8.0 (5 mL/g cell pellet) and disrupted by sonication
using a Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice.
All the following steps were performed at 4°C. Cell debris was removed by
centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was added to a
final concentration of 1% w/v, incubated on ice for 10 min, then spun (30,000g, 10 min).
Ammonium sulfate fractionation was performed by the addition of solid ammonium
sulfate over the course of 30 min and letting the solution equilibrate for another 30 min;
0-25% (144 g/L) and 25-45% (123 g/L). Precipitated protein was cleared by
centrifugation (30,000g, 10 min). The 25-45% pellet was resuspended in a minimal
amount of 50 mM Tris-HCl pH 8.0 and loaded onto a nickel-charged and equilibrated (in
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50 mM Tris-HCl pH 8.0) Ni-NTA agarose column (1.75 cm x 2.2 cm, 5.3 mL) and
washed with 10x column volumes of 10 mM imidazole in 50 mM Tris-HCl pH 8.0. The
protein was eluted using a linear imidazole gradient (10-500 mM in 50 mM Tris-HCl pH
8.0, 30 mL x 30 mL). Fractions containing pure protein by SDS-PAGE were pooled,
concentrated to 36.2 mg/mL (145 mg total), and buffer exchanged into 50 mM Tris-HCl
pH 8.0 using an Amicon Ultra-15 30,000 MWCO centrifugal device (4,000 rpm, 15 min).
Isolated E. coli PurTH6 was stored at -80°C.
E. coli H6PlsA (pJK669) [1]. Protocol adapted from Schultheisz et. al [1]. A single
colony of BL21 (DE3) cells transformed with pJK669 [1] was used to inoculate a 50 mL
LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L of ZYM-5052Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200 rpm). Cells
were harvested (5,000g, 15 min) and used immediately or stored at -80°C until use. All
the following steps were performed at 4°C. The cell pellet was resuspended in 40 mL of
50 mM Tris-HCl pH 7.5, 250 mM NaCl and disrupted by sonication using a Fisher Sonic
Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell debris was
removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was
added to a final concentration of 1% w/v, incubated on ice for 10 min, then spun
(30,000g, 10 min). The cleared lysate was loaded onto a nickel-charged and equilibrated
(in 50 mM Tris-HCl pH 7.5, 250 mM NaCl) Ni-NTA agarose column (1.5 cm x 1.5 cm,
2.7 mL) and washed with 10x column volumes of the above buffer with 20 mM
imidazole. The protein was eluted using 250 mM imidazole in the above buffer.
Fractions containing pure protein by SDS-PAGE were pooled, concentrated to 7.5
mg/mL (37 mg protein total), and buffer exchanged into 50 mM postassium phosphate, 5
mM β-ME, 50% glycerol using an an Amicon ultrafiltration 8050 cell with a Millipore
PL-5 membrane. Isolated E. coli H6PlsA was stored at -20°C.
PrsA
E. coli H6PrsA (pJK670 [1]) prep 1. Same protocol as for the isolation of E. coli H6PlsA
above, using a JM109(DE3) cell pellet grown by T. J. Kappock. The Ni-NTA column
was 1.5 cm x 1.5 cm, 2.7 mL. The protein was discarded due to low yield.
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E. coli H6PrsA (pJK670 [1]) Prep 2. Same protocol as prep 1 but using BL21(DE3) cells
grown in ZYM-5052-Amp [2]. A Millipore YM-10 was used in the Amicon
ultrafiltration 8050 cell. The protein was discarded due to low yield.
E. coli H6PrsA (pJK670 [1]) Prep 3. Protocol adapted from [6]. In short, the BL21(DE3)
cell pellet (ZYM-5052-Amp [2]) was resuspended in 35 mL 50 mM KP , pH 6.9 and
i

disrupted by sonication using a Fisher Sonic Dismembrator at 20-25% output (3 cycles: 1
min on, 1 min off) on ice. Cell debris was removed by centrifugation (30,000g, 30 min).
Streptomycin sulfate (10% w/v stock) was added to a final concentration of 1% w/v,
incubated on ice for 10 min, then spun (30,000g, 10 min). The soluble lysate was heated
to 55°C as follows. The beaker containing lysate was placed in a boiling water bath until
the temperature reached 54°C and transferred to a 55°C water bath for 5 min. The
solution was transferred into an ice cold beaker and chilled for 5 min. Denatured proteins
were removed by centrifugation (13,000g, 20 min). Ammonium sulfate fractionation was
performed as described previously: 0-35% (209 g/L). After centrifugation, the pellet
was resuspended in a minimal amount of 50 mM KP , pH 6.9 buffer. The protein was
i

discarded due to low yield.
E. coli H6PrsA (pJK670 [1]) Prep 4. Protocol adapted from [7]. In short, the BL21(DE3)
cell pellet (ZYM-5052-Amp [2]) was resuspended in 50 mM NaH PO pH 8.0, 1 M NaCl
2

4

(5 mL/g pellet) and disrupted by sonication using a Fisher Sonic Dismembrator at 20-25%
output (3 cycles: 1 min on, 1 min off) on ice. Cell debris was removed by centrifugation
(30,000g, 30 min). The soluble lysate was loaded onto a nickel-charged and equilibrated
Ni-NTA agarose column (in 50 mM NaH PO pH 8.0, 1 M NaCl, 1.5 cm x 1.5 cm, 2.7
2

4

mL) and washed with 10x column volumes of the above buffer with 75 mM imidazole.
The protein was eluted using 75 mM imidazole in the above buffer. Fractions containing
pure protein by SDS-PAGE were pooled, concentrated to 0.2 mg/mL, and buffer
exchanged into 50 mM NaH PO pH 8.0, 400 mM NaCl using an an Amicon
2

4

ultrafiltration 8050 cell with a Millipore YM-10 membrane. The protein was discarded
due to low yield.

90
E. coli H6PrsA (pJK670 [1]) Prep 5. Protocol adapted from [8]. The BL21(DE3) cell
pellet (ZYM-5052-Amp [2]) was resuspended in 50 mM KPi, pH 7.5 (5 mL/g cell pellet)
and disrupted by sonication using a Fisher Sonic Dismembrator at 20-25% output (3
cycles, 1 min on, 1 min off). All the following steps were performed at 4°C. Cell debris
was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock)
was added to a final concentration of 1% and the lysate was cleared by centrifugation
(30,000g,10 min). The streptomycin sulfate pellet was resuspended in a minimal amount
of 50 mM KPi, pH 7.5 and dialyzed overnight against 200 volumes (1 L) of 50 mM KPi,
pH 7.5 (no changes). The dialyzed extract was cleared by centrifugation as above and
loaded onto a previously equilibrated (in 50 mM KPi, pH 7.5) and charged Ni-NTA
column (4.8 cm x 1.5 cm, 8.5 mL). The column was washed with 10 column volumes of
10 mM imidazole in 50 mM KPi, pH 7.5 buffer and the protein was eluted using a linear
10-500 mM imidazole gradient in 50 mM KPi, pH 7.5 (25 mL x 25 mL, 200 drop
fractions). Ammonium sulfate precipitation (0-25%, 144 g/L) was performed on the
flowthrough of the column. The protein was stored as an ammonium sulfate 75% (516
g/L) slurry at 4°C.
A. aceti PrsAH6 (pJK631). pJK631 was expressed in BL21(DE3) using ZYM-5052
(37°C) [2], C41(DE3) using LB-IPTG, and C41(DE3)/pREP4-GroESL using LB-IPTG
as described above.
GlnA
E. coli H6GlnA Y397F (pJK642) Prep 1. BL21(DE3) cells transformed with pJK642
were used to inoculate a 50 mL LB-Kan starter culture and grown to saturation (37°C,
200 rpm). 1 L of ZYM-5052-Kan [2] was inoculated 1:100 from a starter culture and
grown overnight (37°C, 200 rpm). The following steps were performed at 4°C. Cells
were harvested (5,000g, 15 min) and used immediately or stored at -80°. All the
following steps were performed at 4°C. The cell pellet was resuspended in 50 mM TrisHCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication (3 cycles, 1 min on,
1 min off) at 20-25% output using a Fisher Sonic Dismembrator. Cell debris was
removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was
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added to a final concentration of 1% and the lysate was cleared by centrifugation
(30,000g for 10 min). The cleared lysate was loaded onto a previously equilibrated (in 50
mM Tris-HCl pH 8.0, 100 mM KCl) and charged Ni-NTA column (1.5 x 1.5 cm, 2.7 mL)
and the column was washed with 10 column volumes of 10 mM imidazole buffer in 50
mM Tris-HCl pH 8.0, 100 mM KCl. A linear imidazole gradient (10-500 mM in 50 mM
Tris-HCl pH 8.0, 100 mM KCl) was used to elute the protein (5 mL x 5 mL). Fractions
containing pure protein by SDS-PAGE were pooled and the protein was concentrated to
2.8 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore PL-30
membrane. Isolated E. coli H6GlnA Y397F was stored at -80°C.
E. coli H6GlnA Y397F (pJK642) Prep 2. Protocol adapted from [9]. In short,
BL21(DE3) cells transformed with pJK642 were grown and harvested as in prep 1. The
cell pellet was resuspended in 10 mM imidazole, 50 mM MgCl pH 7.0 (3 mL/g pellet)
2

and disrupted as in prep 1. The pH of the soluble lysate was adjusted to pH 5.85 by the
addition of fresh 1 M KOH or 1 M acetic acid and monitored using a pH meter. 1 g of
solid streptomycin sulfate was added for each 100 mL of extract and equilibrated with
mixing on ice. The pH was again adjusted to pH 5.85 following the streptomycin sulfate
equilibration with fresh 1 M KOH or 1 M acetic acid and monitored using a pH meter.
The cleared supernatant (30,000g, 30 min) was brought to 25˚C using a water bath.
ZnSO was added to 1.5 mM [final Zn ] and the solution was incubated at 25˚C for 30
2+

4

min. The precipitated protein was centrifuged (30,000g, 30 min) and the pellet was
washed in half the original volume of cold resuspension buffer (1.5 mL/g original cell
pellet) and centrifuged (30,000g, 30 min). The washed protein pellet was dissolved in 2.5
mM MgCl , 10 mM imidazole, pH 7.0 (1.5 mL/g original cell pellet). Insoluble material
2

was pelleted (12,000g, 15 min). MgCl was added to the supernatant to 50 mM [final
2

MgCl ] and incubated at 25˚C for 30 min with occasional stirring (gradual increase in
2

turbidity over time). The solution was centrifuged (30,000g, 30 min). The pellet was
dissolved in 75% of the volume of the post-12,000g spin in 2.5 mM MgCl , 10 mM
2

imidazole, pH 7.0. Insoluble material was removed by centrifugation (12,000g, 15 min).
The isolation was stopped at this point due to the lack of a visible pellet.
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E. coli GlnA (pJK650). Same protocol as for prep 2 for the isolation of E. coli H6GlnA.
Following the 25˚C Mg crystallization, another MgCl crystallization was repeated at
2+

2

37˚C as previously described [9]. In short, the same procedure as the 25˚C crystallization
was used for the 37˚C crystallization. The protein pellet was resuspended in a minimal
amount of 2.5 mM MgCl , 10 mM imidazole, pH 7.0 buffer and dialyzed overnight in
2

200 volumes (1 L) of 10 mM imidazole, 100 mM KCl, 1 mM MgCl , pH 7.0 and stored at
2

4˚C as previously described [10].
E. coli H6PurL (pJK556). A single colony of BL21(DE3) transformed with pJK556 was
used to inoculate a 50-mL LB-Amp starter culture and grown to saturation (37°C, 200
rpm). 1 L of ZYM-5052-Amp medium [2] was inoculated 1:100 and grown overnight
(37°C, 200 rpm). Cells were harvested (5,000g, 15 min) and stored at -80°C until use.
All the following steps were performed at 4°C. The cell pellet was resuspended in 50
mM Tris-HCl pH 8.0, 100 mM KCl (5 mL/g pellet) and disrupted by sonication using a
Fisher Sonic Dismembrator at 20% output (3 cycles: 1 min on, 1 min off) on ice. Cell
debris was removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v
stock) was added to a final concentration of 1% w/v, incubated on ice for 10 min, then
spun (30,000g, 10 min). The cleared lysate was loaded onto a previously equilibrated (50
mM Tris-HCl pH 8.0, 100 mM KCl) and charged Ni-NTA column (4.9 cm x 1.5 cm, 8.7
mL) and the column was washed with 10 column volumes of 10 mM imidazole buffer in
50 mM Tris-HCl pH 8.0, 100 mM KCl. A linear imidazole gradient (10-500 mM in 50
mM Tris-HCl pH 8.0, 100 mM KCl) was used to elute the protein (20 mL x 20 mL).
Fractions containing pure protein by SDS-PAGE were pooled and the protein was
concentrated to 16.0 mg/mL using an an Amicon ultrafiltration 8050 cell with a Millipore
PL-30 membrane. Isolated E. coli H6PurL was stored at -80°C.
E. coli H6PurM (pJK633). BL21(DE3) cells transformed with pJK633 were used to
inoculate a 50 mL LB-Amp starter culture and grown to saturation (37°C, 200 rpm). 1 L
of ZYM-5052-Amp medium [2] was inoculated 1:100 and grown overnight (37°C, 200
rpm). Cells were harvested (5,000g, 15 min) and used immediately or stored at -80°. All
the following steps were performed at 4°C. The cell pellet was resuspended in 50 mM

93
Tris pH 8.0, 300 mM KCl. (5 mL/g pellet) and disrupted by sonication (3 cycles, 1 min
on, 1 min off) at 20-25% output using a Fisher Sonic Dismembrator. Cell debris was
removed by centrifugation (30,000g, 30 min). Streptomycin sulfate (10% w/v stock) was
added to a final concentration of 1% and the lysate was cleared by centrifugation
(30,000g for 10 min). The cleared lysate was loaded onto a previously equilibrated (in 50
mM Tris pH 8.0, 300 mM KCl) and charged Ni-NTA column (1.5 cm x 4.9 cm, 8.7 mL)
and the column was washed with 5 column volumes of 10 mM imidazole in 50 mM Tris
pH 8.0, 300 mM KCl buffer. A linear imidazole gradient (10-500 mM in 50 mM Tris pH
8.0, 300 mM KCl) was used to elute the protein (15 mL x 15 mL). Fractions containing
pure protein by SDS-PAGE were pooled and the protein was concentrated to 18.6 mg/mL
(136 mg total) using an an Amicon ultrafiltration 8050 cell with a Millipore YM-10
membrane. Isolated E. coli H6PurM was stored at -80°C.
Activity Assays
PurF. The final assay conditions for PurF were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 1
mM magnesium acetate, 2 mM glycine, 2 mM glutamine, 2 mM ATP, 2 mM PEP, 0.2
mM NADH, 15 units/mL LDH/PK mix (Sigma P0294 solution, according to the
manufacturer’s determined activity), 0.5 mM phosphoribosylpyrophosphate (PRPP), 5 U
PurD, and PurF in a final volume of 700 uL. The reaction mix was pre-incubated at 24°C
for 2 min, and the reaction was initiated by the addition of PRPP in a quartz 0.5 mL
cuvette (1 cm pathlength). Enzymatic activity was monitored at 24°C in an Agilent
diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1. No
detectable activity was observed prior to PRPP addition.
PurD. The final assay conditions were 100 mM Tris-HCl (pH 8.0), 50 mM KCl, 1 mM
phosphoenolpyruvate (PEP), 0.2 mM NADH, 15 units/mL each of LDH/PK (Sigma
P0294 solution, according to the manufacturer’s determined activity), 2 mM magnesium
acetate, 1 mM phosphoribosylamine (PRA), 2 mM glycine, 2 mM ATP, and PurD in a
final volume of 700 uL. The reaction mix was pre-incubated at 18°C for 2 min, and the
reaction was initiated by the addition of PRA in a quartz 0.5 mL cuvette (1 cm
pathlength). PRA was prepared as previously described [5]. Enzymatic activity was
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monitored at 18°C in an Agilent diode-array spectrophotometer or an Agilent Cary
spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1. No detectable
activity was observed prior to PRA addition.
PurTH6. Assay conditions were adapted from the PurD assay above. The final assay
conditions for PurTH6 were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 2 mM magnesium
acetate, 2 mM glycine, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 1 mM
phosphoribosylamine (PRA), 5 units/mL LDH/PK mix (Sigma P0294 solution, according
to the manufacturer’s determined activity), 4 units H6PurD, 5 units H6PrsA, and PurTH6
in a final volume of 700 uL. The reaction mix was pre-incubated at 18°C for 2 min, and
the reaction was initiated by the addition of PRA in a quartz 0.5 mL cuvette (1 cm
pathlength). Enzymatic activity was monitored at 18°C in an Agilent diode-array
spectrophotometer by the decrease at 340 nm with ε = 6200 M-1 cm-1. No detectable
activity was observed prior to PRA addition. Calculated activity was divided by 2 to take
into account the generation of 2 ADP molecules from the PurD and PurT reactions.
H6PlsA. The final assay conditions for H6PlsA were 100 mM Tris-HCl pH 8.0, 50 mM
KCl, 2 mM magnesium acetate, 2 mM AMP, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 5
units/mL LDH/PK mix (Sigma P0294 solution, according to the manufacturer’s
determined activity), and H6-PlsA in a final volume of 700 uL. The reaction mix was
pre-incubated at 24°C for 2 min, and the reaction was initiated by the addition of AMP in
a quartz 0.5 mL cuvette (1 cm pathlength). Enzymatic activity was monitored at 24°C in
an Agilent diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1
cm-1. No detectable activity was observed prior to AMP addition. Calculated activity
was divided by 2 to take into account the generation of 2 ADP molecules per reaction.
H6PrsA. The final assay conditions for H6PrsA were 100 mM Tris-HCl pH 8.0, 50 mM
KCl, 2 mM magnesium acetate, 2 mM ATP, 1 mM PEP, 0.2 mM NADH, 2 mM ribose-5phosphate (R5P), 5 units/mL LDH/PK mix (Sigma P0294 solution, according to the
manufacturer’s determined activity), 5 units H6-PlsA, and H6-PrsA in a final volume of
700 uL. The reaction mix was pre-incubated at 24°C for 2 min, and the reaction was
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initiated by the addition of R5P in a quartz 0.5 mL cuvette (1 cm pathlength). Enzymatic
activity was monitored at 24°C in an Agilent diode-array spectrophotometer by the
decrease at 340 nm with ε = 6200 M-1 cm-1. No detectable activity was observed prior
to R5P addition.
GlnA. Assay conditions were adapted from the PurD assay above. The final assay
conditions for GlnA were 100 mM Tris-HCl pH 8.0, 50 mM KCl, 1 mM magnesium
acetate, 3 mM ATP, 2 mM PEP, 0.2 mM NADH, 15 units/mL LDH/PK mix (Sigma
P0294 solution, according to the manufacturer’s determined activity), 50 mM glutamate,
and 40 mM ammonium chloride in a final volume of 700 uL. The reaction mix was preincubated at 37°C for 2 min, and the reaction was initiated by the addition of glutamate in
a quartz 0.5 mL cuvette (1 cm pathlength). Enzymatic activity was monitored at 37°C in
an Agilent diode-array spectrophotometer by the decrease at 340 nm with ε = 6200 M-1
cm-1. No detectable activity was observed prior to glutamate addition.

3.3

Results and Discussion

E. coli PurF. The JRW construct (pJK673 [1]) was purified (data not shown), however,
previous characterization of the non-iron sulfur cluster enzyme indicated that the N-term
cysteine residue is the catalytic nucleophile [11]. Therefore the protein encoded by
pJK673 should code for a catalytically inactive PurF since it codes for H6PurF, so the
activity was not tested. The C-term His-tagged construct was obtained (pJK639) and
purified (data not shown). A total of 95 mgs of protein was isolated; however, no activity
was detected, even when PRPP was used as the starting substrate. The untagged
construct E. coli PurF (pJK649) was obtained as it was characterized previously [12]
(Figure 3.2 and Table 3.3).
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Figure 3.2 Purification of E. coli PurF (pJK649).
Final purification gel. SDS-PAGE (9% acrylamide), 5 ug protein/lane. Legend: C crude; S - soluble; PSS- post streptomycin sulfate; W1 and W2 - washes 1 and 2; P pooled elution fractions; F - pure PurF.
Table 3.3 Summary of the PurF purification.
Step
Soluble
Strep Sulf
DEAE
Pure PurF

Volume (mL)
35
37.5
90
2.6

Protein (mg)
495.4
464.3
184.32
28.34

Sp. Activity (U/mg)
0.081
0.115
0.244
18.46

Activity (U)
40.1
53.4
45.0
523

Purification (fold)
1
1.4
3.0
228

28.3 mg of E. coli PurF was obtained from 2 L of culture with a specific activity of 18.5
U/mg at 24°C, compared to 17.7 U/mg glutamine-dependent specific activity as
previously reported at 37°C [11].
E. coli PurD (pJK592). pJK72 [1] contained silent A38 and G382 mutations and multiple
sequencing attempts from the T7 promoter region failed, so the gene was cloned in-house
(purD - pJK592; purDH6 - pJK614; H6purD - pJK621). B. subtilis PurD (pJK034) was
purified by K. Nyffeler; however the protein sat diluted for over a week at 4°C and
activity was very low; since then, isolating B. subtilis PurD again has not been attempted.
Although there were issues at the beginning with setting up the activity assay, all of the
purified PurD proteins (tagged and untagged) were assayed again for activity as soon as
the assay was confirmed to work with H6PurD (pJK621).
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The E. coli PurD (pJK592) construct was shown to be leaky (data not shown); growth in
ZYM-5052 failed to reproducibly induce expression of the protein. Prep 1 failed to yield
active or clean protein (data not shown). Prep 2 yielded 20 mg of isolated protein (gels
not shown) , with a specific activity of 3 U/mg. Future isolations of untagged PurD
should include a low-salt wash (100-150 mM KCl) of the DE52 column prior to elution
and the DE52 elution should be performed in a higher linear salt gradient (150 mM - 1M
KCl) since PurD was found in the last 3 fractions (data not shown).
E. coli PurDH6 (pJK614). PurDH6 had the same leaky expression as the untagged
version (data not shown). A total of 186 mg of protein was obtained (gels not shown)
and had 0.19 U/mg activity. A doublet was observed in the purified protein lane that may
correspond to proteolytic cleavage products. Since both the untagged and the C-term
His-tagged proteins were not very active, the N-terminally tagged protein construct
(which has been previously characterized [13]) was obtained.
E. coli H6PurD (pJK621). Prep 1 yielded 14.4 mg of protein (gels not shown) with a
specific activity of 79.9 U/mg, which is about four times the specific activity that was
reported previously [13]. Error in calculations and the Bradford may be attributed to the
large difference in specific activity. A doublet was again observed in the purified protein
lane so PMSF may be a necessary addition to the buffers. Since not much protein was
obtained, the purification was attempted once more.
Prep 2. Cells were grown in ZYM-5052 [2] to increase protein yield. The purification
gels are shown in Figure 3.3.
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Figure 3.3 Purification of H6PurD (pJK621) prep 2.
Left, elution gel, 10 uL/lane (protein amount unknown). Numbers denote elution
fractions. Right, final purification gel, 5 ug protein/lane. SDS-PAGE (9% acrylamide).
A total of 117 mg of protein was isolated with a specific activity of 40 U/mg, which is
similar to the previously characterized wild-type E. coli PurD [14] but twice of that of
H6PurD [13]. Even though PMSF was present in the buffers, the lower molecular weight
band, likely due to proteolysis was still present. Active PurD has finally been isolated!
E. coli PurTH6 (pJK515). PurT, or GAR tranformylase, catalyzes the third step in the de
novo purine pathway and the C-terminally His-tagged version was isolated as shown in
Figure 3.4.
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Figure 3.4 Purification of PurTH6 (pJK515).
Left, elution profile, 10 uL/lane (protein amount unknown). Numbered lanes denote the
elution fractions. Right, final purification gel, 5 ug/protein/lane. SDS-PAGE (9%
acrylamide).
The column was overloaded as PurTH6 was present in the wash; however 145 mg of
protein was isolated (fractions 2-6 were pooled, Figure 3.4). When formate was omitted
from the activity assay, the total ATPase activity was calculated to be 0.25 U. Once
formate was added, the total ATPase activity increased to 0.29 U (previous calculation of
1.5 U/mg value was wrong). The C-term form of the enzyme has not been characterized
previously; however, the untagged E. coli protein was reported to have a specific activity
of 52 ug/min*mg*mL [15]. It is important to note that the enzymatic activity of PurTH6
was tested over a year after purification and no enzyme dilutions were made. The C-term
His-tag may be to blame as it may interfere with homodimer formation as it is located
close to the dimer interface (PDB 1KJ8). H6PurT (not previously characterized) may
yield active protein as a maltose-binding protein (MBP) N-term tag PurT was
characterized previously [16].
E. coli H6PlsA (pJK669 [1]). PlsA, or adenylate kinase, catalyzes the γ-phosphate
transfer from ATP to AMP to yield two ADPs. The elution and purification gels are
shown in Figure 3.5.
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Figure 3.5 Purification of H6PlsA.
Left, elution gel, 10 uL/lane (protein amount unknown). Numbered lanes denote the
elution fractions. Right, final purification gel, 5 ug/lane. SDS-PAGE (12% acrylamide).
37 mg of protein was isolated with a specific activity of 1.9 U/mg for the reaction, or 0.9
U/mg/ADP; compared to 1 U for the N-term tagged-protein [1] (taking into account of
the ADP molecules in activity calculation was not mentioned).
PrsA. PrsA, or PRPP synthase, catalyzes the phosphorylation of ribose-5-phosphate to
yield PRPP.
E. coli H6PrsA (pJK670 [1]). Sequencing of this construct did not reveal any mutations.
Expression in JM109(DE3) cells showed no induction (prep 1, data not shown) so the
construct was isolated from BL21(DE3) cells in prep 2, where 1 mg was isolated with a
specific activity of 0.9 U/mg, compared to 2.5 U/mg as previously reported for the Cterm tagged form [1]. The protein was observed to precipitate out after streptomycin
sulfate treatment in preps 2 and 3 (data not shown).
The A. aceti PrsAH6 construct was obtained (pJK631), however, the protein was
found to be insoluble (data not shown). Co-expression with GroESL did not improve its
solubility (data not shown), so the E. coli protein was revisited. The protocol for prep 5
was adapted from a study on the human ortholog which took advantage of PrsA
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precipitating in the presence of streptomycin sulfate [8]. The purification gels are shown
in Figure 3.6.
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Figure 3.6 Purification of E. coli H6PrsA (pJK670).
Left, elution, 10 uL/lane (protein amount unknown). Right, final purification gel, 5 ug
protein/lane. SDS-PAGE (12% acrylamide). Legend: D - dialyzed extract after
streptomycin precipitation; FT - flowthrough; W - wash; F - fraction; 0-25 - ammonium
sulfate fractionation.
A doublet in the elution fractions was observed which may indicate proteolytic products,
therefore no protein was pooled off of the Ni-NTA column. However, since the column
was overloaded and much recombinant protein was found in the flowthrough, an
ammonium sulfate step (0-25%) was performed. A total of 95 mgs was obtained with a
specific activity of 3.7 U/mg. Future isolations of E. coli H6PrsA should omit the NiNTA column. After dialysis of the resuspension of the streptomycin pellet, a simple 0-25%
ammonium sulfate cut should yield pure H6PrsA.
E. coli GlnA. GlnA, or glutamine synthase, catalyzes the ATP-dependent condensation
of glutamate with ammonium to yield glutamine.
E. coli H6GlnA Y397F (pJK642). pJK668 [1] contained multiple base insertion at the Nterminus, a silent G157 mutation, and a Y397F mutation, which is one of the sites of
adenylation [10]. The Y397F mutant was reported to have a lower turnover number but
is less subject to feedback inhibition and monovalent cation inhibition [10] therefore
pJK668 was used as a PCR template to yield pJK642. For prep 1, a very low yield of
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protein was obtained by affinity chromatography (data not shown) despite reprocessing
the flowthrough. Prep 1 enzyme activity was not tested. A Zn precipitation protocol
was attempted as previously reported and described [9, 10], however, it did not work for
H6GlnA as most of the expressed protein was insoluble (data not shown). The
insolubility of H6GlnA was not observed for prep 1. The N-term His-tag may interfere
with the homomultimeric complex formation which led to the failure of zinc precipitation
therefore the untagged protein construct was obtained.
E. coli GlnA (pJK650) purification. The zinc crystallization protocol was used to isolate
untagged GlnA as shown in Figure 3.7.
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Figure 3.7 Purification of EcGlnA (pJK650).
Legend: C, crude; S, soluble; PSS, post streptomycin sulfate; ZP, Zn precipitation pellet;
M1-M4, magnesium steps 1-4; D, dialyzed protein. SDS-PAGE (9% acrylamide), 10 uL
(protein amount unknown) except for the last lane which contained 5 ug protein.
10 mg of protein were isolated, and despite the low yield, the Zn precipitation protocol
yielded pure material. Activity was not used to track the protein therefore the appropriate
resuspension time was unknown (for this prep, the pellets were resuspended for 1 hour).
The specific activity of purified GlnA for this prep was 3 U/mg compared to 50 U/mg as
previously reported using the Zn crystallization method [9].
E. coli H6PurL (pJK556). Large PurL from E. coli will be used as a control for FS
activity. The purification gels are shown in Figure 3.8.
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Figure 3.8 Purification of EcH6PurL (pJK556).
Left, elution profile, 10 uL/lane (protein amount unknown). Right, final gel, 5 ug
protein/lane. Legend: PSS, post streptomycin sulfate; FT, flowthrough; W, wash; F,
fraction. SDS-PAGE (9% acrylamide).
H6PurL was found to be a very soluble protein. A total of 136 mgs were isolated;
however activity was not tested.
E. coli H6PurM (pJK633). PurM catalyzes the cyclization of FGAM to aminoimidazole
ribonucleotide (AIR). FGAM, the FS substrate, is unstable, but AIR, the product of the
PurM reaction, which follows FS in the de novo pathway, is not. Additionally, the
Bratton Marshall assay is very sensitive to diazotizable amines, including the exocyclic
one on AIR. Sequencing of the pJK675 [1] revealed a G324E mutation. Site-directed
mutagenesis was performed to yield pJK633 and the protein was isolated as shown in
Figure 3.9.
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Figure 3.9 Purification of H6PurM (pJK633).
Left, elution gel, 10 uL/lane (protein amount unknown). Right, final purification gel, 5
ug protein/lane. SDS-PAGE (12% acrylamide). Legend: PSS- post streptomycin sulfate;
FT - flowthrough; W - wash; F - fraction.
75 mgs of protein was isolated in this prep. Activity has not yet been tested.

3.4

Conclusion

All the constructs for the enzymes needed for FGAR biosynthesis have been
obtained. E. coli PurF (pJK649), H6PurD (pJK621), H6PlsA (pJK669), and H6PrsA
(pJK670) have been purified and shown to be active. Activity was not determined for E.
coli H6PurL and H6PurM since the other enzymes needed for FGAR synthesis were not
available at the time. PurTH6 (pJK515) was tested more than one year post-purification
and low activity was observed. C and N-term His-tagged PurT have not been
characterized; however one study has demonstrated that MBP-PurT was active [16] so
H6PurT or the untagged protein may be a better candidates than PurTH6. Purification of
GlnA (pJK650) still needs to be optimized. Although the zinc precipitation protocol
seemed to yield a significant amount a material, the amount of time required to fully
resuspend the various pellets after zinc and magnesium precipitation to fully recuperate
active GlnA still has to be determined (i.e. by monitoring activity). Once GlnA is
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obtained, combinations of the purine (PurF, PurD, and PurT) and regeneration pathway
enzymes (PrsA, PlsA, and GlnA) will be able to be mixed together in one reaction to
synthesize FGAR as proposed in Figure 3.1.
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CHAPTER 4. THE AAFS OPERON

4.1

Introduction

Previous observations in the AaFS protein co-expressions and functional
complementation profiles (Chapters 1 and 2, respectively) have determined that
functional AaFS does not contain OrfY and that the presence of the latter affects PurQ
expression. If OrfY does have a regulatory role for AaFS, its position allows for the
encoding of the much smaller PurS protein without expending too much energy on
transcribing and translating PurQ and PurL (Figure 4.1).

Figure 4.1 FS gene cluster alignment in select Gram-negative α-proteobacteria.
Alignment includes A. aceti, Gram-negative E. coli, and Gram-positive B. subtilis. To
date, acetic acid bacteria are the only Gram-negative bacteria that may contain PurS,
PurQ, PurL, and even OrfY in some. Legend: S = purS ; Y = orfY.
As mentioned previously, purS, orfY, purQ, and purL all overlap (by four
nucleotides) and are likely co-translated. The current hypothesis is that purC, purS, orfY,
purQ, purL, bolA, and grx are transcribed on the same transcript. purC is 28 bp upstream
of purS, purL 26 bp upstream of bolA, which is 26 bp upstream of grx. purB is located
155 bp upstream of purC and it is unclear if purB is co-transcribed/translated with the
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remaining genes. In B. subtilis, all the de novo purine genes are clustered [1, 2]; however
this is not the case in A. aceti.
Since OrfY shows a repressive effect on PurQ expression by SDS-PAGE
(Chapter 1), OrfY may have a regulatory role. Previously reported purine pathway
regulation mechanisms include feedback inhibition, riboswitches, and the presence of a
transcription repressor protein [3-5]. Previous studies elucidated the negative feedback
inhibition mechanism of purines on the first enzyme of the de novo purine biosynthetic
pathway, PurF [6, 7], as well as the presence of a repressor protein, PurR, that binds the
promoter region and prevents transcription from occuring [8]. Another method of
regulation is at the mRNA level, where upon the presence of purines, RNA forms a
secondary structure, preventing the ribosome from binding [2].
A prediction of the secondary structure of OrfY mRNA by RibEx [9] reveals the
potential formation of an attenuator sequence within the orfY gene (Figure 2).

Figure 4.2 RibEx prediction of the attenuator formation within orfY.
Top, DNA coding sequence and corresponding amino acids of OrfY. Bottom, the
formation of an anti-antiterminator loop allows for the formation of a terminator loop
thus terminating transcription and turning off FS activity. Upon binding of an unknown
RNA binding protein, the anti-antiterminator loop cannot form but instead an
antiterminator loop which allows for transcription to proceed and produce an active FS.

109
The hypothesis presented in Figure 4.2 follows that of the B. subtilis pyrimidine pathway
[10]. In short, in B. subtilis, the RNA binding protein PyrR interacts with mRNA
carrying pyrimidine synthesis genes in the presence of uridine nucleotides, causing
changes in the mRNA secondary structure and inhibiting transcription. Similarly, in the
regulation of AaFS, the absence of a currently unknown orfY mRNA binding protein
would allow for the formation of an anti-antiterminator loop and therefore a terminator
loop leading to the termination of transcription of AaFS. Upon the binding of the RNA
binding protein to the orfY mRNA sequence, an antiterminator loop is able to form which
allows for transcription to proceed and produce an active FS. The export of OrfY may or
may not affect the attenuator hypothesis. This chapter focuses on the isolation and
characterization of RNA from A. aceti, specifically the AaFS operon.

4.2

Materials and Methods

Materials
All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the
highest purity unless otherwise noted. Taq polymerase was from the Chapple laboratory
(Purdue University) or Promega. SuperScript II and Mu-MLV reverse transcriptases
were from Invitrogen and NEB, respectively.
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Table 4.1 Oligodeoxynucleotides used in this chapter.
ODN
404 (aka 404AC)
410
614
622
1012*
2130
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2322
2323
2326
2327
2370
2371

Sequence (5'=>3')a
GAAACATGGCGCGCATTGCAGACGGCCTCT
GATATACATATGACCTCCTTACATTCTCC
CCCACCCATATGATGAGCGAAACCGCCC
GATCATCATACTTGCCGC
CATACCCGGCAGATcTGCAGCTCCAC
GAGACAGGACATATGCTGCGAGATC
CCAGTTGGTTGATTTCAAACTGGAG
AAAGCGATGATGTGGTCTTCTGAAA
GCGTGGGTAAGGTGATTGAACTG
GGCCTTTTTCTGGGCTTCCTC
ATGGGGTCTCTCTTTCCAAAATCAA
GAGCGCATAACGGGCATGGT
CATCAACAGCATTGCGGGTATTCT
GAAGCCCTGTTTCCGTTAAAATCTG
CGCTATCTGGCTTGTGTAGCAAAC
CCTGATAGGGTTCGATAAAGGATGG
GGGATGGTGATCATTATGCCTGTT
CTGCCGGATATAGGTTTCGAGTTCT
TTTCCTTGAACAGGTTTTGCAGTTC
GGCGCGTATTCATTGGTAGT
AATTCTGCGCCGATAATGTC
AAACTAGTCCATATTTGGCCCGGTTAGC
CCATCGATTGGATCCTGCAGAAATTC
GCTATAAGAAGGGTGCGCTTCA
TGTTTTACAGTCCTGTGCTGATCTG
TTGAAGCCGAACTGGTGCG
CCACGCTCCTACGTAACG

*Primer originally designed for mutagenesis

Table 4.2 Plasmids used in this chapter.
pJK

Vector

537

pDrive

Description
AamutS

Source
This study

Aa denotes A. aceti gene.
Construction of A. aceti mutS construct plasmid pJK637. A 1.5 kb product was amplified
from A. aceti 1023 genomic DNA, using Taq Polymerase from the Chapple laboratory
(Purdue University) and ODNs 2322 and 2323 [11] with an annealing temperature of
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55°C and melting, annealing, and extension times of 20 s, 30 s, and 1 min 30 s for 25
cycles. The product was purified using a Qiagen PCR purification kit and ligated into
pDrive with the Qiagen QIAexpress UA cloning kit following the manufacturer’s
instructions. The plasmid encodes for a fragment of A. aceti MutS.
PCR controls. Previously isolated A. aceti 1023 genomic DNA (E. A. Mullins) was used
as the template for PCR using ODNs from Table 2 and Taq polymerase (Chapple
laboratory, Purdue University) with an annealing temperature of 55°C and melting,
annealing, and extension times of 30 s, 30 s, and 30 s for 25 cycles.
Denaturing formaldehyde agarose gel electrophoresis. A 1% gel was used to check RNA
integrity. A 50 mL gel was prepared by melting 0.5 g of agarose in 36 mL of water. 5
mL 10X MOPS buffer (0.4 M MOPS pH 7.0, 0.1 M NaOAc, 0.01 M EDTA), 1.8 mL 37%
formaldehyde (0.22M final), and 5 uL 1 mg/mL ethidium bromide was added once the
melted agarose had cooled slightly. Once solidified, the gel was presoaked for 30 min in
1X MOPS buffer and prerun for 10 min at 70 V.
RNA quantification. The Nanodrop 2000 (Thermo Scientific, Inc.) was used. 1.25 uL of
sample was analyzed after blanking the instrument in TE buffer (10 mM Tris-HCl pH 8.0,
1 mM EDTA). For later O.D. readings, samples were diluted from 1:20 to 1:50 for
quantification. Typically, 3 reads were averaged.
RNA isolation. Buffers including lysozyme, proteinase K, and TE were made in-house in
RNase-free water (autoclaved MilliQ water in RNase-free setting); all other buffers were
provided by the Qiagen or Ambion kits.
RNA isolation using Qiagen RNeasy Mini Kit. A. aceti 1023 cell pellets grown in YPD
for 36-38 hrs (OD600 ~1.1) were stored at -80˚C and treated with Qiagen RNAProtect
according to the manufacturer’s instructions. In short, 1 volume of A. aceti culture was
incubated with 2 volumes of RNAProtect reagent for 5 min, after which cells were
pelleted and stored at -80°C for up to 4 weeks until use. Cell pellets were thawed on ice.
15 mg/mL lysozyme was added to 1 mL TE buffer (30 mM TrisHCl, 1 mM EDTA, pH
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8.0), and 20 mg/mL proteinase K was added to a separate 1 mL TE buffer. 200 uL of
lysozyme-TE buffer and 20 uL of proteinase K-TE buffer solutions were added to the cell
pellets and resuspended by pipetting. The mixture was vortexed for 10 s and incubated at
room temperature for 30 min. Samples were vortexed for 10 s every 2 min. 700 uL of
Buffer RLT (Qiagen) was added to each sample and mixed by vortexing. 10 uL of BME
was added for every mL of buffer RLT. 500 uL of 100% EtOH was added to each
sample and mixed by pipetting up and down. Lysate was transferred to the spin columns
in 700 uL aliquots. Columns were centrifuged for 30 s at 8,000g. Liquid was discarded
and the process was repeated until all the lysate was processed. 350 uL of RW1 (Qiagen)
was applied to the spin column and centrifuged. 10 uL of Qiagen DNase I stock was
added to 70 uL Buffer RDD (Qiagen) and 80 uL of the DNase-RDD solution was added
to the column membrane. The columns were incubated at room temperature for 15 min.
350 uL of RW1 buffer was added to the column, incubated for 5 min, and removed by
centrifugation. The on-column DNase treatment was repeated once more. The column
was washed twice with 500 uL RPE buffer (Qiagen). The column was placed in a new
1.5 mL tube, and eluted with 50 uL RNase-free water by centrifuging for 1 min. The
same 50 uL was used again to elute more RNA from the same column. An additional insolution DNase treatment was performed where the reaction was incubated at 37°C for 30
min. The RNA was aliquoted, frozen, and stored at -80C until use. Alternatively, New
England Biolabs DNase was used in the same way as Qiagen’s.
RNA isolation using Ambion PureLink RNA Mini Kit. A. aceti 1023 cell pellets grown
in YPD for 36-38 hrs (OD600 ~1.1) were stored at -80˚C. E. coli DH5α cells were
grown to saturation overnight and the cells were used immediately. The cell pellet (E.
coli or A. aceti) was thawed on ice. Following the manufacturer’s instructions, 100 uL of
lysozyme solution (1 mg lysozyme in 10 mM Tris-HCl pH 8.0, 0.1 M EDTA) was added
to the cell pellet with resuspension by vortexing. 0.5 uL of 10% SDS (w/v) solution was
added and mixed by vortexing. 350 uL of lysis buffer (with 3.5 uL βME) was added and
mixed by vortexing. For the homogenization of the cells, the lysate was passed 5 times
through an 18-gauge needle with a syringe. The homogenized lysate was centrifuged at
12,000g for 2 min at room temperature. The supernatant was transferred to a clean
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RNase-free tube. 250 uL of 100% ethanol was added to the cell homogenate and mixed
by vortexing to disperse any precipitate. The sample (including any precipitate) was
transferred to a Spin Cartridge with collection tube. After a spin at 12,000g for 15 s at
room temperature, the flowthrough was discarded. 350 uL of Wash buffer I (Ambion)
was added to the column and spun at 12,000g for 15 s. On-column DNase digest was
performed here; otherwise, 500 uL of Wash Buffer II (Ambion) was added to the column
and spun. After 1 min spin to remove any residual solvent, RNA was eluted by placing
the spin cartridge into a clean RNase-free recovery tube. RNase-free water (Ambion)
was added to the column and incubated at room temperature for 1 min. The RNA was
eluted by centrifuging at 12,000g for 2 min. The elution step was repeated once more.
On-column NEB DNase treatment. 50 uL of the DNase mixture (5 uL 10X reaction
buffer; 1.25 uL 200 mM EDTA, 1 uL DNase, 42.75 uL RNase-free water) was loaded
onto the column. The column was incubated at 37˚C for 10 min. 350 uL of Wash buffer
I was added and spun and the rest of the protocol above was followed.
On-column Qiagen DNase treatment. As described previously, 10 uL of Qiagen DNase I
stock was added to 70 uL Buffer RDD and 80 uL of the DNase-RDD solution was added
to the column membrane. The columns were incubated at room temperature for 15 min.
350 uL of Wash buffer I was added and spun and the rest of the protocol above was
followed.
A. aceti RNA isolation using hot acid phenol. Cells from 10 mL of culture were
harvested and the supernatant was discarded. Cell pellets were frozen for storage at 80˚C or used immediately. Cells were resuspended in 400 uL freshly made and cold AE
buffer (50 mM NaOAc pH 5.2, 10 mM EDTA pH 8.0) and transferred to an RNase-free
tube. 40 uL of 10% SDS (w/v) and 400 uL acid phenol:chloroform (Amresco
Phenol:Chloroform::5:1) was added. The mixture was vortexed briefly and placed in a
65˚C heat block for 10 min, vortexing for 5 s every minute. Cells were incubated on ice
for 5 min and spun for 5 min at 14,000 g at 4˚C. The aqueous (upper) layer was
transferred to a new tube and 300 uL chloroform was added. The tube was gently shaken
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to mix and spun for 5 min at 14,000 g at 4˚C. The aqueous layer was transferred to
another tube. 50 uL of ice cold 3M NaOAc (pH 5.2) and 1 mL ice cold 100% ethanol
was added to the tube and mixed by inverting several times. The tube was chilled at 80˚C for 30 min or at -20˚C overnight and spun down for 10 min at 14,000 g at 4˚C.
Ethanol was removed, the pellet was rinsed with ice cold 70% ethanol, and the tube was
spun for 5 min at 14,000 g at 4˚C. As much of the 70% ethanol was removed using a
pipettor and the pellet was allowed to air dry (~5 min at room temperature). The pellet
was resuspended in 100 uL of RNase-free water by vortexing and samples were stored at
-20°C or -80°C.
In solution Qiagen DNase treatment. 87.5 uL DNA-contaminated RNA (at ~1 ug/uL
[RNA]), 10 uL RDD buffer, and 2.5 uL DNaseI reconstituted DNase I were mixed
together. The reaction was incubated at 37˚C for 30 min. DNase was removed by
phenol:chloroform extraction as described above.
In solution cDNA synthesis. Invitrogen SuperScript II or NEB M-MuLV Reverse
Transcriptase (RT) was used according to the manufacturers’ instructions. In short, 100500 ng total RNA, 2 pmol of gene specific antisense primer, and 0.5 mM dNTPs were
mixed in a tube in a final volume of 12 uL. The RNA mixture was heated to 65°C for 5
min and chilled on ice. 1X Buffer, 10 mM DTT, and 200 U of enzyme was added to the
RNA mixture and the whole reaction was incubated at 42°C for 30 min. The reverse
transcriptase was heat inactivated at 65°C for 20 min.
Two-step RT-PCR. 1 uL of the cDNA reaction above with 200ng RNA input was used
for the +RT reactions. 200ng of total RNA was used for the -RT reactions. GoTaq
polymerase (Promega) or Taq polymerase from the Chapple laboratory (Purdue
University) was used for the amplification reactions. 30 cycles were run.
rRNA depletion. The Ambion MICROBExpress™ Bacterial mRNA Enrichment Kit
was used according to the manufacturer’s instructions. In short, 10 ug RNA (subjected to
2 in-solution Qiagen DNase treatments) in a maximum volume of 15 uL was added to
200 µL Binding Buffer in a 1.5 mL tube and the tube gently vortexed to mix. 4 µL of
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Capture Oligo Mix was added to the RNA in Binding Buffer and the tube was gently
vortexed to mix. The tube was microfuged briefly to get the mixture to the bottom of the
tube. The RNA/Capture Oligo reaction was heated to 65°C for 10 min and incubated at
37°C for 15 min. During this incubation, the Oligo MagBeads were prepared by
resuspending the beads by vortexing. 50 uL of beads were aliquoted into a 1.5 mL tube.
The beads were captured using a magnetic stir bar and the supernatant was removed
carefully and discarded. The beads were washed by adding 50 uL of nuclease-free water
and resuspending the beads by brief, gentle vortexing. The beads were recaptured and
the supernatant was removed and discarded. The beads were equilibrated by adding 50
uL of Binding Buffer and resuspending them by brief, gentle vortexing. The beads were
recaptured and the supernatant was removed and discarded. The Oligo MagBeads were
resuspended in 50 uL Binding Buffer, and the slurry was incubated at 37°C until use.
The Wash solution was heated to 37°C. The washed and equilibrated beads were
resuspended by gentle vortexing and 50 uL was added to the RNA/Capture Oligo Mix.
The reaction was gently vortexed to mix, microfuged briefly, and incubated for 15 min at
37°C. The beads were recaptured and the supernatant (containing the enriched mRNA)
was carefully aspirated into a Collection Tube on ice. 100 uL of preheated Wash
Solution was added to the Oligo MagBeads and the latter were resuspended by brief,
gentle vortexing. The beads were recaptured and the supernatant was pooled with the
RNA already in the Collection Tube on ice. The enriched mRNA was ethanol
precipitated by adding 1/10th volume of 3 M sodium acetate, 1/50th volume 5 mg/mL
glycogen, and 3 volumes ice cold 100% ethanol. After mixing thoroughly by vortexing,
the RNA was precipitated at –20°C for 1 hr. The tube was centrifuged for 10 min at
14,000g and the supernatant was decanted and discarded. 750 uL of ice cold 70%
ethanol was added to the RNA pellet and the tube was vortexed briefly. The tube was
centrifuged for 5 min at 14,000g. The supernatant was discarded and an additional wash
was performed. Any remaining supernatant was removed with a pipettor and the pellet
was air dried for 5 min. The RNA pellet was resuspended in 10 uL TE (10 mM Tris-HCl
pH 8, 1 mM EDTA) by vortexing. Any remaining Oligo MagBeads were removed here
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by capturing the beads and removing the enriched mRNA solution to a new RNase-free
tube. Samples were stored at -20°C or -80°C.

4.3

Results and Discussion

PCR controls. A. aceti 1023 genomic DNA was used to test primers designed for RTPCR. Figure 4.3 shows the general annealing region for the AaFS cluster.
2299

Acetobacter aceti

purB

purC

2301

S

2303

Y

2305

2307

purQ

2300 2302 2304 23262306

purL
2308

2309

b

grx

0.5 kb

2310 2311

Figure 4.3 ODN priming sites for the AaFS operon.
Primers were designed to yield amplification products ~750 bp as summarized in Table
4.3 for all amplicons used in this chapter. PCR controls for the AaFS and purXEK
operons are shown in Figure 4.4 and 4.5, respectively.
Table 4.3 RT-PCR amplicon characteristics summary.
Spanning
Expected Size (bp) ODN (fwd) ODN (rev)
purC-purS
458
2299
2302
purS-orfY (post-attenuator)
393
2301
2304
purS-orfY (pre-attenuator)
153
2301
2326
orfY-purQ
500
2303
2306
purS-purQ
790
2301
2306
purQ-purL
454
2305
2308
purL-bolA
254
2307
2310
bolA-grx
485
2309
2311
purF (short)
167
2312
2313
purF (long)
397
2371
2313
mutS (short)
200
2327
2322
mutS (medium)
662
2370
2322
mutS (long)
1363
2323
2322
orfX-purE
541
2130
1012
purE-purK (short)
246
404
622
purE-purK (long)
744
614
622
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Figure 4.4 PCR controls for the AaFS operon of A. aceti 1023.
5 uL/lane, 1.4% agarose.
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Figure 4.5 PCR controls for the purXEK operon of A. aceti 1023.
5 uL/lane, 2% agarose.
The primers designed for RT-PCR were shown to work on A. aceti 1023 genomic DNA
so RNA isolation from A. aceti was the next step.
RNA isolation optimization. Very low yields of total RNA (<40 ng) were obtained when
the Qiagen or the Ambion kits were used. Note that buffers including lysozyme,
proteinase K, and TE were made in-house in RNase-free water; all other buffers were
provided by the Qiagen or Ambion kits. Kit-isolated samples could not be visualized by
denaturing formaldehyde agarose gels and RT-PCR results showed extensive genomic
DNA contamination (data not shown). Elizabeth Tran suggested acid phenol extraction
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since cell pellets would not be used for any other assays (i.e. kinetic characterization) and
to increase isolated RNA yield. Additionally, in-solution DNase treatments appeared to
be more effective than on-column treatments (data not shown). The final preps included
two in-solution DNase I treatments.
MutS, involved in DNA double-strand break repair, was previously established as a qRTPCR control for Acetobacter pasteurianus, as growth under various stressors such as heat,
higher ethanol concentrations, and acidic conditions in the growth media did not affect
mutS transcription levels [11]. Since A. aceti does not have a characterized housekeeping
gene and is closely related to A. pasteurianus, MutS was chosen as a control.
Additionally, purF was chosen as a purine pathway control since PurF catalyzes the first
committed step in de novo purine biosynthesis [12].
A successful total RNA isolation with no detectable genomic DNA contamination by
PCR is shown in Figure 4.6.
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Figure 4.6 Total RNA from A. aceti 1023.
Left, denaturing formaldehyde agarose gel (1%, 5 ug RNA). Right, RT-PCR, 2% agarose,
5 uL/lane (200 ng starting RNA). 30 cycles of PCR. 2 amplicon sizes were tested for
mutS and purF (S- short; L- long). M - marker. NB - the “mutS L” product here
corresponds to the “mutS medium” product in Table 4.3.
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A. aceti ribosomal RNA, unlike E. coli rRNA, appears to have two distinct bands at ~1.2
kb. 10 mL of culture would typically yield ~100 ug of total RNA. Two in-solution
DNase treatments followed by 30 cycles of RT-PCR showed a strong signal in the +RT
reactions, and no amplification from contaminating DNA in the -RT reactions. Smaller
amplicons, except for mutS and purF, were found to amplify contaminating genomic
DNA even after three DNase treatments (data not shown), therefore larger amplicons
were used for characterization of the AaFS and orfX-purE-purKK operons. The
transcripts for orfY and orfX seem to be encoded on the same mRNA as AaFS and PurEPurK, respectively.
Transcriptome analysis via RNA-Seq requires enrichment of mRNAs (as
recommended by Phillip San Miguel from the Purdue University Genomics Core
Facility). 10 ug of the total RNA isolated in Figure 4.6 was used as the input for rRNA
depletion by the Ambion MICROBExpress Bacterial mRNA Purification kit, which relies
upon hybridization of capture oligonucleotides to rRNA. RT-PCR results post-rRNA
depletion are shown in Figure 4.7.
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Figure 4.7 Enriched mRNA from A. aceti 1023 and RT-PCR.
Left, denaturing formaldehyde agarose gel (1%) before (AaRNA, 1ug) and after rRNA
depletion (Aa mRNA, 50 ng). Right, RT-PCR, 2% agarose, 5 uL/lane (200 ng starting
RNA). 30 cycles of PCR. M - 100 bp marker.
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No detectable genomic DNA contamination was observed by RT-PCR, even after mRNA
enrichment (Figure 4.7). Very faint amplification products were observed in the mutS
and EK lanes, which was not the case for purF, SQ, QL, and XE. Ambion mentioned that
the typical yield of enriched mRNA would be roughly 10% of the input total RNA
(therefore from the recommended 10 ug total RNA, 1 ug of mRNA should be obtained).
The yield of mRNA was ~30 ng. The absence of the 23S and 16S bands by denaturing
agarose gel electrophoresis or the Agilent Bioanalyzer is the only indicator of
(presumably) successful rRNA depletion. The latter method has been implemented as a
typical quality control step for next generation sequencing (i.e. RNA-Seq).
A. aceti total RNA and rRNA-depleted mRNA samples were sent for a quality
control check on the Agilent Bioanalyzer. Allison Sorg from the Purdue Genomics
Center noted that the RNA concentrations (by Nanodrop) were very low. They
recommend submitting 2 ug of RNA with an RNA integrity number (RIN) of 8 of higher
before proceeding forward to making a library and sequencing. On a scale of 1-10, a
high RIN indicates a high quality RNA sample [13]. Bioanalyzer traces for total RNA
and rRNA-depleted samples can be accessed through the following link:
http://www.genomics.purdue.edu/cgibin/cgiwrap/core/wiki.cgi/hr_00571_kappock_acetobacter_1_2013-06-05. The RIN for
total RNA and rRNA-depleted A. aceti 1023 samples were determined to be 7.1 and 8.6,
respectively. It is important to note that in order to get a RIN number for the rRNAdepleted sample (AA2), Allison Sorg changed the threshold of zero due to the low
concentration of the RNA. Peaks at ~1200 and 1400 nt are rRNA peaks, which were also
observed by denaturing formaldehyde agarose gels in lanes containing total RNA
(Figures 4.6 and 4.7). The peak at 25 nt is a standard. For the total RNA sample, peaks
at ~100 nt may be degradation products. A strong signal was observed for the rRNA
peaks, which decreased significantly to below 15 FU after rRNA-depletion, indicating
that mRNA enrichment with the MICROBExpress kit is compatible with A. aceti RNA.
The Life Technologies website lists compatible, partially compatible, and incompatible
bacteria for the kit, where A. aceti was not listed. Although the rRNA depletion was not
complete, a significant amount of ribosomal RNA was removed from total RNA despite
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the low yield. More mRNA is required for RNA-Seq therefore one suggestion is to
process multiple rRNA-depletion reactions, pool, and concentrate the enriched mRNA in
order to proceed forward.
orfY was established to be on the same mRNA transcript as purSQL, therefore the
other genes (purC, bolA, and grx) in the gene cluster were also tested as shown in Figure
4.8. ODN 2311 was used for cDNA synthesis of the whole gene cluster (starting from
grx) using the same batch of mRNA-enriched sample that was sent to the BioAnalyzer.
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Figure 4.8 RT-PCR for the AaFS gene cluster
2% agarose, 5 uL/lane from 200 ng starting RNA. 30 cycles of PCR. Legend: M - 100
bp marker; 1 - A. aceti genomic DNA template (PCR control), 2 - A. aceti total RNA
template (-RT); 3 - A. aceti cDNA template (+RT); B - blank lane.
No contaminating genomic DNA was observed in the -RT reactions. Amplification
products were observed for all targets in the +RT reactions, therefore bolA and grx are
likely transribed on the same mRNA as orfY (Figure 4.8).

4.4

Conclusion

RNA was successfully isolated from A. aceti 1023 grown in YPDE via the hot
acid phenol extraction method. When total RNA is analyzed by denaturing formaldehyde
agarose gel electrophoresis, two rRNA bands were observed at ~ 1.2 kb. mRNAs for
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mutS, purF, orfX-purE-purK, and purC-purS-orfY-purQ-purL-bolA-grx were detected by
RT-PCR. orfX-purE-purK and purC-purS-orfY-purQ-purL-bolA-grx were found to be on
the same mRNA transcript, respectively. For mRNA enrichment, the Ambion
MICROBExpress kit was found to be compatible with A. aceti 1023 although a scale-up
will be required to obtain enough material for quality control on the Agilent Bioanalyzer
(and ultimately RNA-Seq).
In Chapters 1 and 2, OrfY was shown to have a regulatory role on PurQ and potentially
PurL protein expression and in functional complementation studies. However, due to its
proximity to bolA and grx in the gene cluster (Figure 4.1), bolA and grx being found on
the same mRNA transcript (Figure 4.8), and four conserved cysteine residues in the OrfY
amino acid sequence (Chapter 1), OrfY may have a role in iron-sulfur cluster biogenesis.
None of the genes in the operon encode for a Fe-S cluster-containing protein... but there
is an iron-sulfur protein in the de novo purine biosynthetic pathway, PurF. PurF in B.
subtilis [14] and chicken [15] were shown to contain a Fe-S cluster; E. coli does not. A.
aceti PurF is predicted to also contain an Fe-S cluster (T. J. Kappock, unpublished
observations). Now that bolA and grx were shown to be on the same mRNA transcript
as orfY, the current hypothesis is that in purine-starvation conditions, PurF, OrfY, BolA,
and Grx (and PurL) would all be expressed together. Preliminary work on developing a
defined minimal medium for A. aceti 1023 to turn on (or off) purine genes can be found
in Chapter 5.
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CHAPTER 5. A. ACETI 1023 GROWTH IN MINIMAL MEDIA

5.1

Introduction

A. aceti has been used for the commercial production of vinegar for centuries [1].
Multiple cytoplasmic A. aceti proteins have been characterized [2-5] and shown to be
acid, and coincidentally, thermo-stable [2-5].
Propagation of A. aceti in rich medium simply uses YPDE [2]; however a defined
minimal medium has not been developed for culturing A. aceti 1023.

5.2

Materials and Methods

All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of
the highest purity unless otherwise noted. CSM-Ade-His-Leu-Trp was from BIO 101,
Inc. Yeast nitrogen base without amino acids was from Difco. Strains used in this
chapter are summarized in Table 5.1. MilliQ water was used for all media prep.
Table 5.1 Strains used in this study.
Organism
Acetobacter aceti
Saccharomyces cerevisiae

Strain
1023
W1588-4C

Genotype
wild type
MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1

YPDE. 10g yeast extract, 20g bacto-peptone, and 20g dextrose [6] were sterilized by
autoclaving. 2% (v/v) ethanol was supplemented prior to inoculation when YPD was
cooled down. A single colony of A. aceti 1023 was used to inoculate 500 mL of YPDE
in a 2.8 L baffled Fernbach flask and grown at 30°C (200 rpm).
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Minimal media. Media were supplemented with hypoxanthine (1.5 ug/mL) wherever
applicable. All cultures contained thiamin (10 uM final) unless otherwise indicated.
Ohmori medium. As previously described [7, 8]. Detailed composition is summarized in
Table 5.2. Cells grown to O.D. ~1 were washed with 1/15 M Na, KP , pH 6.5 buffer
600

i

and used to inoculate 100 mL of Ohmori medium in 500 mL Klett meter flasks. Cultures
with starting O.D. ~0.005-0.1 were grown at 30°C (200 rpm). “Modified Ohmori”
600

medium was Ohmori medium supplemented with the AMM metals. “Ohmori+” medium
was modified Ohmori supplemented with 2% (w/v) peptone.
Table 5.2 Summary of minimal media composition.
pH 5.0
Acetobacter Minimal Medium
K2HPO4
KH2PO4
(NH4)2SO4
MgSO4(7H2O)
CaCl2(2H2O)
Na2MoO4(2H2O)
FeCl3(6H2O)
CuSO4
MnCl2
ZnSO4
FeSO4(7H2O)
Na Glutamate
KCl
Glucose
Reference

7.3 mM
25 mM
1 mM
0.1 mM
0.001 mM

pH 6.5
Ohmori
0.57 mM
3.67 mM
1 mM
0.68 mM
0.03 mM

2E-4 mM
0.006 mM
0.006 mM
0.013 mM

2%
[9]

23.7 mM
1.3 mM
3%
[7]

pH 6.0
modified Ohmori
0.57 mM
3.67 mM
25 mM
1 mM
0.68 mM
0.001 mM
0.03 mM
2E-4 mM
0.006 mM
0.006 mM
23.7 mM
1.3 mM
3%

Complete supplement medium (CSM). Plates were prepared as described [10]. Plates
were kept at 30°C for 72 hrs.
Supplements
Amino Acid mix. A 1:1000 stock was used to supplement minimal media. The final
concentrations of 1.5 nM each of Asp, His, Ile, Leu, Phe, Val, Ala, Lys, and Arg; 1 nM
Trp and Tyr were used.
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UHWL mix. A 1:1000 stock was used to supplement minimal media. The final
concentrations of 1.5 ug/mL uracil, 1 mM His, Leu, Trp were used.
Vitamin mix. A 1:1000 stock was used to supplement minimal media. The final
concentrations of 0.1 nM biotin and 1 nM pantothenate were used.

5.3

Results and Discussion

YPDE propagation. A. aceti 1023 was shown to exhibit biphasic growth [11, 12] in rich
medium. A. aceti propagation in YPDE was monitored up to the first log phase to
determine when cells should be harvested for future growths in various minimal media
(Figure 5.1).

Figure 5.1 Propagation of A. aceti 1023 in YPDE.
The growth curve for A. aceti 1023 was similar to that of previous studies [11, 12]. The
first log phase was determined to end ~36-40 hrs post-inoculation with an O.D. ~0.75-1.
600

A. aceti minimal media propagation.
Multiple attempts at growing A. aceti 1023 on Ohmori medium [7] yielded
unreproducible and unpredictable results. Some cultures grew after 72 hrs as previously
observed [8] while others did not grow even after 10 days (data not shown). When
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supplemented with 0.2% peptone however, cultures in both Ohmori and AMM media
showed some growth, even though O.D. did not surpass 0.4 (data not shown).
600

Aeration was important as cultures grown in baffled flasks reached a higher O.D.
Ohmori medium supplemented with peptone in a baffled flask, followed by plain Ohmori
medium in a baffled flask, seemed to work well for A. aceti growth. AMM, which was
designed for Acetobacter xylinus [9], was not as good of a medium for A. aceti, therefore
it will not be used for subsequent studies. Ohmori et. al did not mention the addition of
micronutrients [7]; however sterilized tap water, which would contain metals, may have
been used. Tap or deionized water have not been tested for A. aceti growth using the
Ohmori medium salts.
Propagation of A. aceti in the modified Ohmori medium (Ohmori + AMM micronutrients)
is shown in Figure 5.2.

Figure 5.3 A. aceti 1023 propagation in supplemented Ohmori medium.
Supplementation with AMM micronutrients (O mod, ☐) or with AMM micronutrients
and 0.2% peptone (O mod +, ❍).
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Cultures with or without peptone in Figure 5.3 were inoculated at a lower starting O.D. ,
600

0.005 rather than 0.1, since there was ambiguity about the complete depletion of nutrients
and if cultures had reached the end of the log phase. Growth was observed in the
presence of peptone where the stationary phase was reached in ~ 100 hrs, compared to >
200 hrs for the media lacking peptone. Peptone may contain some nutrient that A. aceti
requires for growth in minimal medium.
Thiamin dependence of A. aceti. The de novo purine and thiamin biosynthetic pathway
share the same first five steps. The necessity of thiamin supplementation in minimal
medium for A. aceti was unknown and always added to minimal media. The thiamin
dependence of A. aceti is shown in Figure 5.3.

Figure 5.3 Thiamin requirement of A. aceti in modified Ohmori medium.
NB - addition of thiamin may have been omitted in the 1 uM curve.
Previous studies in the lab utilized 10 uM thiamin, but it seems that 0.5 uM is sufficient,
although the culture containing 1 uM thiamin grew the most poorly (addition of thiamin
in that flask might have been omitted). Thiamin seems to be required in order for A. aceti
to grow since the culture without any thiamin grew to O.D. ~0.1. No peptone was
600

added in this experiment, where A. aceti grew very slowly, reaching stationary phase
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after 10 days. A. aceti may need some other nutritional requirement that is in peptone.
An amino acid mix designed from the results of a JGI/DOE search for A. aceti amino
acid requirements is listed in the Methods and Materials and was tested below with
supplementation with the vitamin mix.
S. cerevisiae was used as a positive control to ensure that the media tested could
sustain growth since A. aceti did not yield reliable results thus far. S. cerevisiae W15884C is a purine auxotroph and contains the ade2 (PurE-PurK fusion) mutation. ade2
colonies appear red due to the accumulation and conversion of aminoimidazole
ribonucleotide (AIR) to the red compound. W1588-4C, when streaked on YPD, had the
expected red pigmentation. Growth of pink colonies was observed on modified Ohmori
plates supplemented with peptone (data not shown) and those results were also seen in
liquid media (Figure 5.4).

Figure 5.4 Growth curves of A. aceti and S. cerevisiae on modified Ohmori medium.
Legend: Sc, S. cerevisiae; Aa, A. aceti; O, Ohmori unsupplemented; H, +hypoxanthine;
P, + peptone; A, +amino acid/vitamin mix.
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In liquid medium, S. cerevisiae grew well in the presence of peptone, and although A.
aceti did not grow as well, there was some observable growth in the peptonesupplemented medium. These results indicate that the use of peptone will not yield
purine starvation conditions since S. cerevisiae W1588-4C, a purine auxotroph, grew,
indicating that peptone contains purines (and potentially pyrimidines). No growth was
observed for either organism in modified Ohmori medium, modified Ohmori medium
supplemented with hypoxanthine, or modified Ohmori medium supplemented with the
amino acid/vitamin mixes.
Additional modified Ohmori plates were poured where a mix containing uracil,
tryptophan, histidine, leucine, and adenine were included to ensure growth of S.
cerevisiae as a positive control. Hypoxanthine was also tested since it had been used in
the past as the go-to purine; however A. aceti’s preference of hypoxanthine over adenine
(or vice versa) was unknown.
Table 5.3 Ohmori Plate results.
Ohmori (water)
Ohmori (peptone)
Ohmori (UWLH)
Ohmori (UWLH ade)
Ohmori (UWLH hyp)
Ohmori (aa)
Ohmori (aa ade ura)
Ohmori (aa hyp ura)

Legend:

+++
++
+
-

S. cerevisiae
+++
+
+++
+++
+++
+++
+++

A. aceti
+
+++
+
+++
++
+++
+++
++

growth observed after 96 hrs
growth observed after 144 hrs
growth observed after 2 weeks
no growth after 2 weeks

Although colonies were very small, a lawn was observed. The amino acid/vitamin and
the uracil/trp/leu/his mixes seem to also have contaminating purines as S. cerevisiae was
able to grow, albeit not well, on both. Although the dry amino acid stocks may have been
contaminated with purines (obtained from old labs), another possibility is the conversion
of AIR to carboxyaminoimidazole ribonucleotide (CAIR) in the presence of carbon
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dioxide. A denser lawn of A. aceti was observed on the Ohmori+peptone plate when
compared to the Ohmori+amino acid/vitamin mix and the UWLH mix plates.
Additionally, A. aceti seems to prefer adenine as a source of purines over hypoxanthine
as growth was observed on adenine 2 days before that on hypoxanthine-supplemented
plates. Another option to try next is yeast nitrogen base (YNB), used in complete
synthetic medium (CSM) or synthetic complete (SC) medium, for S. cerevisiae. Yeast
nitrogen base contains defined salts, vitamins, and micronutrients; SC medium
supplements YNB with amino acids, adenine, and/or uracil, and a carbon source. No
growth was observed for either A. aceti or S. cerevisiae at the first attempt using solid
CSM medium, possibly due to too large of a dilution when plating cells and the short
amount of time (72 hrs) the plates were left at 30°C. CSM and SC differ in the amount of
supplied amino acids, where CSM contains less of them [10].

5.4

Conclusion

Growth of A. aceti in Ohmori medium could not be reproducibly observed, even
when micronutrients were added (modified Ohmori). Some growth was observed when
peptone was present, but an unknown key nutrient maybe found in tap water (not yet
tested) is required by A. aceti. S. cerevisiae was used as a positive control in order to
ensure that any manipulations would not yield toxic effects. A. aceti was found to require
proper aeration (baffled flasks), thiamin supplementation, and a preference for adenine
over hypoxanthine. Further work needs to be done in finding a defined minimal medium
for A. aceti 1023 as peptone contains purines and has the disadvantage of batch-to-batch
variability. CSM and SC media, which both utilize YNB, have been developed as
defined minimal media for yeast. Since A. aceti and S. cerevisiae have similar culturing
conditions (growth at 30°C; propagation in YPD for yeast, YPDE for the acidophile),
CSM and SC could be explored as potential culture media for A. aceti even though
growth was not observed during the first attempt on solid CSM medium.
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CHAPTER 6. MISCELLANEOUS WORK

6.1

Materials and Methods

All materials and chemicals were from Sigma Aldrich or Fisher Scientific and of the
highest purity unless otherwise noted. Oligodeoxynucleotides (ODNs, Table 1) were
obtained from IDT. OneTaq and Vent polymerases were obtained from NEB.
FlexiGoTaq polymerase was purchased from Promega. Chapple Taq polymerase was
isolated in the Chapple laboratory by Joann Cusumano (Purdue University).
Table 6.1 Oligodeoxynucleotides used in this chapter.
ODN
603/850/2124

Sequence (5'=>3')a
TAATACGACTCACTATAGGG

851/2125

GCTAGTTATTGCTCAGCGG

2138

GGATCTCGACGCTCTCCCT

2139

ATGCGTCCGGCGTAGA

2140

TTGTACACGGCCGCATAATC

2141

GATTATGCGGCCGTGTACAA

2283

TTCCTTAAGCTTCTAAGACTAAACCGTGGCTTTTGCAATAC

2284

TTCCTTGAATTCTTAGCCGATTTTGTTACGTTGTGCG

Table 6.2 Plasmids used in this chapter.
pJK

Vector

Description

Source

358

pET23a

uctD

[3]

551

pET28a

H6uctD

This study

634

pDrive

evgA R153W

This study
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Construction of H6uctD construct plasmid pJK551. pJK358 was digested with NdeI and
EcoRI and ligated into the NdeI and EcoRI restriction sites of the destination vector
pET28a to yield pJK551. The plasmid encodes for A. aceti H6UctD.
Construction of evgA R153W construct plasmid pJK634. A Taq PCR product obtained
by K. Nyffeler using ODNs 2283 and 2284 was purified using a Qiagen PCR purification
kit and ligated into pDrive with the Qiagen QIAexpress UA cloning kit following the
manufacturer’s instructions. The plasmid contains the endogenous promoter region of
EvgA and encodes for A. aceti EvgA R153W.
Colony PCR protocol. Protocol adapted from [1]. In short, PCR reactions were set up as
delineated in Tables 6.3, 6.5 and 6.7 and amplified according to the conditions in Table
6.4, 6.6, and 6.8, respectively. Colonies were first picked from transformation plates,
patched onto a fresh LB-antibiotic plate, and the remainder of the colony on the pipette
tip was transferred into the PCR reaction by pipetting up and down 5-6 times while
avoiding the introduction of air bubbles. Occasionally, to obtain more material, colonies
were patched on fresh LB-antibiotic plates first and left to grow for 4-6 hrs at 37°C prior
to colony PCR. Antibiotics were ampicillin at 100 ug/mL, streptomycin at 50 ug/mL, or
kanamycin at 70 ug/ml final concentrations. PCR products were analyzed on 0.7%-1.5%
agarose depending on the size of the amplification products. Controls usually consisted
of a PCR reaction using colonies carrying the parent vector (pET23a, pET23d, pET28a,
pET-Duet, or pCDF-Duet) or the actual plasmid as template.

Table 6.3 Cocktail for Vent.
Vent polymerase
Mix
[Final]
10X ThermoPol buffer
1X
MgSO4
5 mM
Primer 1 (5 uM)
0.25 uM
Primer 2 (5 uM)
0.25 uM
dNTPs (2.5 mM)
200 uM
Template
Vent
0.3 U
Water
total:

Table 6.4 PCR conditions for Vent.
Volume (uL)
3
1.5
1.5
1.5
2.4
0.3
19.5
30 uL

Conditions
Step
Hot start
Init. Den.
Den.
Anneal
Extension
Final Ext.
Hold

Vent
Temp (C)
98
98
98
55 (varies!)
72
72
4

Time
5 min
30 sec
20 sec
20 sec
1 min/kb
7 min
infinity

repeat
25X
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Table 6.5 Cocktail for OneTaq.
OneTaq polymerase
Mix
5X OneTaq Buffer
Primer 1 (5 uM)
Primer 2 (5 uM)
dNTPs (2.5 mM)
Template
OneTaq
Water

Table 6.6 PCR conditions for OneTaq.

[Final]
1X
0.25 uM
0.25 uM
200 uM

Volume (uL)
6
1.5
1.5
2.4

total:

0.5
18.1
30 uL

Table 6.7 Cocktail for Taq.
Taq (Chapple or Promega)
Mix
[Final]
5X Flexi GoTaq Buffer
1X
Primer 1 (5 uM)
5 uM
Primer 2 (5 uM)
5 uM
MgCl2 (25 mM)
1.25 mM
dNTPs (2.5 mM)
200 uM
Template
OneTaq
Chapple Taq (1:50 dil)
Water
total:

Conditions
Step
Hot start
Init. Den.
Den.
Anneal
Extension
Final Ext.
Hold

OneTaq
Temp (C)
94
94
94
55 (varies!)
68
68
4

Time
5 min
30 sec
20 sec
20 sec
1 min/kb
7 min
infinity

repeat
25X

Table 6.8 PCR conditions for Taq.
Volume (uL)
6
1.5
1.5
1.5
2.4
0.5
1.5
18.1
30 uL

Conditions
Step
Hot start
Init. Den.
Den.
Anneal
Extension
Final Ext.
Hold

Taq
Temp (C)
95
95
95
55 (varies!)
72
72
4

Time
5 min
30 sec
20 sec
20 sec
1 min/kb
7 min
infinity

repeat
25X

ESI-MS of A. aceti proteins. OrfYH6 from prep 1 (Chapter 1) and previously isolated A.
aceti proteins were analyzed on a Thermo Scientific LTQ (Parker laboratory) with S.
Ouellette’s assistance. Samples were diluted in 50:50:01 water: acetonitrile: formic acid.
A minimum of the top 3 peaks from each MS spectrum was input into ESIprot1.0 [2] for
analysis.

6.2

Results and Discussion

Colony PCR. Figure 6.1 shows the annealing sites for the ODNs (listed in Table 6.1)
used for screening construct candidates. It is important to note that gene specific primers
can also be used in this protocol.
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Figure 6.1 Colony PCR annealing sites.
Plasmids not to scale.
Colony PCR was used as a method to screen for candidates as an alternative to restriction
mapping, the latter which requires isolating the plasmid first and digesting the DNA prior
to running a gel. If colony PCR failed, restriction mapping was used to screen constructs.
Use of the empty vector as a control ensured that the PCR reaction worked and
determined a baseline where successful ligation of inserts would yield an amplification
product larger than ~250 bp (size of the T7 promoter-terminator region).
Cloning. H6UctD (pJK551) was obtained for comparison with the untagged protein
(Benjamin Carter and Funmi Adebesin rotations). EvgA R153W (pJK634) was obtained
for UctB and acid adaptation of A. aceti studies (Kayleigh Nyffeler).
ESI-MS. Steven Ouellette (Parker Lab) ran some samples on their LTQ. A minimum of
the top 3 peaks from each spectrum were analyzed by ESIprot 1.0 [2] and the
deconvoluted data obtained is summarized in Table 6.9.
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Table 6.9 ESI-MS results as analyzed by ESIprot 1.0 [2].
Sample

Dilution Expected Mass Calculated Mass
(Da)
(Da)

Std Dev.

Difference % Diff.
(Da)

PurE H59Q*

1:100

18856.8

18859.95

1.77

-3.15

-0.02

E. coli PurE
(500)

1:100

17741.94

17677.03

19.24

64.91

0.37

E. coli PurE
(501)

1:100

17741.94

17697.95

37.28

43.99

0.25

507*

1:50

18788.37

18788.99

1.66

-0.62

0

508*

1:100

18765.34

18765.2

0.44

0.14

0

509*

1:100

18804.37

18801.85

0.92

2.52

0.01

510*

1:100

18804.37

18804.72

1.11

-0.35

0

526*

1:20

18804.37

18809.82

18.62

-5.45

-0.03

527*

1:100

18804.37

18809.82

1.53

-5.45

-0.03

*A. aceti genes
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